

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
12 April 2001 (12.04.2001)

PCT

(10) International Publication Number  
**WO 01/25466 A1**

(51) International Patent Classification<sup>7</sup>: **C12N 15/867**,  
15/90, 5/10, 7/01, A61K 48/00

(UK) Limited, Medawar Centre, Robert Robinson Avenue,  
The Oxford Science Park, Oxford OX4 4GA (GB).

(21) International Application Number: PCT/GB00/03837

(74) Agents: **HARDING, Charles, Thomas et al.**; D Young &  
Co., 21 New Fetter Lane, London EC4A 1DA (GB).

(22) International Filing Date: 5 October 2000 (05.10.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
9923558.2 5 October 1999 (05.10.1999) GB

(71) Applicant (for all designated States except US): **OXFORD  
BIOMEDICA (UK) LIMITED** [GB/GB]; Medawar Cen-  
tre, Robert Robinson Avenue, The Oxford Science Park,  
Oxford OX4 4GA (GB).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,  
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,  
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,  
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,  
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,  
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **SLINGSBY, Jason**  
[GB/GB]; 91 Lacy Road, Putney, London SW15 1NR  
(GB). **KINGSMAN, Susan, Mary** [GB/GB]; Oxford  
BioMedica (UK) Limited, Medawar Centre, Robert  
Robinson Avenue, The Oxford Science Park, Oxford  
OX4 4GA (GB). **ROHLL, Jonathan** [GB/GB]; Oxford  
BioMedica (UK) Limited, Medawar Centre, Robert Robin-  
son Avenue, The Oxford Science Park, Oxford OX4 4GA  
(GB). **SLADE, Andrew** [GB/GB]; Oxford BioMedica

**Published:**

- With international search report.
- Before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments.

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

**Best Available Copy**

WO 01/25466 A1

(54) Title: PRODUCER CELL FOR THE PRODUCTION OF RETROVIRAL VECTORS

(57) Abstract: A method is provided for modifying a producer cell which producer cell comprises integrated into its genome a provirus which provirus comprises one or more recombinase recognition sequences within or upstream of its 3' LTR, the method comprising: introducing into the cell a construct comprising a 5' recombinase recognition sequence, an LTR and a 3' recombinase recognition sequence in that order, in the presence of a recombinase which is capable of acting on the recombinase recognition site(s) such that the nucleotide sequence between the 5' and 3' recombinase recognition sequences in the construct is introduced into the provirus.

## PRODUCER CELL FOR THE PRODUCTION OF RETROVIRAL VECTORS

## FIELD OF THE INVENTION

5

The present invention relates to retroviral vectors, in particular to high titre regulatable retroviral vectors.

## BACKGROUND TO THE INVENTION

10

Retroviruses have been proposed as a delivery system (otherwise expressed as a delivery vehicle or delivery vector) for *inter alia* the transfer of a nucleotide sequence of interest (NOI), or a plurality of NOIs, to one or more sites of interest. The transfer can occur *in vitro*, *ex vivo*, *in vivo*, or combinations thereof. When used in this fashion, the retroviruses are typically called retroviral vectors or recombinant retroviral vectors. Retroviral vectors have been exploited to study various aspects of the retrovirus life cycle, including receptor usage, reverse transcription and RNA packaging (reviewed by Miller, 1992 Curr Top Microbiol Immunol 158:1-24).

15

In a typical recombinant retroviral vector for use in gene therapy, at least part of one or more of the *gag*, *pol* and *env* protein coding regions may be removed from the virus. This makes the retroviral vector replication-defective. The removed portions may even be replaced by a NOI in order to generate a virus capable of integrating its genome into a host genome but wherein the modified viral genome is unable to propagate itself due to a lack of structural proteins. When integrated in the host genome, expression of the NOI occurs - resulting in, for example, a therapeutic effect. Thus, the transfer of a NOI into a site of interest is typically achieved by: integrating the NOI into the recombinant viral vector; packaging the modified viral vector into a virion coat; and allowing transduction of a site of interest - such as a targetted cell or a targetted cell population.

25

30

It is possible to propagate and isolate quantities of retroviral vectors (e.g. to prepare suitable titres of the retroviral vector) for subsequent transduction of, for example, a site of interest by using a combination of a packaging or helper cell line and a recombinant vector.

-2-

In some instances, propagation and isolation may entail isolation of the retroviral *gag*, *pol* and *env* genes and their separate introduction into a host cell to produce a "packaging cell line". The packaging cell line produces the proteins required for packaging retroviral RNA but it does not produce RNA-containing retroviral vectors. However, when a recombinant vector carrying a NOI and a *psi* region is introduced into the packaging cell line, the helper proteins can package the *psi*-positive recombinant vector to produce the recombinant virus stock. This can be used to infect cells to introduce the NOI into the genome of the cells. The recombinant virus whose genome lacks all genes required to make viral proteins can infect only once and cannot propagate. Hence, the NOI is introduced into the host cell genome without the generation of potentially harmful retrovirus. A summary of the available packaging lines is presented in "Retroviruses" (1997 Cold Spring Harbour Laboratory Press Eds: JM Coffin, SM Hughes, HE Varmus pp 449).

Retroviral packaging cell lines have been developed to produce retroviral vectors. These cell lines are designed to express three components, which may be located on three separate expression constructs. The *gag/pol* expression construct encodes structural and enzymatic components required in particle formation, maturation, reverse transcription and integration. The envelope (*env*) construct expresses a retroviral or non-retroviral envelope protein, which mediates viral entry into cells by binding to its cognate receptor. The third expression construct produces the retroviral RNA genome containing a *psi* region, which is packaged into mature, enveloped retroviral particles.

It has been observed that different methods, such as electroporation, transfection and retroviral transduction, which have been used to introduce the retroviral expression construct for the RNA genome, termed "the genome", into packaging cells produce different results. These different results can include different end points or "yield" of retroviral producer lines resulting from the derived cell lines. Moreover, electroporation and transfection methods can be problematic in the sense that the titre levels are not always at a satisfactory level.

By way of example, the transfection of a plasmid DNA construct into packaging cells from a MLV packaging cell line of human origin, called FLYA13, yielded low retroviral

-3-

vector titres even when different transfection reagents such as calcium phosphate precipitation and fugene transfection reagent were used. The average titres from selected stably transfected cell lines clones ranged from about  $10^3$  to about  $10^4$  per ml. In addition, clones generated by electroporation of constructs gave similar titres of from about  $10^3$  to about  $10^4$  per ml with no clones identified producing at  $>10^5$  per ml. However, when MLV vector particles are prepared in a transient transfection system with a different envelope pseudotype to the packaging cell, and used to transduce a retroviral packaging cell, stably transduced cell lines made by this transduction method produce retrovirus at  $10^6$  to  $10^7$  per ml. Therefore, these results suggest that retroviral transduction is a preferred method for genome introduction into packaging cell lines in order to generate high titre producer cell lines. However, when retroviral transduction is used to introduce a regulated/inactivated retroviral vector genome into packaging cell lines, the regulated retroviral vectors may not be produced in sufficient quantities from these cell lines.

15

By way of example, some retroviral vectors may comprise (i) internal expression constructs which are themselves regulated or (ii) regulated elements which are present in retroviral 3' LTR sequences, either by design or by their nature. Examples of these regulated vectors include but are not limited to hypoxic regulated vectors and self inactivating (SIN) vectors. If transduced producer cell lines are generated with these regulated vectors, the regulated or inactivated 3' U3 sequence of the LTR is copied to the 5' LTR by the process of retroviral reverse transcription and integration. Therefore, in the producer cell line, the 5' U3 promoter sequence directing expression of retroviral RNA genomes is identical to the regulated or inactivated 3' U3 promoter. This will result in very low levels of retroviral genome production and consequently low titres of functional retrovirus vectors being produced.

One example of such a regulated retroviral system includes MLV and lentivirus vector constructs where the 3' retroviral U3 enhancer element is replaced with a hypoxia responsive element (HRE) or other physiologically regulated, tumour specific or tissue-specific promoters. When these vectors are used to make a transduced producer cell line, the 3' U3 sequence containing the HRE element is copied to the 5' LTR position and retroviral genomes will only be produced under hypoxic conditions or chemical mimics

30



-4-

of hypoxia, such as heavy metal ions and desferrioxamine. Such a requirement for "induction for retroviral production" is not preferable as the different hypoxia induction protocols negatively affect retroviral producer cell viability.

- 5 By way of further example, lentivector U3 enhancers are dependent on the transactivator TAT for transcriptional activation. Therefore, a lentivector producer cell line generated by transduction requires the presence of TAT for high level expression of the lentivector genome construct. The expression of TAT is not preferable in such a packaging cell line and therefore, in the absence of TAT, only very low titres will be produced from  
10 transduced producer cells generated in this way.

Another example of a regulated retroviral systems includes MLV or lentivirus self-inactivating (SIN) vectors. These vectors contain deletions of the elements in their 3' U3 sequences responsible for transcriptional activity. Therefore, on transduction of target  
15 cells, the transcriptionally inactive 3' U3 sequence is copied to the 5' LTR position. In standard configurations, an internal expression cassette directs therapeutic or marker gene expression. However, if SIN vectors are used to make a transduced retroviral producer line, there will be no transcriptional elements present to direct high levels of retroviral RNA genome expression.

20

Although it is possible to carry out retroviral transduction with much lower-titre vector stocks, for practical reasons, high-titre retrovirus is desirable, especially when a large number of cells must be infected. In addition, high titres are a requirement for transduction of a large percentage of certain cell types. For example, the frequency of  
25 human hematopoietic progenitor cell infection is strongly dependent on vector titre, and useful frequencies of infection occur only with very high-titre stocks (Hock and Miller 1986 Nature 320: 275-277; Hogge and Humphries 1987 Blood 69: 611-617). In these cases, it is not sufficient simply to expose the cells to a larger volume of virus to compensate for a low virus titre. On the contrary, in some cases, the concentration of  
30 infectious vector virions may be critical to promote efficient transduction.

## SUMMARY OF THE INVENTION

We have now shown that it is possible to obtain transduced producer cells capable of producing high titre regulated retroviral vectors by replacing at least the 3'LTR of the integrated provirus using a recombinase based system. Thus whereas with the prior art, the U3 region of the 3'LTR is the same as that of the U3 region of the 5' LTR (and vice versa for the U5 region) in the provirus due to the way in which the viral vector integrates, the introduction of, for example, a replacement 3'LTR results in a provirus that has a 5'LTR and a 3'LTR that differ. The packaged viral vectors produced by transcription of the proviral genome within the producer cells may then ultimately be used to transduce target cells where the regulatable sequences present in the 3'LTR of the provirus in the producer cells are then present in the 5'LTR of the provirus in the target cells and consequently regulate transcription from the provirus as required.

This allows the introduction of a 3'LTR, for example a regulatable 3'LTR, into the provirus that was not desirable in the original viral vector used to transduce the producer cells since the consequential appearance of the regulatable 3'LTR U3 sequences in the 5'LTR in the provirus may lead to a reduced viral titre.

Consequently, the present invention allows transduced producer cells to be constructed that are capable of producing high titre regulated retroviral vectors by virtue of comprising a 5'LTR that directs high level expression of the viral genome in the producer cell and a different 3'LTR which as a result of the process of integration into a target cell will then result in a provirus in the target cell genome that exhibits regulatable expression.

In particular, the present invention allows the modification of a provirus integrated into the genome of the producer cells that have been selected for their high titre virus production such that the resulting packaged viral particles produced from the provirus may be used to transduce target cells resulting in a provirus integrated into the genome of the target cells that has a different, and preferably regulatable 5'LTR to that of the producer cell provirus.

The present invention is not limited to replacement of the 3'LTR of the provirus in the high titre producer cells, but may also include replacement of the 5'LTR and other viral sequences and/or the introduction of NOIs by the use of suitable constructs, as shown in the Figures.

5

Accordingly, the present invention provides a method of modifying a producer cell which producer cell comprises integrated into its genome a provirus which provirus comprises one or more recombinase recognition sequences within or upstream of its 3' LTR, the method comprising: introducing into the cell a construct comprising a 5' recombinase  
10 recognition sequence, an LTR and a 3' recombinase recognition sequence in that order, in the presence of a recombinase which is capable of acting on the recombinase recognition site(s) such that the nucleotide sequence between the 5' and 3' recombinase recognition sequences in the construct is introduced into the provirus.

15 Preferably the LTR is a heterologous regulatable LTR.

The present invention further provides a nucleic acid vector comprising a 5' recombinase recognition sequence, a regulatable LTR and a 3' recombinase recognition sequence in that order.

20

In any of the above aspects and embodiments of the invention, preferably the construct, nucleic acid molecule and/or nucleic acid vector further comprises at least one NOI between the 5' recombinase recognition sequence and the regulatable LTR.

25 Preferably the construct, nucleic acid molecule and/or nucleic acid vector further comprises a 5'LTR and/or a packaging signal

In one embodiment of the invention, the LTR is inactive/transcriptionally quiescent.

30 The construct, nucleic acid molecule and/or nucleic acid vector of the invention may be used in a recombinase assisted method to introduce a regulated LTR into a proviral genome integrated into a producer cell genome.

-7-

The present invention also provides a producer cell obtainable by the method of the invention, preferably a high titre producer cells. Also provided is an infectious retroviral particle obtained by the above method.

5 The present invention further provides a high titre producer cell comprising integrated into its genome a provirus, which provirus comprises a recombinase recognition site, a 5' LTR and a 3'LTR which 3'LTR differs from the 5'LTR. Such a producer cell will typically have been produced by the method of the invention.

10 Preferably the 5'LTR and the 3'LTR referred to for the purposes of comparison are both "active". The term "active" within the present context means transcriptionally active, that is to say, the 5'LTR comprises a promoter that directs transcription of the viral genome and the 3'LTR comprises a transcriptional stop sequence to terminate transcription. This distinction is relevant since if a provirus produced by the method of the invention  
15 comprises more than one 5' LTR or 3'LTR, at least one but not all must be active to allow viral production. Further, if the provirus comprises more than one 3'LTR then it is generally the upstream one that will be active since transcription will tend not to read through to the downstream 3' LTR.

20 In addition, where the method of the invention results in an insertion of a 3'LTR upstream of the original 3'LTR, the comparison should be performed between the additional 3'LTR and the original 5'LTR and not the two original LTRs. Thus it is permitted to have a 5'LTR and 3'LTR within the same provirus that are the same provided that there is also a 5'LTR and 3'LTR that differ.

25

In another aspect, the present invention provides a derived producer cell comprising integrated into its genome a retroviral vector comprising in the 5' to 3' direction a first 5' LTR; a second NOI operably linked to a second regulatable 3' LTR; and a third 3'LTR; wherein the third 3'LTR is positioned downstream of the second regulatable 3'LTR in the  
30 producer cell.

-8-

Preferably the first 5' LTR comprising 5'R and 5' U5 sequences is derivable from a first vector; the second NOI operably linked to a second regulatable 3' LTR is derivable from a second vector; and the third 3'LTR is derivable from the first vector.

- 5 In a preferred embodiment, the first vector further comprises an internal LTR located upstream of the first NOI and downstream of the packaging signal wherein the internal LTR comprises a heterologous U3 sequence linked to heterologous R and U5 sequences.

Preferably the heterologous R and U5 sequences are lentiviral derivable R and U5  
10 sequences, such as EIAV R and U5 sequences.

In a further preferred embodiment, the third 3'LTR is transcriptionally active but expression is directed away from the second regulatable 3'LTR.

- 15 In another embodiment, the second vector comprises a second NOI operably linked to a second regulatable 3'LTR comprising at least one recombinase recognition sequence. Preferably the second regulatable 3'LTR comprises a deletion in the U3 sequences in the 3'LTR.

- 20 Preferably, the second NOI comprises a discistronic construct, more preferably a discistronic construct comprising a therapeutic gene, an internal ribosomal entry site (IRES) and a reporter gene.

The present invention further provides in another embodiment, a method for producing a  
25 high titre regulatable retroviral vector, the method comprising the steps of:

- (i) providing a derived producer cell comprising integrated into its genome a first vector;  
(ii) introducing a second vector into the derived producer cell using a recombinase assisted method; wherein the derived producer cell comprises a retroviral vector comprising in the 5' to 3' direction a first 5' LTR; a second NOI operably linked to a  
30 second regulatable 3' LTR; and a third 3'LTR; wherein the third 3'LTR is positioned downstream of the second regulatable 3'LTR in the derived producer cell.

-9-

The present invention also provides the use of a recombinase assisted mechanism to introduce a regulated 3'LTR into a derived producer cell line to produce a high titre regulated retroviral vector.

- 5 Aspects of the present invention are also presented in the accompanying claims and in the following description and discussion.

These aspects are presented under separate section headings. However, it is to be understood that the teachings under each section heading are not necessarily limited to  
10 that particular section heading.

#### DETAILED DESCRIPTION OF THE INVENTION

The present invention is advantageous because:

15

(i) it enables regulated retroviral vectors to be produced at high titres from transduced producer cell lines.

(ii) it removes the uncertainty associated with the process of producer cell line derivation  
20 and the necessity to screen large numbers of producer cell lines each time a new retroviral expression construct is introduced into a producer cell line.

(iii) it greatly facilitates the generation of high titre retroviral stocks without the use of marker genes (such as but not limited to  $\beta$ -galactosidase, green fluorescent protein) and  
25 antibiotic resistance genes.

(iv) it avoids the derivation of low titre transfected producer cell lines or the use of hypoxic conditions or chemical mimics for production from traditionally derived transduced producer lines.

30

(v) it enables the production of SIN vectors by stable cell line producer technology. Previously, SIN vectors have not been amenable to production by stable cell line producer technology because the deletion of the 3'U3 sequence resulted in at least a tenfold lower

-10-

titre of self-inactivating (SIN) vectors in comparison with vectors having intact LTRs. Consequently, SIN vectors have had to be prepared using transfection-based transient expression systems.

## 5 PRODUCER CELL

The high titre regulated retroviral vector particles of the present invention are typically generated in a suitable producer cell. Producer cells are generally mammalian cells but can be, for example, insect cells. A producer cell may be a packaging cell containing the virus structural genes, normally integrated into its genome into which the regulated retroviral vectors of the present invention are introduced. Alternatively the producer cell may be transfected with nucleic acid sequences encoding structural components, such as *gag/pol/env* on one or more vectors such as plasmids, adenovirus vectors, herpes viral vectors or any method known to deliver functional DNA into target cells. The vectors according to the present invention are then introduced into the packaging cell by the methods of the present invention.

As used herein, the term "producer cell" or "vector producing cell" refers to a cell which contains all the elements necessary for production of regulated retroviral vector particles and regulated retroviral delivery systems.

Preferably, the producer cell is obtainable from a stable producer cell line.

Preferably, the producer cell is obtainable from a derived stable producer cell line.

Preferably, the producer cell is obtainable from a derived producer cell line

As used herein, the term "derived producer cell line" is a transduced producer cell line which has been screened and selected for high expression of a marker gene. Such cell lines contain retroviral insertions in integration sites that support high level expression from the retroviral genome. The term "derived producer cell line" is used interchangeably with the term "derived stable producer cell line" and the term "stable producer cell line"

-11-

Preferably the derived producer cell line includes but is not limited to a retroviral and/or a lentiviral producer cell.

Preferably the derived producer cell line is an HIV or EIAV producer cell line, more preferably an EIAV producer cell line.

Preferably the envelope protein sequences, and nucleocapsid sequences are all stably integrated in the producer and/or packaging cell. However, one or more of these sequences could also exist in episomal form and gene expression could occur from the episome.

### PACKAGING CELL

As used herein, the term "packaging cell" refers to a cell which contains those elements necessary for production of infectious recombinant virus which are lacking in a recombinant viral vector. Typically, such packaging cells contain one or more expression cassettes which are capable of expressing viral structural proteins (such as *gag*, *pol* and *env*) but they do not contain a packaging signal.

The term "packaging signal" which is referred interchangeably as "packaging sequence" or "*psi*" is used in reference to the non-coding sequence required for encapsidation of retroviral RNA strands during viral particle formation.

Packaging cell lines suitable for use with the above-described vector constructs may be readily prepared (see also WO 92/05266), and utilised to create producer cell lines for the production of retroviral vector particles. As already mentioned, a summary of the available packaging lines is presented in "Retroviruses" (1997 Cold Spring Harbour Laboratory Press Eds: JM Coffin, SM Hughes, HE Varmus pp 449).

The packaging cell lines are useful for providing the gene products necessary to encapsidate and provide a membrane protein for a high titre regulated retrovirus vector and regulated nucleic gene delivery vehicle production. When regulated retrovirus sequences are introduced into the packaging cell lines, such sequences are encapsidated



-12-

with the nucleocapsid (*gag/pol*) proteins and these units then bud through the cell membrane to become surrounded in cell membrane and to contain the envelope protein produced in the packaging cell line. These infectious regulated retroviruses are useful as infectious units *per se* or as gene delivery vectors.

5

The packaging cell may be a cell cultured *in vitro* such as a tissue culture cell line. Suitable cell lines include but are not limited to mammalian cells such as murine fibroblast derived cell lines or human cell lines. Preferably the packaging cell line is a human cell line, such as for example: HEK293, 293-T, TE671, HT1080.

10

Alternatively, the packaging cell may be a cell derived from the individual to be treated such as a monocyte, macrophage, blood cell or fibroblast. The cell may be isolated from an individual and the packaging and vector components administered *ex vivo* followed by re-administration of the autologous packaging cells.

15

Methods for introducing retroviral packaging and vector components into packaging/producer cells are described in the present invention.

Preferably the method of the present invention utilises a recombinase assisted mechanism.

20

Preferably the method of the present invention utilises a recombinase assisted mechanism which facilitates the production of high titre regulated retroviral vectors from the producer cells of the present invention.

## 25 RECOMBINASE ASSISTED MECHANISM

As used herein, the term "recombinase assisted system" includes but is not limited to a system using the Cre recombinase / loxP recognition sites of bacteriophage P1 or the site-specific FLP recombinase of *S. cerevisiae* which catalyses recombination events between  
30 34 bp FLP recognition targets (FRTs).

The site-specific FLP recombinase of *S. cerevisiae* which catalyses recombination events between 34 bp FLP recognition targets (FRTs) has been configured into DNA constructs

-13-

in order to generate high level producer cell lines using recombinase-assisted recombination events (Karreman *et al.* (1996) NAR 24, 1616-1624). A similar system has been developed using the Cre recombinase / loxP recognition sites of bacteriophage P1. This was configured into a retroviral genome such that high titre retroviral producer cell lines were generated (Vanin *et al.* (1997) J Virol 71, 7820-7826). However, the use of the second method (Vanin *et al. ibid*) has centered around the exchange of the central portions of a retroviral cassette using a recombinase-assisted system. Moreover, these methods have used genes encoding selectable markers such as neo<sup>R</sup> and puro<sup>R</sup> (Vanin *et al. ibid*) and luciferase and puro<sup>R</sup> linked by an IRES sequence (Karreman *et al. ibid*).  
10 Karreman and Vanin do not demonstrate or *suggest* that: (i) a regulated or inactive 3'U3 sequence of the 3'LTR can be introduced into a producer cell via a recombinase-assisted mechanism or (ii) that therapeutic genes under the control of a regulated LTR may be introduced into a producer cell line via a recombinase assisted step. Vanin *et al. ibid* suggests that his Cre-mediated recombination approach to retroviral producer cell line  
15 production may be used in combination with other modifications which should result in improved vector performance. Vanin *et al. ibid* also suggests that his approach provides a means to generate high titre SIN vectors. However, there is no worked example and in fact no enabling disclosure because the skilled person would not have been aware, on the basis of the Vanin *et al.* paper, of the necessary modifications to make the suggested  
20 approach work. Vanin *et al.* makes no reference to hypoxic regulated vectors and/or regulated/inactivated lentiviral vectors.

#### LTRs

25 As already indicated, each retroviral genome comprises genes called *gag*, *pol* and *env* which code for virion proteins and enzymes. In the provirus, these genes are flanked at both ends by regions called long terminal repeats (LTRs). The LTRs are responsible for proviral integration, and transcription. They also serve as enhancer-promoter sequences. In other words, the LTRs can control the expression of the viral gene. Encapsulation of  
30 the retroviral RNAs occurs by virtue of a *psi* sequence located at the 5' end of the viral genome.

-14-

As used herein, the term "long terminal repeat (LTR)" is used in reference to domains of base pairs located at the end of retroviral DNAs.

The LTRs themselves are identical sequences that can be divided into three elements, which are called U3, R and U5. U3 is derived from the sequence unique to the 3' end of the RNA. R is derived from a sequence repeated at both ends of the RNA and U5 is derived from the sequence unique to the 5' end of the RNA. The sizes of the three elements can vary considerably among different retroviruses.

For ease of understanding, a simple, generic structures (not to scale) of the RNA and the DNA forms of the MLV retroviral genome is presented in Figure 7 in which the elementary features of the LTRs and the relative positioning of *gag/pol* and *env* are indicated. Please note that (i) *gag/pol* and *env* are normally not spaced apart; and (ii) the overlap normally present between the *pol* and *env* genes and the poly A tail normally present at the 3' end of the RNA transcript are not illustrated in Figure 7.

As shown in Figure 7, the basic molecular organisation of an infectious retroviral RNA genome is (5') R - U5 - *gag/pol*, *env* - U3-R (3'). In a defective retroviral vector genome *gag*, *pol* and *env* may be absent or not functional. The R regions at both ends of the RNA are repeated sequences. U5 and U3 represent unique sequences at the 5' and 3' ends of the RNA genome respectively.

Upon cellular transduction, reverse transcription of the virion RNA into double stranded DNA takes place in the cytoplasm and involves two jumps of the reverse transcriptase from the 5' terminus to the 3' terminus of the template molecule. The result of these jumps is a duplication of sequences located at the 5' and 3' ends of the virion RNA. These sequences then occur fused in tandem on both ends of the viral DNA, forming the long terminal repeats (LTRs) which comprise R U5 and U3 regions. On completion of the reverse transcription, the viral DNA is translocated into the nucleus where the linear copy of the retroviral genome, called a preintegration complex (PIC), is randomly inserted into chromosomal DNA with the aid of the virion integrase to form a stable provirus. The number of possible sites of integration into the host cellular genome is very large and very widely distributed.

-15-

Preferably the retroviral genome is introduced into packaging cell lines using retroviral transduction.

Preferably retroviral vector particles (such as MLV vector particles) are prepared in a transient expression system with a different envelope pseudotype to the packaging cell, and used to transduce a retroviral packaging cell.

Preferably the retroviral transduction step identifies retroviral insertions in integration sites that support high level expression of the resulting regulated retroviral genome.

Preferably stable transduced producer cell lines made by this initial retroviral transduction step produce retrovirus at titres of at least  $10^6$  per ml, such as from about  $10^6$  to about  $10^7$  per ml, more preferably at least about  $10^7$  per ml.

#### HIGH TITRE

As used herein, the term "high titre" means an effective amount of a retroviral vector or particle which is capable of transducing a target site such as a cell.

As used herein, the term "effective amount" means an amount of a regulated retroviral or lentiviral vector or vector particle which is sufficient to induce expression of an NOI at a target site.

Preferably the titre is from at least  $10^6$  retrovirus particles per ml, such as from about  $10^6$  to about  $10^7$  per ml, more preferably at least about  $10^7$  retrovirus particles per ml.

#### TRANSCRIPTIONAL CONTROL

The control of proviral transcription remains largely with the noncoding sequences of the viral LTR. The site of transcription initiation is at the boundary between U3 and R in the left hand side LTR (as shown in Figure 7) and the site of poly (A) addition (termination) is at the boundary between R and U5 in the right hand side LTR (as shown in Figure 7). The 3'U3 sequence contains most of the transcriptional control elements of the provirus,

-16-

which include the promoter and multiple enhancer sequences responsive to cellular and in some cases, viral transcriptional activator proteins.

#### REGULABLE LTRs

5

AN LTR present, for example, in the construct of the invention and as a 3'LTR in the provirus of the producer cell of the invention may be a native LTR or a heterologous regulatable LTR. It may also be a transcriptionally quiescent LTR for use in SIN vector technology.

10

As used herein, the terms "regulatable LTR" and "regulatable 3'LTR" include vectors which contain responsive elements which are present in retroviral 3' LTR sequences, either by design or by their nature. As used herein, vectors comprising a "regulatable 3'LTR" are referred to as "regulated retroviral vectors". Within the regulatable 3'LTR region, the 3'U3 sequence contains most of the transcriptional control elements of the provirus, which include the promoter and multiple enhancer sequences responsive to cellular and in some cases, viral transcriptional activator proteins.

15

Responsive elements include but are not limited to elements which comprise, for example, promoter and multiple enhancer sequences responsive to cellular and in some cases, viral transcriptional activator proteins and/or elements which have been modified to render them inactive. As used herein, the term "modified" includes but is not limited to silencing, disabling, mutating, deleting or removing all of the U3 sequence or a part thereof.

25

The term "regulated LTR" also includes an inactive LTR such that the resulting provirus in the target cell can not produce a packagable viral genome (self-inactivating (SIN) vector technology) - see the Examples and Figure 6 for a particular embodiment.

30

## ENHANCER

As used herein, the term "enhancer" includes a DNA sequence which binds other protein components of the transcription initiation complex and thus facilitates the initiation of transcription directed by its associated promoter.

In one preferred embodiment of the present invention, the enhancer is an ischaemic like response element (ILRE).

## 10 ILRE

The term "ischaemia like response element" - otherwise written as ILRE - includes an element that is responsive to or is active under conditions of ischaemia or conditions that are like ischaemia or are caused by ischaemia. By way of example, conditions that are like ischaemia or are caused by ischaemia include hypoxia and/or low glucose concentration(s).

The term "hypoxia" means a condition under which a particular organ or tissue receives an inadequate supply of oxygen.

20

Ischaemia can be an insufficient supply of blood to a specific organ or tissue. A consequence of decreased blood supply is an inadequate supply of oxygen to the organ or tissue (hypoxia). Prolonged hypoxia may result in injury to the affected organ or tissue.

25 A preferred ILRE is an hypoxia response element (HRE).

## HRE

In one preferred aspect of the present invention, there is hypoxia or ischaemia regulatable expression of the retroviral vector components. In this regard, hypoxia is a powerful regulator of gene expression in a wide range of different cell types and acts by the induction of the activity of hypoxia-inducible transcription factors such as hypoxia inducible factor-1 (HIF-1; Wang & Semenza 1993 Proc Natl Acad Sci 90:430), which

30

-18-

bind to cognate DNA recognition sites, the hypoxia-responsive elements (HREs) on various gene promoters. Dachs *et al* (1997 Nature Med 5: 515) have used a multimeric form of the HRE from the mouse phosphoglycerate kinase-1 (PGK-1) gene (Firth *et al* 1994 Proc Natl Acad Sci 91:6496-6500) to control expression of both marker and therapeutic genes by human fibrosarcoma cells in response to hypoxia *in vitro* and within solid tumours *in vivo* (Dachs *et al ibid*).

Hypoxia response enhancer elements (HREEs) have also been found in association with a number of genes including the erythropoietin (EPO) gene (Madan *et al* 1993 Proc Natl Acad Sci 90: 3928; Semenza and Wang 1992 Mol Cell Biol 1992 12: 5447-5454). Other HREEs have been isolated from regulatory regions of both the muscle glycolytic enzyme pyruvate kinase (PKM) gene (Takenaka *et al* 1989 J Biol Chem 264: 2363-2367), the human muscle-specific  $\beta$ -enolase gene (ENO3; Peshavaria and Day 1991 Biochem J 275: 427-433 ) and the endothelin-1 (ET-1) gene (Inoue *et al* 1989 J Biol Chem 264: 14954-14959).

Preferably the HRE of the present invention is selected from, for example, the erythropoietin HRE element (HREE1), muscle pyruvate kinase (PKM), HRE element, phosphoglycerate kinase (PGK) HRE, B-enolase (enolase 3; ENO3) HRE element, endothelin-1 (ET-1)HRE element and metallothionein II (MTII) HRE element.

#### RESPONSIVE ELEMENT

Preferably the ILRE is used in combination with a transcriptional regulatory element , such as a promoter, which transcriptional regulatory element is preferably active in one or more selected cell type(s), preferably being only active in one cell type.

As outlined above, this combination aspect of the present invention is called a responsive element.

Preferably the responsive element comprises at least the ILRE as herein defined.

-19-

Non-limiting examples of such a responsive element are presented as OBHRE1 and XiaMac. Another non-limiting example includes the ILRE in use in conjunction with an MLV promoter and/or a tissue restricted ischaemic responsive promoter. These responsive elements are disclosed in WO99/15684.

5

Other examples of suitable tissue restricted promoters/enhancers are those which are highly active in tumour cells such as a promoter/enhancer from a *MUC1* gene, a *CEA* gene or a *5T4* antigen gene. The alpha fetoprotein (AFP) promoter is also a tumour-specific promoter. One preferred promoter-enhancer combination is a human  
10 cytomegalovirus (hCMV) major immediate early (MIE) promoter/enhancer combination.

## PROMOTER

The term "promoter" is used in the normal sense of the art, e.g. an RNA polymerase  
15 binding site.

The promoter may be located in the retroviral 5' LTR to control the expression of a cDNA encoding an NOI.

20 Preferably the NOI is capable of being expressed from the retrovirus genome such as from endogenous retroviral promoters in the long terminal repeat (LTR)

Preferably the NOI is expressed from a heterologous promoter to which the heterologous gene or sequence is operably linked.

25

Alternatively, the promoter may be an internal promoter.

Preferably the NOI is expressed from an internal promoter.

30 Vectors containing internal promoters have also been widely used to express multiple genes. An internal promoter makes it possible to exploit promoter/enhancer combinations other than those found in the viral LTR for driving gene expression. Multiple internal promoters can be included in a retroviral vector and it has proved



-20-

possible to express at least three different cDNAs each from its own promoter (Overell *et al* 1988 Mol Cell Biol 8: 1803-1808). Internal ribosomal entry site (IRES) elements have also been used to allow translation of multiple coding regions from either a single mRNA or from fusion proteins that can then be expressed from an open reading frame.

5

## TISSUE SPECIFIC PROMOTERS

The promoter of the present invention may be constitutively efficient, or may be tissue or temporally restricted in their activity.

10

Preferably the promoter is a constitutive promoter such as CMV.

Preferably the promoters of the present invention are tissue specific.

15 That is, they are capable of driving transcription of a NOI or NOI(s) in one tissue while remaining largely "silent" in other tissue types.

The term "tissue specific" means a promoter which is not restricted in activity to a single tissue type but which nevertheless shows selectivity in that they may be active in one group of tissues and less active or silent in another group.

20

The level of expression of an NOI or NOIs under the control of a particular promoter may be modulated by manipulating the promoter region. For example, different domains within a promoter region may possess different gene regulatory activities. The roles of these different regions are typically assessed using vector constructs having different variants of the promoter with specific regions deleted (that is, deletion analysis). This approach may be used to identify, for example, the smallest region capable of conferring tissue specificity or the smallest region conferring hypoxia sensitivity.

25

30 A number of tissue specific promoters, described above, may be particularly advantageous in practising the present invention. In most instances, these promoters may be isolated as convenient restriction digestion fragments suitable for cloning in a selected vector. Alternatively, promoter fragments may be isolated using the polymerase chain

-21-

reaction. Cloning of the amplified fragments may be facilitated by incorporating restriction sites at the 5' end of the primers.

5 The NOI or NOIs may be under the expression control of an expression regulatory element, such as a promoter and enhancer.

Preferably the ischaemic responsive promoter is a tissue restricted ischaemic responsive promoter.

10 Preferably the tissue restricted ischaemic responsive promoter is a macrophage specific promoter restricted by repression.

Preferably the tissue restricted ischaemic responsive promoter is an endothelium specific promoter.

15 Preferably the regulated retroviral vector of the present invention is an ILRE regulated retroviral vector.

20 Preferably the regulated retroviral vector of the present invention is an ILRE regulated lentiviral vector.

Preferably the regulated retroviral vector of the present invention is an autoregulated hypoxia responsive lentiviral vector.

25 Preferably the regulated retroviral vector of the present invention is regulated by glucose concentration.

30 For example, the glucose-regulated proteins (grp's) such as grp78 and grp94 are highly conserved proteins known to be induced by glucose deprivation (Attenello and Lee 1984 Science 226 187-190). The grp 78 gene is expressed at low levels in most normal healthy tissues under the influence of basal level promoter elements but has at least two critical "stress inducible regulatory elements" upstream of the TATA element (Attenello 1984 *ibid*; Gazit *et al* 1995 Cancer Res 55: 1660-1663). Attachment to a truncated 632 base

-22-

pair sequence of the 5' end of the *grp78* promoter confers high inducibility to glucose deprivation on reporter genes *in vitro* (Gazit *et al* 1995 *ibid*). Furthermore, this promoter sequence in retroviral vectors was capable of driving a high level expression of a reporter gene in tumour cells in murine fibrosarcomas, particularly in central relatively ischaemic/fibrotic sites (Gazit *et al* 1995 *ibid*).

Preferably the regulated retroviral vector of the present invention is a self-inactivating (SIN) vector.

By way of example, self-inactivating retroviral vectors have been constructed by deleting the transcriptional enhancers or the enhancers and promoter in the U3 region of the 3' LTR. After a round of vector reverse transcription and integration, these changes are copied into both the 5' and the 3' LTRs producing a transcriptionally inactive provirus (Yu *et al* 1986 Proc Natl Acad Sci 83: 3194-3198; Dougherty and Temin 1987 Proc Natl Acad Sci 84: 1197-1201; Hawley *et al* 1987 Proc Natl Acad Sci 84: 2406-2410; Yee *et al* 1987 Proc Natl Acad Sci 91: 9564-9568). However, any promoter(s) internal to the LTRs in such vectors will still be transcriptionally active. This strategy has been employed to eliminate effects of the enhancers and promoters in the viral LTRs on transcription from internally placed genes. Such effects include increased transcription (Jolly *et al* 1983 Nucleic Acids Res 11: 1855-1872) or suppression of transcription (Emerman and Temin 1984 Cell 39: 449-467). This strategy can also be used to eliminate downstream transcription from the 3' LTR into genomic DNA (Herman and Coffin 1987 Science 236: 845-848). This is of particular concern in human gene therapy where it is of critical importance to prevent the adventitious activation of an endogenous oncogene.

## RETROVIRAL VECTORS

The regulated retroviral vector of the present invention includes but is not limited to: murine leukemia virus (MLV), human immunodeficiency virus (HIV), equine infectious anaemia virus (EIAV), feline immunodeficiency virus (FIV), caprine encephalitis-arthritis virus (CAEV), mouse mammary tumour virus (MMTV), Rous sarcoma virus (RSV), Fujinami sarcoma virus (FuSV), Moloney murine leukemia virus (Mo-MLV), FBR murine osteosarcoma virus (FBR MSV), Moloney murine sarcoma virus (Mo-MSV),

-23-

Abelson murine leukemia virus (A-MLV), Avian myelocytomatosis virus-29 (MC29), and Avian erythroblastosis virus (AEV).

5 A detailed list of retroviruses may be found in Coffin *et al* ("Retroviruses" 1997 Cold Spring Harbour Laboratory Press Eds: JM Coffin, SM Hughes, HE Varmus pp 758-763).

Preferred vectors for use in accordance with the present invention are retroviral vectors, such as MLV vectors.

10 Preferably the recombinant retroviral vectors of the present invention are lentiviral vectors, more preferably HIV or EIAV vectors.

#### LENTIVIRAL VECTORS

15 The lentiviruses can be divided into primate and non-primate groups. Examples of primate lentiviruses include but are not limited to: the human immunodeficiency virus (HIV), the causative agent of human auto-immunodeficiency syndrome (AIDS), and the simian immunodeficiency virus (SIV). The non-primate lentiviral group includes the prototype "slow virus" visna/maedi virus (VMV), as well as the related caprine arthritis-  
20 encephalitis virus (CAEV), equine infectious anaemia virus (EIAV) and the more recently described feline immunodeficiency virus (FIV) and bovine immunodeficiency virus (BIV).

A distinction between the lentivirus family and other types of retroviruses is that  
25 lentiviruses have the capability to infect both dividing and non-dividing cells (Lewis *et al* 1992 EMBO. J 11: 3053-3058; Lewis and Emerman 1994 J. Virol. 68: 510-516). In contrast, other retroviruses - such as MLV - are unable to infect non-dividing cells such as those that make up, for example, muscle, brain, lung and liver tissue.

30 Preferred vectors for use in accordance with the present invention are recombinant retroviral vectors, in particular recombinant lentiviral vectors, in particular minimal lentiviral vectors which are disclosed in WO 99/32646 and in WO98/17815.

## VECTOR

As used herein, a "vector" denotes a tool that allows or facilitates the transfer of an entity from one environment to another. In accordance with the present invention, and by way of example, some vectors used in recombinant DNA techniques allow entities, such as a segment of DNA (such as a heterologous DNA segment, such as a heterologous cDNA segment), to be transferred into a target cell. Optionally, once within the target cell, the vector may then serve to maintain the heterologous DNA within the cell or may act as a unit of DNA replication. Examples of vectors used in recombinant DNA techniques include plasmids, chromosomes, artificial chromosomes or viruses.

## OPERABLY LINKED

The term "operably linked" denotes a relationship between a regulatory region (typically a promoter element, but may include an enhancer element) and the coding region of a gene, whereby the transcription of the coding region is under the control of the regulatory region.

## DERIVABLE

The term "derivable" is used in its normal sense as meaning a nucleotide sequence such as an LTR or a part thereof which need not necessarily be obtained from a vector such as a retroviral vector but instead could be derived therefrom. By way of example, the sequence may be prepared synthetically or by use of recombinant DNA techniques.

## VECTOR PARTICLES

In the present invention, several terms are used interchangeably. Thus, "virion", "virus", "viral particle", "retroviral particle", "retrovirus", and "vector particle" mean virus and virus-like particles that are capable of introducing a nucleic acid into a cell through a viral-like entry mechanism. Such vector particles can, under certain circumstances, mediate the transfer of NOIs into the cells they infect. A retrovirus is capable of reverse

-25-

transcribing its genetic material into DNA and incorporating this genetic material into a target cell's DNA upon transduction. Such cells are designated herein as "target cells".

5 A vector particle includes the following components: a retrovirus nucleic acid, which may contain one or more NOIs, a nucleocapsid encapsidating the nucleic acid, the nucleocapsid comprising nucleocapsid protein of a retrovirus, and a membrane surrounding the nucleocapsid.

### NUCLEOCAPSID

10

The term "nucleocapsid" refers to at least the group specific viral core proteins (*gag*) and the viral polymerase (*pol*) of a retrovirus genome. These proteins encapsidate the retrovirus-packagable sequences and themselves are further surrounded by a membrane containing an envelope glycoprotein.

15

Preferably a high titre retroviral vector is produced using a codon optimised *gag* and a codon optimised *pol* or a codon optimised *env*.

### CODON OPTIMISATION

20

As used herein, the terms "codon optimised" and "codon optimisation" refer to an improvement in codon usage. By way of example, alterations to the coding sequences for viral components may improve the sequences for codon usage in the mammalian cells or  
25 other cells which are to act as the producer cells for retroviral vector particle production. This is referred to as "codon optimisation". Many retroviruses, including HIV and other lentiviruses, use a large number of rare codons and by changing these to correspond to commonly used mammalian codons, increased expression of the packaging components in mammalian producer cells can be achieved. Codon usage tables are known in the art  
30 for mammalian cells, as well as for a variety of other organisms.

Preferably a high titre lentiviral vector is produced using a codon optimised *gag* and a codon optimised *pol* or a codon optimised *env*.

-26-

Preferably a high titre retroviral vector is produced using a modified and/or extended packaging signal.

### PACKAGING SIGNAL

5

As used herein, the term "packaging signal" or "packaging sequence" refers to sequences located within the retroviral genome which are required for insertion of the viral RNA into the viral capsid or particle. Several retroviral vectors use the minimal packaging signal (also referred to as the psi sequence) needed for encapsidation of the viral genome.

10 By way of example, this minimal packaging signal encompasses bases 212 to 563 of the Mo-MLV genome (Mann et al 1983: Cell 33: 153).

As used herein, the term "extended packaging signal" or "extended packaging sequence" refers to the use of sequences around the psi sequence with further extension into the gag  
15 gene. The inclusion of these additional packaging sequences may increase the efficiency of insertion of vector RNA into viral particles.

Preferably a high titre lentiviral vector is produced using a modified packaging signal.

20 Preferably the lentiviral construct is based on an EIAV vector genome where all the accessory genes are removed except Rev.

### ACCESSORY GENES

25 As used herein, the term "accessory genes" refer to a variety of virally encoded accessory proteins capable of modulating various aspects of retroviral replication and infectivity. These proteins are discussed in Coffin et al (ibid) (Chapters 6 and 7). Examples of accessory proteins in lentiviral vectors include but are not limited to tat, rev, nef, vpr, vpu, vif, vpx. An example of a lentiviral vector useful in the present invention is one which  
30 has all of the accessory genes removed except rev.

Preferably the production of lentiviral vector particles is increased by about 10 fold in the presence of EIAV Rev.

-27-

## ENV

If the retroviral component includes an *env* nucleotide sequence, then all or part of that sequence can be optionally replaced with all or part of another *env* nucleotide sequence  
5 such as, by way of example, the amphotropic Env protein designated 4070A or the influenza haemagglutinin (HA) or the vesicular stomatitis virus G (VSV-G) protein. Replacement of the *env* gene with a heterologous *env* gene is an example of a technique or strategy called pseudotyping. Pseudotyping is not a new phenomenon and examples may be found in WO-A-98/05759, WO-A-98/05754, WO-A-97/17457, WO-A-96/09400,  
10 WO-A-91/00047 and Mebatsion *et al* 1997 Cell 90, 841-847.

In one preferred aspect, the retroviral vector of the present invention has been pseudotyped. In this regard, pseudotyping can confer one or more advantages. For example, with the lentiviral vectors, the *env* gene product of the HIV based vectors would  
15 restrict these vectors to infecting only cells that express a protein called CD4. But if the *env* gene in these vectors has been substituted with *env* sequences from other RNA viruses, then they may have a broader infectious spectrum (Verma and Somia 1997 Nature 389:239-242). By way of example, workers have pseudotyped an HIV based vector with the glycoprotein from VSV (Verma and Somia 1997 *ibid*).

20

In another alternative, the Env protein may be a modified Env protein such as a mutant or engineered Env protein. Modifications may be made or selected to introduce targeting ability or to reduce toxicity or for another purpose (Valsecia-Wittman *et al* 1996 J Virol 70: 2056-64; Nilson *et al* 1996 Gene Therapy 3: 280-6; Fielding *et al* 1998 Blood 9: 1802  
25 and references cited therein).

## TARGET CELL

As used herein the term "target cell" simply refers to a cell which the regulated retroviral  
30 vector of the present invention, whether native or targeted, is capable of infecting or transducing.



-28-

The lentiviral vector particle according to the invention will be capable of transducing cells which are slowly-dividing, and which non-lentiviruses such as MLV would not be able to efficiently transduce. Slowly-dividing cells divide once in about every three to four days including certain tumour cells. Although tumours contain rapidly dividing  
5 cells, some tumour cells especially those in the centre of the tumour, divide infrequently.

Alternatively the target cell may be a growth-arrested cell capable of undergoing cell division such as a cell in a central portion of a tumour mass or a stem cell such as a haematopoietic stem cell or a CD34-positive cell.

10

As a further alternative, the target cell may be a precursor of a differentiated cell such as a monocyte precursor, a CD33-positive cell, or a myeloid precursor..

As a further alternative, the target cell may be a differentiated cell such as a neuron,  
15 astrocyte, glial cell, microglial cell, macrophage, monocyte, epithelial cell, endothelial cell, hepatocyte, spermatocyte, spermatid or spermatozoa.

Target cells may be transduced either *in vitro* after isolation from a human individual or may be transduced directly *in vivo*.

20 NOI

In accordance with the present invention, it is possible to manipulate the viral genome or the regulated retroviral vector nucleotide sequence, so that viral genes are replaced or supplemented with one or more NOIs which may be heterologous NOIs.

25

The term "heterologous" refers to a nucleic acid sequence or protein sequence linked to a nucleic acid or protein sequence which it is not naturally linked.

With the present invention, the term NOI (i.e. nucleotide sequence of interest) includes  
30 any suitable nucleotide sequence, which need not necessarily be a complete naturally occurring DNA sequence. Thus, the DNA sequence can be, for example, a synthetic DNA sequence, a recombinant DNA sequence (i.e. prepared by use of recombinant DNA techniques), a cDNA sequence or a partial genomic DNA sequence, including

-29-

combinations thereof. The DNA sequence need not be a coding region. If it is a coding region, it need not be an entire coding region. In addition, the DNA sequence can be in a sense orientation or in an anti-sense orientation. Preferably, it is in a sense orientation. Preferably, the DNA is or comprises cDNA.

5

The NOI(s) may be any one or more of selection gene(s), marker gene(s) and therapeutic gene(s). As used herein, the term "selection gene" refers to the use of a NOI which encodes a selectable marker which may have an enzymatic activity that confers resistance to an antibiotic or drug upon the cell in which the selectable marker is expressed.

10

## SELECTABLE MARKERS

Many different selectable markers have been used successfully in retroviral vectors. These are reviewed in "Retroviruses" (1997 Cold Spring Harbour Laboratory Press Eds: JM Coffin, SM Hughes, HE Varmus pp 444) and include, but are not limited to, the bacterial neomycin (neo) and hygromycin phosphotransferase genes which confer resistance to G418 and hygromycin respectively; a mutant mouse dihydrofolate reductase gene which confers resistance to methotrexate; the bacterial *gpt* gene which allows cells to grow in medium containing mycophenolic acid, xanthine and aminopterin; the bacterial *hisD* gene which allows cells to grow in medium without histidine but containing histidinol; the multidrug resistance gene (*mdr*) which confers resistance to a variety of drugs; and the bacterial genes which confer resistance to puromycin or phleomycin. All of these markers are dominant selectable and allow chemical selection of most cells expressing these genes. Other selectable markers are not dominant in that their use must be in conjunction with a cell line that lacks the relevant enzyme activity. Examples of non-dominant selectable markers include the thymidine kinase (*tk*) gene which is used in conjunction with *tk* cell lines.

25

Particularly preferred markers are blasticidin and neomycin, optionally operably linked to a thymidine kinase coding sequence typically under the transcriptional control of a strong viral promoter such the SV40 promoter.

30

## NOIs WITH THERAPEUTIC AND/OR DIAGNOSTIC APPLICATIONS

In accordance with the present invention, suitable NOI sequences include those that are of therapeutic and/or diagnostic application such as, but are not limited to: sequences  
5 encoding cytokines, chemokines, hormones, antibodies, engineered immunoglobulin-like molecules, a single chain antibody, fusion proteins, enzymes, immune co-stimulatory molecules, immunomodulatory molecules, anti-sense RNA, a transdominant negative mutant of a target protein, a toxin, a conditional toxin, an antigen, a tumour suppressor protein and growth factors, membrane proteins, vasoactive proteins and peptides, anti-  
10 viral proteins and ribozymes, and derivatives thereof (such as with an associated reporter group). When included, such coding sequences may be typically operatively linked to a suitable promoter, which may be a promoter driving expression of a ribozyme(s), or a different promoter or promoters, such as in one or more specific cell types.

## 15 NOIs FOR TREATING CANCER

Suitable NOIs for use in the invention in the treatment or prophylaxis of cancer include NOIs encoding proteins which: destroy the target cell (for example a ribosomal toxin), act  
as: tumour suppressors (such as wild-type p53); activators of anti-tumour immune  
20 mechanisms (such as cytokines, co-stimulatory molecules and immunoglobulins); inhibitors of angiogenesis; or which provide enhanced drug sensitivity (such as pro-drug activation enzymes); indirectly stimulate destruction of target cell by natural effector cells (for example, strong antigen to stimulate the immune system or convert a precursor substance to a toxic substance which destroys the target cell (for example a prodrug  
25 activating enzyme).

## PRO-DRUG ACTIVATING ENZYMES

Examples of prodrugs include but are not limited to etoposide phosphate (used with  
30 alkaline phosphatase; 5-fluorocytosine (with cytosine deaminase); Doxorubin-N-p-hydroxyphenoxyacetamide (with Penicillin-V-Amidase); Para-N-bis (2-chloroethyl)aminobenzoyl glutamate (with Carboxypeptidase G2); Cephalosporin nitrogen mustard carbamates (with B-lactamase); SR4233 (with p450 reductase);

-31-

Ganciclovir (with HSV thymidine kinase); mustard pro-drugs with nitroreductase and cyclophosphamide or ifosfamide (with cytochrome p450).

## NOIs FOR TREATING HEART DISEASE

5

Suitable NOIs for use in the treatment or prevention of ischaemic heart disease include NOIs encoding plasminogen activators. Suitable NOIs for the treatment or prevention of rheumatoid arthritis or cerebral malaria include genes encoding anti-inflammatory proteins, antibodies directed against tumour necrosis factor (TNF) alpha, and anti-  
10 adhesion molecules (such as antibody molecules or receptors specific for adhesion molecules).

## BYSTANDER EFFECT

15 The expression products encoded by the NOIs may be proteins which are secreted from the cell. Alternatively the NOI expression products are not secreted and are active within the cell. In either event, it is preferred for the NOI expression product to demonstrate a bystander effector or a distant bystander effect; that is the production of the expression product in one cell leading to the killing of additional, related cells, either neighbouring or  
20 distant (e.g. metastatic), which possess a common phenotype. Encoded proteins could also destroy bystander tumour cells (for example with secreted antitumour antibody-ribosomal toxin fusion protein), indirectly stimulated destruction of bystander tumour cells (for example cytokines to stimulate the immune system or procoagulant proteins causing local vascular occlusion) or convert a precursor substance to a toxic substance  
25 which destroys bystander tumour cells (eg an enzyme which activates a prodrug to a diffusible drug). Also, the delivery of NOI(s) encoding antisense transcripts or ribozymes which interfere with expression of cellular genes for tumour persistence (for example against aberrant *myc* transcripts in Burkitts lymphoma or against *bcr-abl* transcripts in chronic myeloid leukemia. The use of combinations of such NOIs is also envisaged.

30

## CYTOKINES

The NOI or NOIs of the present invention may also comprise one or more cytokine-encoding NOIs. Suitable cytokines and growth factors include but are not limited to:

5 ApoE, Apo-SAA, BDNF, Cardiotrophin-1, EGF, ENA-78, Eotaxin, Eotaxin-2, Exodus-2, FGF-acidic, FGF-basic, fibroblast growth factor-10 (Marshall 1998 Nature Biotechnology 16: 129).FLT3 ligand (Kimura *et al* (1997), Fractalkine (CX3C), GDNF, G-CSF, GM-CSF, GF- $\beta$ 1, insulin, IFN- $\gamma$ , IGF-I, IGF-II, IL-1 $\alpha$ , IL-1 $\beta$ , IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8 (72 a.a.), IL-8 (77 a.a.), IL-9, IL-10, IL-11, IL-12, IL-13, IL-15, IL-16, IL-17, IL-

10 18 (IGIF), Inhibin  $\alpha$ , Inhibin  $\beta$ , IP-10, keratinocyte growth factor-2 (KGF-2), KGF, Leptin, LIF, Lymphotoxin, Mullerian inhibitory substance, monocyte colony inhibitory factor, monocyte attractant protein (Marshall 1998 *ibid*), M-CSF, MDC (67 a.a.), MDC (69 a.a.), MCP-1 (MCAF), MCP-2, MCP-3, MCP-4, MDC (67 a.a.), MDC (69 a.a.), MIG, MIP-1 $\alpha$ , MIP-1 $\beta$ , MIP-3 $\alpha$ , MIP-3 $\beta$ , MIP-4, myeloid progenitor inhibitor factor-1

15 (MPIF-1), NAP-2, Neurturin, Nerve growth factor,  $\beta$ -NGF, NT-3, NT-4, Oncostatin M, PDGF-AA, PDGF-AB, PDGF-BB, PF-4, RANTES, SDF1 $\alpha$ , SDF1 $\beta$ , SCF, SCGF, stem cell factor (SCF), TARC, TGF- $\alpha$ , TGF- $\beta$ , TGF- $\beta$ 2, TGF- $\beta$ 3, tumour necrosis factor (TNF), TNF- $\alpha$ , TNF- $\beta$ , TNIL-1, TPO, VEGF, GCP-2, GRO/MGSA, GRO- $\beta$ , GRO- $\gamma$ , HCC1, 1-309.

20

The NOI or NOIs may be under the expression control of an expression regulatory element, such as a promoter and/or a promoter enhancer as known as "responsive elements" in the present invention.

## 25 VIRAL DELIVERY SYSTEMS

When the regulated retroviral vector particles are used to transfer NOIs into cells which they transduce, such vector particles also designated "viral delivery systems" or "retroviral delivery systems". Viral vectors, including retroviral vectors, have been used

30 to transfer NOIs efficiently by exploiting the viral transduction process. NOIs cloned into the retroviral genome can be delivered efficiently to cells susceptible to transduction by a retrovirus. Through other genetic manipulations, the replicative capacity of the retroviral

-33-

genome can be destroyed. The vectors introduce new genetic material into a cell but are unable to replicate.

The regulated retroviral vector of the present invention can be delivered by viral or non-viral techniques. Non-viral delivery systems include but are not limited to DNA transfection methods. Here, transfection includes a process using a non-viral vector to deliver a gene to a target mammalian cell.

Typical transfection methods include electroporation, DNA biolistics, lipid-mediated transfection, compacted DNA-mediated transfection, liposomes, immunoliposomes, lipofectin, cationic agent-mediated, cationic facial amphiphiles (CFAs) (Nature Biotechnology 1996 14; 556), multivalent cations such as spermine, cationic lipids or polylysine, 1, 2-bis (oleoyloxy)-3-(trimethylammonio) propane (DOTAP)-cholesterol complexes (Wolff and Trubetskoy 1998 Nature Biotechnology 16: 421) and combinations thereof.

Viral delivery systems include but are not limited to adenovirus vector, an adeno-associated viral (AAV) vector, a herpes viral vector, a retroviral vector, a lentiviral vector, or a baculoviral vector. These viral delivery systems may be configured as a split-intron vector. A split intron vector is described in WO 99/15683.

Other examples of vectors include *ex vivo* delivery systems, which include but are not limited to DNA transfection methods such as electroporation, DNA biolistics, lipid-mediated transfection, compacted DNA-mediated transfection.

The vector may be a plasmid DNA vector. Alternatively, the vector may be a recombinant viral vector. Suitable recombinant viral vectors include adenovirus vectors, adeno-associated viral (AAV) vectors, Herpes-virus vectors, or retroviral vectors, lentiviral vectors or a combination of adenoviral and lentiviral vectors. In the case of viral vectors, gene delivery is mediated by viral infection of a target cell.

-34-

If the features of adenoviruses are combined with the genetic stability of retro/lentiviruses then essentially the adenovirus can be used to transduce target cells to become transient retroviral producer cells that could stably infect neighbouring cells.

## 5 PHARMACEUTICAL COMPOSITION

The present invention also provides a pharmaceutical composition for treating an individual by gene therapy, wherein the composition comprises a therapeutically effective amount of a regulated retroviral vector according to the present invention. The  
10 pharmaceutical composition may be for human or animal usage. Typically, a physician will determine the actual dosage which will be most suitable for an individual subject and it will vary with the age, weight and response of the particular patient.

The composition may optionally comprise a pharmaceutically acceptable carrier, diluent,  
15 excipient or adjuvant. The choice of pharmaceutical carrier, excipient or diluent can be selected with regard to the intended route of administration and standard pharmaceutical practice. The pharmaceutical compositions may comprise as - or in addition to - the carrier, excipient or diluent any suitable binder(s), lubricant(s), suspending agent(s), coating agent(s), solubilising agent(s), and other carrier agents that may aid or increase  
20 the viral entry into the target site (such as for example a lipid delivery system).

Where appropriate, the pharmaceutical compositions can be administered by any one or more of: minipumps, inhalation, in the form of a suppository or pessary, topically in the form of a lotion, solution, cream, ointment or dusting powder, by use of a skin patch,  
25 orally in the form of tablets containing excipients such as starch or lactose, or in capsules or ovules either alone or in admixture with excipients, or in the form of elixirs, solutions or suspensions containing flavouring or colouring agents, or they can be injected parenterally, for example intracavernosally, intravenously, intramuscularly or subcutaneously. For parenteral administration, the compositions may be best used in the  
30 form of a sterile aqueous solution which may contain other substances, for example enough salts or monosaccharides to make the solution isotonic with blood. For buccal or sublingual administration the compositions may be administered in the form of tablets or lozenges which can be formulated in a conventional manner.

## DISORDERS

The present invention is believed to have a wide therapeutic applicability - depending on *inter alia* the selection of the one or more NOIs.

5

For example, the present invention may be useful in the treatment of the disorders listed in WO-A-98/05635. For ease of reference, part of that list is now provided: cancer, inflammation or inflammatory disease, dermatological disorders, fever, cardiovascular effects, haemorrhage, coagulation and acute phase response, cachexia, anorexia, acute  
10 infection, HIV infection, shock states, graft-versus-host reactions, autoimmune disease, reperfusion injury, meningitis, migraine and aspirin-dependent anti-thrombosis; tumour growth, invasion and spread, angiogenesis, metastases, malignant, ascites and malignant pleural effusion; cerebral ischaemia, ischaemic heart disease, osteoarthritis, rheumatoid arthritis, osteoporosis, asthma, multiple sclerosis, neurodegeneration, Alzheimer's disease,  
15 atherosclerosis, stroke, vasculitis, Crohn's disease and ulcerative colitis; periodontitis, gingivitis; psoriasis, atopic dermatitis, chronic ulcers, epidermolysis bullosa; corneal ulceration, retinopathy and surgical wound healing; rhinitis, allergic conjunctivitis, eczema, anaphylaxis; restenosis, congestive heart failure, endometriosis, atherosclerosis or endosclerosis.

20

In addition, or in the alternative, the present invention may be useful in the treatment of disorders listed in WO-A-98/07859. For ease of reference, part of that list is now provided: cytokine and cell proliferation/differentiation activity; immunosuppressant or immunostimulant activity (e.g. for treating immune deficiency, including infection with  
25 human immune deficiency virus; regulation of lymphocyte growth; treating cancer and many autoimmune diseases, and to prevent transplant rejection or induce tumour immunity); regulation of haematopoiesis, e.g. treatment of myeloid or lymphoid diseases; promoting growth of bone, cartilage, tendon, ligament and nerve tissue, e.g. for healing wounds, treatment of burns, ulcers and periodontal disease and neurodegeneration;  
30 inhibition or activation of follicle-stimulating hormone (modulation of fertility); chemotactic/chemokinetic activity (e.g. for mobilising specific cell types to sites of injury or infection); haemostatic and thrombolytic activity (e.g. for treating haemophilia and stroke); antiinflammatory activity (for treating e.g. septic shock or Crohn's disease); as



antimicrobials; modulators of e.g. metabolism or behaviour; as analgesics; treating specific deficiency disorders; in treatment of e.g. psoriasis, in human or veterinary medicine.

- 5 In addition, or in the alternative, the present invention may be useful in the treatment of disorders listed in WO-A-98/09985. For ease of reference, part of that list is now provided: macrophage inhibitory and/or T cell inhibitory activity and thus, anti-inflammatory activity; anti-immune activity, i.e. inhibitory effects against a cellular and/or humoral immune response, including a response not associated with inflammation;
- 10 inhibit the ability of macrophages and T cells to adhere to extracellular matrix components and fibronectin, as well as up-regulated fas receptor expression in T cells; inhibit unwanted immune reaction and inflammation including arthritis, including rheumatoid arthritis, inflammation associated with hypersensitivity, allergic reactions, asthma, systemic lupus erythematosus, collagen diseases and other autoimmune diseases,
- 15 inflammation associated with atherosclerosis, arteriosclerosis, atherosclerotic heart disease, reperfusion injury, cardiac arrest, myocardial infarction, vascular inflammatory disorders, respiratory distress syndrome or other cardiopulmonary diseases, inflammation associated with peptic ulcer, ulcerative colitis and other diseases of the gastrointestinal tract, hepatic fibrosis, liver cirrhosis or other hepatic diseases, thyroiditis or other
- 20 glandular diseases, glomerulonephritis or other renal and urologic diseases, otitis or other oto-rhino-laryngological diseases, dermatitis or other dermal diseases, periodontal diseases or other dental diseases, orchitis or epididymo-orchitis, infertility, orchidial trauma or other immune-related testicular diseases, placental dysfunction, placental insufficiency, habitual abortion, eclampsia, pre-eclampsia and other immune and/or
- 25 inflammatory-related gynaecological diseases, posterior uveitis, intermediate uveitis, anterior uveitis, conjunctivitis, chorioretinitis, uveoretinitis, optic neuritis, intraocular inflammation, e.g. retinitis or cystoid macular oedema, sympathetic ophthalmia, scleritis, retinitis pigmentosa, immune and inflammatory components of degenerative fundus disease, inflammatory components of ocular trauma, ocular inflammation caused by
- 30 infection, proliferative vitreo-retinopathies, acute ischaemic optic neuropathy, excessive scarring, e.g. following glaucoma filtration operation, immune and/or inflammation reaction against ocular implants and other immune and inflammatory-related ophthalmic diseases, inflammation associated with autoimmune diseases or conditions or disorders

where, both in the central nervous system (CNS) or in any other organ, immune and/or inflammation suppression would be beneficial, Parkinson's disease, complication and/or side effects from treatment of Parkinson's disease, AIDS-related dementia complex HIV-related encephalopathy, Devic's disease, Sydenham chorea, Alzheimer's disease and other  
5 degenerative diseases, conditions or disorders of the CNS, inflammatory components of stokes, post-polio syndrome, immune and inflammatory components of psychiatric disorders, myelitis, encephalitis, subacute sclerosing pan-encephalitis, encephalomyelitis, acute neuropathy, subacute neuropathy, chronic neuropathy, Guillain-Barre syndrome, Sydenham chora, myasthenia gravis, pseudo-tumour cerebri, Down's Syndrome,  
10 Huntington's disease, amyotrophic lateral sclerosis, inflammatory components of CNS compression or CNS trauma or infections of the CNS, inflammatory components of muscular atrophies and dystrophies, and immune and inflammatory related diseases, conditions or disorders of the central and peripheral nervous systems, post-traumatic inflammation, septic shock, infectious diseases, inflammatory complications or side  
15 effects of surgery, bone marrow transplantation or other transplantation complications and/or side effects, inflammatory and/or immune complications and side effects of gene therapy, e.g. due to infection with a viral carrier, or inflammation associated with AIDS, to suppress or inhibit a humoral and/or cellular immune response, to treat or ameliorate monocyte or leukocyte proliferative diseases, e.g. leukaemia, by reducing the amount of  
20 monocytes or lymphocytes, for the prevention and/or treatment of graft rejection in cases of transplantation of natural or artificial cells, tissue and organs such as cornea, bone marrow, organs, lenses, pacemakers, natural or artificial skin tissue.

## INTRODUCTION TO THE EXAMPLES SECTION AND THE FIGURES

25

The present invention will now be described only by way of example in which reference is made to the following Figures:

Figure 1 shows an MLV-based transduction method using a Cre/LoxP system as  
30 described by Vanin *et al ibid* (1997);

Figure 2 shows an EIAV-based transduction method using a Cre/Lox system;

Figure 3 shows an MLV SIN vector construct transduction method with an EIAV/HIV genome insertion using a Cre/Lox system;

Figure 4 shows an MLV-based transduction method with HRE 3'LTR using a Cre/Lox P system;

Figure 5 shows an MLV-based transduction method for MLV SIN vector production using a Cre/Lox P system;

Figure 6 shows an MLV-based transduction method with integration of a complete second genome construct using a Cre/LoxP system;

Figure 7 shows the basis molecular organisation of an RNA genome and a proviral DNA genome;

Figure 8 shows a schematic diagram of pTrap2 and pONY8z-loxP plasmids;

Figure 9 shows an overall summary of the recombinase method;

Figure 10a shows a FACS analysis of EV1 packaging cells prior to transduction with Trap2 vector;

Figure 10b shows FACS analysis of EV1 packaging cell line transduced with Trap2 at an MOI of 0.3. A 5% top slice of the highest expressers was carried out;

Figure 11 shows a validation of the method for quantitation of GFP mRNA, relative to  $\beta$ -actin. A titration of the total RNA from EV1 clone A was used. The difference in Ct values between the two assays is shown on the y axis. The magnitude of the gradient must be  $<0.1$  for the method to be valid. The gradient is 0.077, so the method is suitable;

Figure 12 shows the quantitation of GFP mRNA relative to control  $\beta$ -actin mRNA. EV2 TD cells are transduced with Trap2 at an MOI of 0.3 and are the calibrator sample with the ratio designated 1.0;

-39-

Figure 13 shows FACS analysis of EV1 clone A:

Figure 13A shows original GFP expression of the clone;

- 5    Figure 13B shows GFP expression 7 days after transfection with Cre recombinase (pBS185). Excision frequency is 64%;

Figure 13C shows recombined clone 4 identified as being negative for GFP:

- 10   Figure 14 shows lacZ expression of transfected cells with and without the addition of the Cre recombinase (pBS185). Figure 14 shows EV1A4 and EV2D4 clones with and without the addition of Cre recombinase (pBS185). The efficiency of the insertion event was estimated to be about 12% by computer image analysis;

- 15   Figure 15 shows the structure of pONY8.1Z MLVHyb;

- Figure 16 shows the alignment of leader and gag regions present in vectors pONY4Z, 8Z and ATG mutated 8Z vector. The latter is referred to as pONY8ZA. The sequences aligned are from the NarI site in the leader to the XbaI site between the EIAV gag sequence and the CMV promoter. Sequences in the leader are shown in italic and a space is present upstream of the position of the gag ATG; and
- 20

Figure 17 shows a schematic representation of the structure of pONY 8.3G +/- vector genome plasmids.

25

## EXAMPLES

### EXAMPLE 1

- 30   Vanin *et al* (*ibid*) describe a recombinase system whereby an initial retroviral transduction event introduces retroviral LTRs and expressed gene/s flanked by two recombinase target sites (exemplified by loxP) into a cell line. Stable transduced cell lines are selected by resistance to the antibiotic neomycin and screened for high expression of

-40-

the expressed gene(s) (see Figure 1). Such cell lines (Cell Line 1) contain retroviral insertions in integration sites that support high level expression from the retroviral genome.

5 The next step involves the transfection of the relevant recombinase expression construct (exemplified here by Cre recombinase) into the identified high expressing cell line. The expressed gene(s) is/are excised and a single loxP site is retained in the construct (Cell Line 2). In this instance, thymidine kinase gene (tk) is used as a negative selectable marker in combination with the drug, gancyclovir. The final step involves the re-  
10 insertion of a therapeutic or marker gene of choice into the single loxP site via a Cre-assisted mechanism. Cell lines are identified that have been successfully recombined (Cell Line 3) and they will produce retroviruses at the same titre as the parental Cell Line 1.

## 15 EXAMPLE 2

Figure 2 and Figure 3 describe the production of EIAV or HIV high titre transduced producer cell lines.

20 Figure 2 shows a minimal EIAV genome construct with the 3' U3 sequences replaced by a strong constitutive promoter, CMV. A reporter gene such as blasticidin resistance gene (*bsr*) is flanked by loxP sites. Virus is made in a transient system and is transduced into an EIAV producer cell line and clones identified that maximally express the blast marker gene. A line is chosen (termed Cell Line 1) and the marker gene is excised by a Cre  
25 recombinase-assisted excision event, generating Cell Line 2.

Construct B comprises two loxP sites which flank an internal expression cassette and also the native EIAV 3' LTR. Therefore, this construct is recombined into the cell line such that the 5' R and U5 sequences are inherited from the packaging cell line, whereas the 3'  
30 LTR sequences are wholly derived from the recombined construct. The 3' LTR from Cell Line 2 is present downstream of the functional EIAV genome expression construct. This CMV-R-U5 module is still transcriptionally active but expression is directed away from the EIAV genome.

Figure 3 shows a further aspect of the invention. Construct C is based on an MLV SIN vector, with a deletion in the 3' U3 sequences. The cassette includes an internal CMV promoter linked to EIAV R and U5 sequences. This is followed by a blasticidin resistance gene (*bsr*) flanked by two loxP sites. Virus is made in a transient transfection system and the genome is transduced into a packaging line. Blast-resistant clones are identified and the highest expressing line is chosen for further analysis. This line is transfected with Cre recombinase and the blast gene is excised. The last step involves the insertion of construct B into the single loxP site. Once again, a complete EIAV 3' LTR is introduced into the producer cell line. This leads to a CMV-driven EIAV genome expression cassette with the EIAV 3' LTR still located at the 3' end of the genome. Transcriptionally quiescent MLV SIN LTRs flanks these EIAV sequences.

### EXAMPLE 3

Figure 4 shows an additional aspect of the invention. Construct D is an MLV-based vector with a CMV promoter in the 3' LTR in place of the U3 sequences. Virus is made in a transient system and is transduced into a packaging cell line as described previously. The neo and TK genes are excised by the action of Cre recombinase and construct E is recombined into the single loxP target sequence. The modified MLV 3' LTR including the HRE or similarly regulated system is transferred into the packaging cell line by the recombinase mechanism. Therefore, the 5' R and U5 sequences are inherited from the producer cell line whereas the therapeutic and marker gene/s and regulated 3' LTR is inherited from construct E. The final producer cell line is constitutively driven by the 5' CMV promoter and will produce high titre retroviral vectors which are regulated in the transduced target cells. This approach avoids the derivation of low titre transfected producer cell lines or the use of hypoxic conditions or chemical mimics for production from traditionally derived transduced producer lines.

### EXAMPLE 4

Figure 5 shows yet another aspect of the invention. Construct D is an MLV-based vector with a CMV promoter in the 3' LTR as previously described. The same process is carried

-42-

out as shown in Figure 4 until the final recombination is performed. Construct F contains a deletion in U3 sequences in the 3' LTR and an internal expression cassette comprising a promoter and gene sequences. The final cell line containing the Cre-mediated recombination will be CMV-driven and will constitutively produce high titre MLV SIN  
5 vectors. Previously, SIN vectors have not been amenable to production by stable cell line producer technology. Instead they have been prepared using transfection-based transient expression systems.

## EXAMPLE 5

10

Figure 6 shows an MLV-based transduction method with integration of complete second genome construct by Cre/LoxP system. In this approach, construct 1 is called TRAP1) is an MLV vector construct containing an internal CMV promoter operably linked to a marker gene (a truncated form of the human low affinity nerve growth factor receptor, called LNGFR). The enhancer elements in the 3' U3 sequence have been excised and  
15 replaced by a 34bp loxP site. Virus stocks are prepared in a transient system and the TRAP1 genome is stably transduced into packaging cell lines.

The modified 3'U3 sequences, including the lox P sequence, is copied from the 3'LTR position to the 5'LTR, such that there is little 5' promoter activity. Cell lines are screened for high levels of expression of LNGFR protein by fluorescent activated cell sorter (FACS) analysis and clonal lines are derived by standard techniques. A Cre recombinase expression plasmid is transfected into the derived cell line to excise all sequences between the two loxP sites. Next, cells are negatively selected by FACS for absence of  
20 LNGFR expression and clonal lines are derived by standard techniques. Construct 2 in this example comprises a complete HIV or EIAV or also MLV retroviral genome, which is flanked by two minimal 34bp loxP recombinase sites. A strong constitutive promoter such as CMV directs transcription of the genome. On transfection of plasmid 2 and Cre expression plasmid, the complete lentivirus vector or MLV vector genome is inserted in  
25 the producer cell line. These sequences are flanked to the 5' by a small portion of MLV U3 sequence and a loxP site and to the 3' by the second loxP site, enhancerless-U3 sequences, R and U5 derived from the MLV construct 1.

30

**Derivation of Plasmid TRAP1 (Figure 6 - Construct 1)**

Oligonucleotides VSAT129 and VSAT130 were synthesised which correspond to the  
5 minimal 34bp loxP sites and contain a 5' overhang for NheI and a 3' overhang for XbaI.  
The sequences 5' to 3' are as follows: VSAT129 (CTAGCATAACTTCGTATA  
ATGTATGCTATACGAAGTTATT) (SEQ ID No 49) and VSAT130  
(CTAGAATAACTTCGTATAGC ATACATTATACGAAGTTATG) (SEQ ID No 50).  
The two oligonucleotides were treated with T4 polynucleotide kinase and were heated to  
10 95°C for 5 minutes, before gradual cooling to room temperature. The annealed and  
kinased oligos were ligated to a 2,830 bp NheI/XbaI fragment from LTR plasmid (SEQ  
ID No 59). Fragments were ligated and correct clones of LTRloxP were identified by  
sequence analysis. Plasmid LTRloxP was then digested with NheI and ScaI and a  
2,185bp fragment was prepared for following cloning steps.

15

Plasmids TRAP1 and TRAP1G were derived from LTRloxP and the MLV genome  
CGCLNGFR (encodes GFP and LNGFR from an internal CMV promoter – see SEQ ID  
No 57). However, the GFP gene was excised by EcoRI/BsmI digestion and the 6,796bp  
fragment was filled in by T4 DNA polymerase and re-ligated, in order to generate  
20 plasmid CXCLNGFR. Plasmid TRAP1 was generated by ligation of a 2,185bp NheI/ScaI  
fragment from LTRloxP (see SEQ ID No 58) to a 4,426bp NheI/ScaI fragment from  
CXCLNGFR. Plasmid TRAP1G was generated by ligation of a 2,185bp NheI/ScaI  
fragment from LTRloxP to a 5,179bp NheI/ScaI fragment from CGCLNGFR.

**25 Derivation of Plasmid pONY8z-lox (Figure 6 - Construct 2)**

In this example, the retroviral genome inserted into the loxP site in Figure 6 was based on  
the EIAV vector genome, pONY8z (for preparation see pONY8.0Z construction below).  
pONY8z was cut with SnaBI and NruI, and the 4358bp fragment purified and self-ligated  
30 to form pONY8z-shuttle. This plasmid has unique 5' sites (DraIII and BglII) and unique  
3' sites (PvuII and BspLUII). Oligonucleotides encoding the 34bp loxP sites were  
inserted with suitable base pair overhangs at the unique 5' DraIII site and then the unique  
3' BspLUII, to generate plasmid pONY-8z-shuttleloxP.



Plasmid pONY8z-loxP was made as follows. Plasmid pONY-8z-shuttleloxP was digested with BsrG I and NspV, and the 3670bp fragment was purified as the vector fragment. The insert for ligation to this fragment was derived from pONY8z by partial  
5 digestion with BsrGI (two sites) followed by digestion with NspV. A 7,328bp fragment was purified and ligated to the 3670bp fragment described above.

The Cre recombinase plasmid as used in this system is pBS185 (Gibco).

## 10 EXAMPLE 6

We constructed an MLV self-inactivating (SIN) vector called pTrap2 (see SEQ ID No 56) by replacing the 3' U3 NheI-XbaI fragment with a 34-bp loxP sequence. The vector transcribes the marker gene GFP from an internal CMV promoter. Trap2 vector was used  
15 to transduce EIAV packaging cell lines EV1 and EV2. The EV cell lines are based on human TE671 cells and express EIAV gag/pol proteins and VSV-G envelope, regulated by a temperature-sensitive switch. High expressing clones of transduced EV1 and EV2 cells were identified by FACS analysis for GFP. Individual clones expressing high levels of GFP were then selected. The GFP expression cassette was excised following transient  
20 transfection with a Cre recombinase expression plasmid. The derived cell line, EV-loxP, contains a single loxP site and minimal sequences derived from the MLV construct pTrap2. An EIAV genome was engineered to contain loxP sites flanking the entire vector genome.

25 This genome construct and Cre recombinase were co-transfected into EV-loxP. Stable cell lines expressing lacZ were selected by FACS and cell lines were cloned by limiting dilution. Therefore, we have introduced an entire EIAV genome expression cassette into a single loxP site. This site was previously identified by MLV transduction as highly permissive for transgene expression. A 5' CMV promoter transcribes the lentiviral  
30 genome in the producer cell line but the expression site was originally identified by MLV transduction. This method is adaptable to the generation of transduced producer cell lines for other lentiviral vector systems.

## Materials and Methods

**Vector construction:** Plasmid pTrap2 was made as follows: A plasmid containing a single MLV LTR plasmid (LTRplasmid – SEQ ID No 59) was digested with *NheI* and *XbaI* and a 34 bp minimal loxP site was introduced with relevant sticky ends. This insertion step removes the MLV U3 enhancer elements which lie within the excised *NheI*-*XbaI* fragment. The LTR-loxP plasmid was linearised by digestion with *NheI* and was ligated to a 6.8kb *NheI* fragment from the MLV construct CZCG (See SEQ ID No 55). This construct expresses lacZ from the 5' U3 promoter and GFP from an internal CMV promoter. The resulting pTrap2 construct is shown in Figure 8.

The EIAV genome construct pONY8.0Z and pONY8.1Z were prepared as follows:

### pONY8.0Z construction

pONY8.0Z was derived from pONY4.0Z (see WO 99/32646) by introducing mutations which 1) prevented expression of TAT by an 83nt deletion in the exon 2 of tat ) prevented S2 ORF expression by a 51nt deletion 3) prevented REV expression by deletion of a single base within exon 1 of rev and 4) prevented expression of the N-terminal portion of gag by insertion of T in ATG start codons, thereby changing the sequence to ATTG from ATG. With respect to the wild type EIAV sequence Acc. No. U01866 these correspond to deletion of nt 5234-5316 inclusive, nt 5346-5396 inclusive and nt 5538. The insertion of T residues was after nt 526 and 543.

### pONY8.1Z construction

pONY8.1Z was obtained directly from pONY8.0Z by digestion with *SalI* and partial digestion with *SapI*. Following restriction the overhanging termini of the DNA were made blunt ended by treatment with T4 DNA polymerase. The resulting DNA was then religated. This manipulation results in a deletion of sequence between the LacZ reporter gene and just upstream of the 3'PPT. The 3' border of the deletion is nt 7895 with respect to wild type EIAV, Acc. No. U01866. Thus pONY8.1Z does not contain sequences corresponding to the EIAV RREs.

Plasmid pONY8z was linearised by *Bgl*II, and a single loxP site was cloned into *Bgl*II, immediately upstream of the 5' CMV promoter, to produce pONY8z-loxP. Plasmids pONY3.2iresHYG and pHCMV-VSVG were used in the derivation of cell lines EV1 and EV2. The plasmid pONY3.2iresHYG was constructed as follows:

#### pONY3.2IREShyg

pONY3.IREShyg was derived from pONY3.2. pONY3.2 is a derivative of pONY3.1 in which expression of TAT and S2 are ablated by an 83nt deletion in the exon 2 of tat a 51nt deletion in S2 ORF. With respect to the wild type EIAV sequence Acc. No. U01866 these correspond to deletion of nt 5234-5316 inclusive and nt 5346-5396 inclusive. This fragment was introduced into the expression vector pHORSE IRES hyg which was made as follows. pHORSE (see WO 99/32646) was cut with *Sna*BI and *Not*I which excises a fragment running from the CMV promoter through EIAV gag/pol and introduced into pIRES1hyg (Clontech) digested with the same enzymes. This plasmid was then cut with *Sse*8387I and *Bst*EII and then ligated with the *Sse*8387I to *Bst*EII fragment from pONY3.2. The sequence of the plasmid is set out in SEQ ID No 51.

#### 20 Virus Production

Transient MLV vector preparations pseudotyped with RD114 cat endogenous envelope were made as described previously (Soneoka et al., 1995). EIAV vector was harvested from confluent monolayers following 3 days induction of VSV-G expression at 32°C. MLV vector preparations were titred in triplicate on HT1080 fibrosarcoma cells. EIAV vector preparations were titred by GFP and lacZ on D17 dog osteosarcoma cells.

#### Flow cytometry of b-galactosidase and GFP activity:

30  $1.5 \times 10^5$  cells from a 12-well plate were analysed for lacZ expression using the FluoReporter lacZ Flow Cytometry kit (Molecular Probes). GFP expression was also directly assessed using the FACSCalibur flow cytometer (Beckton Dickinson).

#### Transfection methods

Calcium phosphate transfections were carried out using the Protection kit (Promega) according to manufacturer's instructions.

## 5 Results

Figure 8 shows a schematic diagram of pTrap2 and pONY8z-loxP<sub>1</sub> plasmids used in this study.

## 10 Introduction of Trap2 genome into EV1 and EV2

An overall summary of the process described here is given in Figure 9. Trap2 MLV vector was made in a transient system with the amphotropic 4070A envelope. It gave a GFP titre of  $1.7 \times 10^6$  T.U. per ml. Trap2 vector however also gave a lacZ titre of  $9.4 \times 10^5$  T.U. per ml. This shows that replacement of the *NheI-XbaI* fragment from the MLV U3 region with loxP does not completely inactivate the MLV U3 promoter. Therefore Trap2, as constructed, is a partial SIN vector.

EV1 and EV2 cells were transduced with Trap2 vector at a multiplicity of infection (MOI) of 0.3. This was done to insert single copies of the MLV genome into the packaging lines.

## Derivation of high expressers of GFP marker gene

25 Transduced EV1 and EV2 cells were analysed by FACS (see Figure 10) and the top 5% of GFP expressing cells were sorted and expanded. Clonal lines were derived by limiting dilution and four clones of EV1 and EV2 were chosen by visual inspection.

30 A quantitative TaqMan RT-PCR reaction was established in order to identify which of the four clones of EV1 and EV2 were the highest expressors of GFP mRNA. Total RNA was analysed by RT-PCR for GFP and  $\beta$ -actin. Quantitation was calculated by direct comparison of the Ct values (Cycle threshold). This was possible as it was proved that the two individual RT-PCR reactions are of similar efficiency (see Figure 11). By identifying an

-48-

optimal chromosomal location for GFP transgene expression. we can ensure that the inserted loxP site will be highly permissive for expression of an inserted lentiviral genome construct.

5 Figure 5 shows the n-fold difference in GFP :  $\beta$ -actin ratio for clones EV1 A to D and EV2 A to D. All ratios are defined relative to a calibrator sample, defined as a ratio of 1.0. The calibrator sample used was RNA from EV2 cells transduced with Trap2 at an MOI of 0.3.

10 This identified the best expressing lines as:

- EV1 clone A - GFP :  $\beta$ -actin ratio is 22.8
- EV2 clone D - GFP :  $\beta$ -actin ratio is 18.6

These two lines were carried forward for further study.

15

#### **Excision of internal expression cassette by Cre recombinase**

The process of retroviral integration copies the loxP-containing modified 3' U3 to the 5' position. Therefore, one can excise the majority of the MLV Trap2 integration by the  
20 action of Cre recombinase. This will leave a single modified LTR, suitable for lentiviral genome integration.

EV1 clone A and EV2 clone D were transfected by the Cre expression plasmid pBS185 (Life Technologies). After one week, the cells were analysed for GFP by FACS (see  
25 Figure 13) to determine the excision frequency. This was measured at 20-70% in all lines.

Recombined clones were identified by limit dilute cloning cells and checking by microscope and FACS for loss of GFP expression.

30

#### **Insertion of EIAV genome into loxP site**

-49-

Plasmid pONY8x-loxP and pBS185 were co-transfected using Fugene into EV1 clone A (excised) and EV2 clone D (excised). A control transfection of pONY8z-loxP in the absence of pBS185 was also carried out.

5 Figure 14 shows lacZ expression of transfected cells with and without the addition of Cre recombinase (pBS185). The efficiency of the insertion event was estimated to be ~12% by computer image analysis.

We analysed cells for lacZ expression by FACS using the FluoReporter lacZ Flow  
10 Cytometry kit. The top 5% of lacZ positive cells were sorted by FACS and clones were derived by limiting dilution. In total, 12 clones of EV1/A/pONY8z-loxP were derived and 13 clones of EV2/D/pONY8z-loxP.

#### 15 EXAMPLE 7

##### Construction of EIAV vectors with LTR driven open reading frames

The EIAV vector configurations described previously utilise a single promoter -  
20 transgene cassette located internally in the vector. For example in pONY8Z the promoter-transgene cassette is CMV-LacZ. However for some uses it would be advantageous to have the option of expressing a gene from the 5'LTR promoter as well. For example a marker gene such as green fluorescent protein (GFP), a resistance marker such as neomycin phosphotransferase (neo) or another protein or a biologically active  
25 entity such as a ribozyme. Previous experiments have shown that the EIAV LTR is weakly active in human cells in the absence of EIAV tat. However the transcriptional activity of the LTR can be increased by replacement of the EIAV U3 region with the MLV U3 region or the CMV promoter. This is achieved by introducing these alterations in the 3'LTRs of the vector plasmids. As a result of the replicative strategy of  
30 retroviruses the modified 3'LTR becomes positioned at the 5'end of the integrated vector and can thus drive expression of a gene placed downstream of the gag region. To ensure optimal levels of expression there should preferably be no ATG start codons prior to the start codon of the gene to be expressed. In pONY8Z the ATG start codon of gag and the next ATG downstream were mutated to ATTG in order to ablate expression of the

-50-

aminoterminal portion of gag present in the vectors, however there are 7 other ATG codons further downstream of these, within gag, from which translation might be initiated.

- 5 Described below are the replacement of the U3 region of EIAV with MLV or CMV promoters and the mutation of ATG codons in the gag region

#### Replacement of the EIAV U3 region with MLV U3 or CMV promoters

- 10 The MLV U3 region was introduced into pONY8Z vector by replacement of the 3'LTR with a synthetic MLV/EIAV LTR made by the overlapping PCR technique, using the following primers and templates.

The EIAV PPT/U3 sequence was amplified from pONY8.1Z using primers:

- 15 KM001: CAAAGCATGCCTGCAGGAATTCG (SEQ ID No 1)

and

KM003:

- 20 GCCAAACCTACAGGTGGGGTCTTTCATTATAAAACCCCTCATAAAAACCCAC  
AG (SEQ ID No 2)

to give the following product:

- 25 CAAAGCATGCCTGCAGGAATTCGATATCAAGCTTATCGATACCGTCGAATTG  
GAAGAGCTTTAAATCCTGGCACATCTCATGTATCAATGCCTCAGTATGTTTAG  
AAAAACAAGGGGGGAAGTGTGGGGTTTTTATGAGGGGTTTTATAATGAAAGA  
CCCCACCTGTAGGTTTGCC (SEQ ID No 3)

- 30 The MLV U3 region was amplified from pHIT111 (Soneoka et al., (1995) Nucleic Acids Res. 23, 628-633) using KM004:

-51-

CTGTGGGGTTTTTATGAGGGGTTTTATAATGAAAGACCCACCTGTAGGTTTG  
GC (SEQ ID No 4)

and

5 KM005:

GAAGGGACTCAGACCGCAGAATCTGAGTGCCCCCGAGTGAGGGGTTGTGGG  
CTCT (SEQ ID No 5) to give the following product:

10 CTGTGGGGTTTTTATGAGGGGTTTTATAATGAAAGACCCACCTGTAGGTTTGGCAAGCTAGCT  
TAAGTAACGCCATTTTGCAAGGCATGGAAAAATACATAACTGAGAATAGAGAAGTTCAGATC  
AAGGTCAGGAACAGATGGAACAGCTGAATATGGGCCAAACAGGATATCTGTGGTAAGCAGTT  
CCTGCCCCGGCTCAGGGCCAAGAACAGATGGAACAGCTGAATATGGGCCAAACAGGATATCT  
GTGGTAAGCAGTTCCTGCCCCGGCTCAGGGCCAAGAACAGATGGTCCCCAGATGCGGTCCAGC  
15 CCTCAGCAGTTTCTAGAGAACCATCAGATGTTTCCAGGGTGCCCCAAGGACCTGAAATGACCC  
TGTGCCTTATTTGAACTAACCAATCAGTTCGCTTCTCGCTTCTGTTTCGCGCGCTTCTGCTCCCCG  
AGCTCAATAAAAGAGCCCAACCCCTCACTCGGGGGGCACTCAGATTCTGCGGTCTGAGTCC  
CTTC (SEQ ID No 6)

20 The MLV U3/EIAV R/U5 was amplified from pONY8.1Z using primers

KM002: GAGCGCAGCGAGTCAGTGAGCGAG (SEQ ID No 7) and

KM006:

25

AGAGCCCACAACCCCTCACTCGGGGGGCACTCAGATTCTGCGGTCTGAGTCC  
CTTC (SEQ ID No 8)

to give the following product:

30

AGAGCCCACAACCCCTCACTCGGGGGGCACTCAGATTCTGCGGTCTGAGTCCCTTCTCTGCTG  
GGCTGAAAAGGCCTTTGTAATAAATATAATTCTCTACTCAGTCCCTGTCTCTAGTTTGTCTGTT  
CGAGATCCTACAGAGCTCATGCCTTGGCGTAATCATGGTCATAGCTGTTTCTGTGTGAAATTG  
TTATCCGCTCACAATTCCACACAACATACGAGCCGGAAGCATAAAGTGTAAGCCTGGGGTGC  
35 CTAATGAGTGAGCTAACTCACATTAATTGCGTTGCGCTCACTGCCCCGCTTTCAGTCGGGAAAC



-52-

CTGTCGTGCCAGCTGCATTAATGAATCGGCCAACGCGCGGGGAGAGGCGGTTTGCGTATTGGG  
CGCTCTTCCGCTTCCTCGCTCACTGACTCGCTGCGCTC (SEQ ID No 9)

The PCR products described above were purified and then used as templates in new PCR  
5 reactions to link them together to obtain a 992bp product. The final product contains two  
SapI sites which flank the hybrid LTR. These allow introduction of the PCR product into  
the corresponding SapI sites present in the pONY8Z or pONY8.1Z vector plasmid,  
thereby creating pONY8Z MLVHyb and pONY8.1 MLVHyb. The sequence of the  
hybrid LTR in these plasmids was confirmed by sequencing. The titres obtained from the  
10 vectos in transient transfection assays are shown in Table 1. The titres were very similar  
to the titres from the parental construct pONY8Z and pONY8.1Z indicating that  
replacement of the EIAV U3 region with that of MLV had little or no detrimental effect  
on the infectious cycle of the vectors.

15 **Table 1. Titres obtained from MLV hybrid LTR vector plasmids**

vector plasmid	#titre (l.f.u./ml)
pONY8Z	$3 \times 10^3$
pONY8Z MLVHyb	$1 \times 10^3$
pONY8.1Z	$6 \times 10^4$
pONY8.1Z MLVHyb	$2 \times 10^4$

# Titre was measured on D17 cells and is expressed as LacZ forming units/ml (l.f.u./ml).  
Transfections were carried out in 293T cells using the vector plasmid shown and pRV67  
20 (VSV-G expression plasmid), and pONY3.1 (EIAV gag/pol expression plasmid).

The structure of pONY8.1Z MLVHyb is shown in Figure 15 and the sequence of this  
plasmid is shown as SEQ ID No 10.

25 The EIAV promoter was also replaced by the human cytomegalovirus (CMV) promoter  
using a similar strategy. The primers and templates were the same except that KM003  
was replaced by KM008:

-53-

GGCCATCGTGCCTCCCCACTCCTGCAGTTATAAAACCCCTCATAAAAACCCCA  
CAG (SEQ ID No 11)

KM004 was replaced by KM009:

5

CTGTGGGGTTTTTATGAGGGGTTTTATAAACTGCAGGAGTGGGGAGGCACGA  
TGGCC (SEQ ID No 12)

KM005 was replaced by KM010:

10

GAAGGGACTCAGACCGCAGAATCTGAGTGCCCGGTTCCTAAACGAGCTCTG  
CTTATATAGACC (SEQ ID No 13) and

KM006 was replaced by KM011:

15

GGTCTATATAAGCAGAGCTCGTTTAGTGAACCGGGCACTCAGATTCTGCG  
GTCTGAGTCCCTTC (SEQ ID No 14)

The template for the PCR reaction with primers KM009 and KM010 was pONY2.1LacZ.

20

This plasmid contains a single CMV promoter. The combined PCR product of 1319 bp was digested with SspI and introduced into the pONY8Z or pONY8.1Z backbone as described above for pONY8Z MLVHyb.

#### **Mutation of remaining ATG codons in the gag of pONY8Z to ATTG**

25

The alignment of the sequence of the leader and gag region present in vectors pONY4Z (an earlier generation EIAV vector), pONY8Z and a derivative of pONY8Z in which the 7 remaining ATG codons are mutated to ATTG is shown in Figure 16. These mutations were created by PCR mutagenesis as follows. The template for the PCR reactions was

30

F1: CGAGATCCTACAGTTGGCGCCCGAACAG (SEQ ID No 15);

-54-

R1:GAGTTACAATCTTCCAGCAATGGAATGACAATCCCTCAGCTGCCAGTCCTT  
TTCTTTTACAAAGTTGGTATCAATGAAATAAGTCTACTAGACTTAGC (SEQ ID  
No 16);

5 F2:TTCCATTGCTGGAAGATTGTA ACTCAGACGCTGTCAGGACAAGAAAGAGA  
GGCCTTTGAAAGAACATTGGTGGGCAATTTCTGCTGTAAAGATTG (SEQ ID No  
17);

R2:CAATATTTGCTCTTAGGAGCTGGAATGATGCCTTTCCAATCTACTACAAT  
10 TATTAATCTGGAGGCCCAATCTTTACAGCAGAAATTGCCCCACCAATG (SEQ ID  
No 18);

R3:CCACTAGTTCTAGAGATATTCTTCAGAGGGCTCAGACTGCTTTTTATTAGC  
AGTCTTCTTTTCAATATTTGCTCTTAGGAGC (SEQ ID No 19)

15

In the first stage of construction two PCR reactions were set up with primer pairs F1/R1  
and F2/R2, respectively. These were purified and then used in a second 'overlapping'  
reaction in which primers F1 and R3 were added after 10 cycles. This procedure results  
in a 552bp PCR product (SEQ ID No 20):

20

CGAGATCCTACAGTTGGCGCCCGAACAGGGACCTGAGAGGGGCGCAGACCCTACCTGTTGAA  
CCTGGCTGATCGTAGGATCCCCGGGACAGCAGAGGAGAACTTACAGAAGTCTTCTGGAGGTGT  
TCCTGGCCAGAACACAGGAGGACAGGTAAGATTGGGAGACCCTTTGACATTGGAGCAAGGCG  
CTCAAGAAGTTAGAGAAGGTGACGGTACAAGGGTCTCAGAAATTA ACTACTGGTAACTGTAAT  
25 TGGGCGCTAAGTCTAGTAGACTTATTTCA TTGATACCAACTTTGTAAAAGAAAAGGACTGGCA  
GCTGAGGGATTGTCATTCCATTGCTGGAAGATTGTA ACTCAGACGCTGTCAGGACAAGAAAGA  
GAGGCCTTTGAAAGAACATTGGTGGGCAATTTCTGCTGTAAAGATTGGGCCTCCAGATTAATA  
ATTGTAGTAGATTGGAAAGGCATCATTCCAGCTCCTAAGAGCGAAATATTGAAAAGAAGACTG  
CTAATAAAAAGCAGTCTGAGCCCTCTGAAGAATATCTCTAGAACTAGTGG

30

This was digested with NarI and XbaI and ligated into pONY8Z. pONY8Z MLVHyb and  
pONY8Z CMVHyb. which had been prepared for ligation by digestion with the same  
enzymes. These plasmids were designated pONY8ZA or pONY8ZA MLVHyb and  
pONY8ZA CMVHyb. The sequence for pONY8ZA CMVHyb is provided in SEQ ID No  
52. These plasmids have a unique XbaI site into which can be inserted genes such as

-55-

GFP or neomycin phosphotransferase or other biologically active entity. This use of the site is demonstrated for GFP. The GFP ORF was obtained from pEGFP-1 (Clontech) by digestion with SmaI and XbaI, and then the ends filled in by treatment with T4 DNA polymerase. This fragment was then ligated into pONY8ZA or pONY8ZA MLVHyb and pONY8ZA CMVHyb prepared for ligation by digestion with XbaI and subsequent filling in with T4DNA polymerase. The resulting vector plasmids were called pONY8GZA or pONY8GZA MLVHyb and pONY8GZA CMVHyb. Other genes can be inserted at this site by manipulations apparent to those skilled in the art.

#### 10 **Creation of EIAV vector genomes containing loxP sites in their LTR's**

The time taken to construct producer cell lines for EIAV vectors would be greatly reduced if it was possible to 1) locate and 2) reutilise a site in the host cell chromosome which was particularly favourable for high levels of transcription of the vector genome. In outline, this can be achieved by engineering loxP sites in the 3'LTR of EIAV vectors, transduction of the packaging cell line with vectors which carry loxP and hybrid LTRs, selection of cells which express the highest levels of vector genome and exchange of the test EIAV vector genome for the vector genome of choice using the cre/loxP recombination system.

The proposed scheme was evaluated using a derivative of pONY8GZA CMVHyb in which a loxP site was introduced into the PstI site between the EIAV sequences (required for efficient integration) and the CMV promoter in the 3'LTR. After transduction the integrated vector will thus have a loxP-CMV cassette located in the 5'LTR and 3'LTR's and therefore full length transcripts of the vector genome will be driven by the CMV promoter, which is a powerful promoter. pONY8GZA CMVHyb contains many PstI sites hence it was modified to allow insertion of the loxP site by digestion with XbaI and NheI and religation to create the subclone, pONY CMVHyb. This plasmid has a unique PstI site in the hybrid LTR. The loxP site was inserted into this site using two complimentary oligonucleotides which when annealed formed PstI-compatible termini. These were termed loxP POS

-56-

PSTI [GATAAC TTCGTATAATGTATGCTATACGAAGTTATCTGCA] (SEQ ID No 21)] and

loxP NEG PstI [GATAACTTCGTATAGCATACATTATACGAAGTTATCTGCA]  
5 (SEQ ID No 22)

The sequence and orientation of the loxP site was confirmed by DNA sequencing and the plasmid called pONY CMVHyb loxP. The central part of the vector genome was then reintroduced into this subclone by transfer of the NotI-BstEII fragment from pONY8GZA  
10 CMVHyb into pONY CMVHyb cut the same way. The resulting vector was termed pONY8GZA CMVHyb loxP.

Two routes for construction of a producer cell line are available using pONY8GZA CMVHyb loxP. The plasmid can be introduced into a packaging cell line by transfection  
15 or vector particles can be made using the 293T and these used to transduce the packaging cell line. Since the vector is derived from EIAV, rather than MLV, it is able to transduce non-dividing cells or slowly dividing cells. In this situation it has been hypothesised that integrations occur at chromosomal sites that are constitutively open; that is, are likely to be sites at which high levels of transcription will be maintained for extended periods.  
20 This may be important for the long term usefulness of the producer cell line and thus represents an advantage of strategy using transduction.

Producer cell lines were made by transfection or transduction of a TE671-derived cell line (EV11E) which has stably integrated copies of VSV-G and the synthetic EIAV gag/pol  
25 under the control of CMV promoters. Prior to transfection with pONY8GZA CMVHyb loxP it was linearised by digestion with AhdI. Seven days following transfection or transduction cells expressing the highest levels of GFP were selected by FACS and then cloned by limiting dilution. A number of clones were analysed for levels of full length vector RNA using Taqman technology based assays in order to confirm the hypothesis  
30 that the highest level of GFP expression correlates with the highest levels of vector RNA.

The cell line which expressed the highest level of RNA was then tested for production of transducing vector particles 5 days after changing the temperature of incubation from 37C

-57-

to 32°C. At 32°C, VSV-G expression is induced however maximal levels of VSV-G are only obtained after 5 days at the permissive temperature (see WO 00/52188). The cell line producing the highest titre, EV11E CMV loxP was selected for further work.

5 In order to exchange the vector genome with for another EIAV vector genome with a more suitable configuration for use in the clinical setting EV11EloxP cells were transfected with cre recombinase expression plasmid, pBS185 (Gibco), which results in excision of the EIAV vector between the loxP sites. This leaves a loxP-CMV promoter R-U5 sequence in the cells. Cells from which the EIAV vector genome had been excised  
 10 were selected on the basis of low levels of GFP expression by FACS and assumed to be clonal on the basis of the clonality of EV11E CMV loxP. These were termed EV11EloxPΔ and used as targets for new EIAV vector genomes.

#### 15 **Construction of EIAV vector genomes with downstream REV expression cassettes and flanking loxP sites**

The production of vector particles from minimal EIAV vectors (those which do not express EIAV REV or any other EIAV proteins) is increased by about 10-fold in the presence of EIAV REV in our 293T transient production system when the codon-  
 20 optimised EIAV gag/pol expression construct is used to drive production of vector particles as set out in Table 2. This may be improved nuclear to cytoplasmic transport of the vector genome in the presence of REV protein. Packaging/producer cell lines for EIAV vectors may be engineered to express Rev protein. One approach would be to engineer cells to express EIAV REV from an independently transfected expression  
 25 cassette. However, the cassette and the vector genome may be subject to differential regulation, for example by methylation or chromosome remodelling. Such an effect may limit the useful life of such cell lines.

Table 2. Effect of REV expression on titres obtained from REV-expressing [REV+] and  
 30 non-expressing [REV-] vectors

vector plasmid	gag/pol	expression	#titre
----------------	---------	------------	--------

-58-

	plasmids	(l.f.u./ml)
pONY4Z [REV+]	pONY3.1	$2.0 \pm 0.4 \times 10^6$
pONY4Z [REV+]	pE SYN GP	$0.9 \pm 0.2 \times 10^6$
pONY8Z [REV-]	pONY3.1	$1.5 \pm 0.2 \times 10^6$
pONY8Z [REV-]	pE SYN GP	$1.9 \pm 0.6 \times 10^5$

\* Titre was measured on D17 cells and is expressed as LacZ forming units/ml (l.f.u./ml). Transfections were carried out in 293T cells using the vector plasmid and gag/pol expression plasmid shown and pRV67 (VSV-G expression plasmid) (See WO 00/52188).

5

REV+ and REV- reflect the rev expression status of the vectors. REV+ reflects vectors which express the REV protein. REV- reflects expression vectors which do not express the REV protein.

#### 10 pESYNGP

The gag/pol expression plasmid shown in Figure called called pESYNGP was constructed as follows: The codon-optimised EIAV gag/pol ORF was synthesised by Operon Technologies Inc., Alameda and supplied in a proprietary plasmid backbone, GeneOp.

15 The complete fragment synthesised included sequences flanking the EIAV gag/pol ORF: tctagaGAATTCGCCACCATG- EIAV gag/pol- UGAACCCGGGgcggccgc (SEQ ID No 44). The ATG start and UGA stop codons are shown in bold. XbaI and NotI sites are in lower case. These were used to transfer the gag/pol ORF from GeneOp into pCIneo (Promega) using the NheI and NotI sites in the latter.

20

#### pESDSYNGP

25 An alternative expression plasmid for expression of the synthetic EIAV gag/pol could also be used. It is called pESDSYNGP and its construction is described as follows:

ESDSYNGP was made from pESYNGP by exchange of the 306bp EcoRI-NheI fragment, from just upstream of the start codon for gag/pol to approximately 300 base pairs inside

-59-

the gag/pol ORF with a 308bp EcoRI-NheI fragment derived by digestion of a PCR made using pESYNGP as template and using the following primers: SD FOR [GGCTAGAGAATTCCAGGTAAGATGGGCGATCCCCTCACCTGG] (SEQ ID No 60) and SD REV [TTGGGTACTCCTCGCTAGGTTC] (SEQ ID No 61). This manipulation replaces the Kozak consensus sequence upstream of the ATG in pESYNGP with the splice donor found in EIAV. The sequence between the EcoRI site and the ATG of gag/pol is thus CAGGTAAG (SEQ ID No 62).

The sequences for pESYNGP (SEQ ID No 53) and pESDSYNGP (SEQ ID No 54) are provided.

Packaging/Producer cells may be engineered by physically linking the genome and EIAV REV expression cassettes. In this way stable transfectants may be generated which contain the vector genome and the EIAV REV expression cassette in the same chromatin environment. This manipulation may ensure that the relative levels of transcription of the vector genome and the REV expression cassette are maintained leading to an increased duration of vector production from the producer cells.

Previous work has suggested that optimisation of the level of REV may be required with respect to the level of vector genome (see WO 98/17815). We have examined the levels of vector production in a transient system in which several different promoters are used to drive REV expression in order to determine which vector genome-rev expression cassette is optimal for use in constructing producer cell lines. The highest titres were obtained with FB29 and PGK promoters driving REV expression.

The following describes the construction of EIAV vector genomes plasmids in which there is a downstream expression cassette for synthetic EIAV REV protein. The promoters tested were FB29, PGK, TK, CMV, SV40 and RSV. In addition the loxP sites were engineered into the vector plasmid backbone in such a way that the genome and introduced promoter-REV expression plasmid was flanked. In this way, the complete vector-REV cassette can be recombined into loxP sites in the target cell.



-60-

The complete construction of the FB29 and PGK containing plasmids is described here. The REV expression construct was inserted in the both orientations with respect to the EIAV vector genome. Plasmids in which the FB29 or PGK promoters drive REV expression are being utilised for construction of stable producer cell lines.

5

### Construction of plasmids

In the first step of construction an SfiI site was inserted downstream of the EIAV vector sequence. This site is the insertion site for the promoter REV cassettes. The construction was made as follows. pONY8Z was digested with EheI and NruI, the ends were blunted by treatment with T4 DNA polymerase and religated. The resulting plasmid, pONY8Z delta, is thus deleted with respect to the leader, gag, reporter cassette and most of the Rev/RRE regions.

pONY8Z delta was mutated to contain loxP sites inserted in the DraII site immediately to the 5' of the CMV promoter and in the BspLU11I site to the 3' of the vector genome. The loxP sites were inserted using complementary nucleotide pairs which when annealed had overhanging termini suitable for cloning into these sites and were inserted in two steps of cloning. The oligonucleotides for insertion into the DraIII site were

20

VSAT 158: [GTGATAACTTCGTATAATGTATGCTATACGAAGTTATCACTAC]  
(SEQ ID No 23)

and

25

VSAT 155 [GTGATAACTTCGTATAGCATACATTATACGAAGTTATCACGTA]  
(SEQ ID No 24)

For the BspLU11I they were:

30

VSAT 156 [CATGTATAACTTCGTATAATGTATGCTATACGAAGTTATA] (SEQ ID  
No 25) and

-61-

VSAT 157 [CATGTATAACTTCGTATAGCATACATTATACGAAGTTATA] (SEQ ID No 26)

Plasmids were selected in which the orientation of the loxP at both sites were the same and the same as the EIAV vector genome. The modified plasmid was called pONY8Z delta 2xloxP.

pONY8Z delta 2xloxP has a unique PvuII site downstream of the deleted EIAV vector genome into which annealed complementary oligonucleotides encoding SfiI sites were inserted. The oligonucleotides were:

SFI SRFPOS [AGTAGGCCGCTCGGCCGCCCCGGGCATCA] (SEQ ID No 27) and

SFI SRF NEG [TGATGCCCCGGCGGCCGAGGCGGCCTACT] (SEQ ID No 28)

Clones which had the SfiI – SrfI sites in either orientation were selected for further work. These were called pONY8Z delta SfiI FOR and REV.

#### Amplification and cloning of FB29 and PGK promoters

The FB29 promoter was amplified from pRDF (Cosset FL, et al. *J Virol* 1995 Dec;69(12):7430-6) using primers:

FB29 POS [TAGCCGAGATCTCAAATTGCTTAGCCTGATAGCC] (SEQ ID No 29) and

FB29 NEG [TGCGTAGCTAGCCTCCCGGTGGTGGGTCGGTG] (SEQ ID No 30) which introduce

5'BglII and 3'NheI sites.

The PGK promoter was amplified from pPE327 using primers

PGK POS [AGCAGTAGATCTGGGGTTGGGGTTGCGCCTTT] (SEQ ID No 31) and

PGK NEG [CGTCATGCTAGCCTGGGGAGAGAGGTCGGTG] (SEQ ID No 32)

-62-

The PGK promoter sequence obtained from this plasmid was the same as the sequence of GenBank Acc. No. M11958 except that it has a single mutation: nucleotide 347 of M11958 is changed from G to A. The TK promoter and intron was amplified from pRL-TK (Promega) with:

- 5 TK POS [TACGGAAGATCTAAATGAGTCTTCGGACCT] (SEQ ID No 33) and  
TK NEG [CTCAACGCTAGCGTACTCTAGCCTTAAGAGCTG] (SEQ ID No 34)

The RSV promoter was amplified from pREP7 (Invitrogen) with

- 10 RSV POS [TACCAGAGATCTTCTAGAGTCGACCAATTCTCATG] (SEQ ID No 35)  
and

RSV NEG [CATCGAGCTAGCAGCTTGGAGGTGCACACCAATG] (SEQ ID No 36)  
and

15

The SV40 promoter was amplified from pCIneo (Promega) with:

SV40 POS [GATGGTAGATCTGCGCAGCACCATGGCCTGAA] (SEQ ID No 37) and

- 20 SV40 NEG [CTCGAAGCTAGCAGCTTTTTGCAAAAGCCTAGGC] (SEQ ID No 38)

- The PCR fragments were digested with BglII and NheI and ligated into pSL1180 (Pharmacia) which had been prepared by digestion using the same enzymes. Following transformation into E.coli DNA was prepared and the sequence of the promoters checked  
25 by DNA sequencing. Clones in which the correct promoter sequence was present were used for further work and were called pSL1180-FB29, pSL1180-PGK, pSL1180-RSV, pSL1180-SV40, pSL1180-TK.

- In the next step the promoter fragments were positioned to drive transcription of synthetic  
30 EIAV REV in pE syn REV. pE syn REV is a pCIneo based plasmid (Promega) which was made by introducing the EcoRI to SalI fragment from the synthetic EIAV REV plasmid into the polylinker region of the plasmid using the same sites. The synthetic

-63-

EIAV REV plasmid made by Operon contains a codon-optimised EIAV REV open reading frame flanked by EcoRI and Sall. The sequence of this fragment is shown as SEQ ID No 39.

5 Prior to replacement of the CMV promoter in pE syn REV it was modified as follows. The SV40 neo region was deleted by digestion with KpnI and BamHI, the ends blunted by treatment with T4 DNA polymerase and then religated. The plasmid was termed pE syn REV delta. Next SfiI sites were introduced into both the BglII site which is just 5' of the CMV promoter and DraIII site downstream of the polyA signal.

10

The oligonucleotides used for this were as follows:

SFI FOR BglII POS [GATCGGCCGCTCGGCCA] (SEQ ID No 40) and

15 SFI FOR BglII NEG [ GATCTGGCCGAGGCGGCC] (SEQ ID No 41)and

SFI FOR DRA POS [ GGCCGCCTCGGCCGTA] (SEQ ID No 42) and

SFI FOR DRA NEG [GGCCGAGGCGGCCTAC] (SEQ ID No 43)

20

Clones in which the SfiI was located 5' of the BglII site were selected were used for further work. The plasmid obtained after this two step manipulation was termed pE syn REV delta 2xSfiI. It has the following features: 5'SfiI sites – BglII site - CMV promoter and intron – NheI site – E syn REV - polyA site – 3'SfiI site. Hence the CMV promoter  
25 can be excised by digestion with BglII and NheI and replaced with the promoter of choice obtained from the pSL1180 series of clones by digestion with the same enzymes. Construction details are included from this point for only the constructs which contained FB29 and PGK promoters, however a similar scheme was used for the other promoters, except that a partial SfiI digestion was required for transfer of the SV40-REV cassette.

30

Promoter fragment were obtained from pSL1180 – FB29 and pSL1180 – PGK by digestion with BglII and NheI and ligated into pE syn REV delta 2xSfiI digested with the

-64-

same enzymes. The resulting plasmids were called FB29 E SYN REV and PGK E SYN REV.

In the next stage the internal regions of pONY8G, pONY8.1G SIN MIN and pONY4G  
 5 were obtained by digestion with SgfI (which has unique site in the CMV promoter driving the EIAV vector genome) and MunI (which cuts in the 3'LTR) and ligated in to pONY8Z delta SfiI FOR and REV prepared for ligation by digestion with the same enzymes. The resulting plasmids were called pONY8G SfiI FOR and REV, pONY8.1G SIN MIN SfiI FOR and REV and pONY4G SfiI FOR and REV.

10

In the final stage the promoter-REV cassettes were moved from FB29 E SYN REV and PGK E SYN REV into pONY8G SfiI FOR and REV, pONY8.1G SIN MIN SfiI FOR and REV and pONY4G SfiI FOR. This manipulation was achieved as follows. FB29 E syn REV, PGK E syn REV, and the vector plasmids described immediately above were  
 15 digested with SfiI and ligations set up with appropriate fragments. The promoter-REV cassettes were orientated in the same or opposite orientations with respect to the EIAV vector genome in the 'FOR' and 'REV' plasmids. The resulting plasmids were called pONY8.3G FB29 + or - and pONY8.3G PGK+ and -. A schematic structure of the pONY 8.3 +/- plasmids is shown in Figure 17.

20

The performance of these constructs was tested in relation to pONY8G in 293T transient production assays and the results are shown in Table 3.

25

**The sequence of the *EcoRI* to *SaII* fragment representing the codon-optimised EIAV REV open reading frame obtained from the plasmid synthesised by Operon (SEQ ID No 39)**

30

*EcoRI* and *SaII* sites are in bold. The ATG start and UGA termination codons are underlined

GAATTCGCCACCAATGGCTGAGAGCAAGGAGGCCAGGGATCAAGAGATG

-65-

ACCTCAAGGAA  
 GAGAGCAAAGAGGAGAAGCGCCGCAACGACTGGTGGGAAGATCGACCCA  
 AAGGCCCCCTG  
 GAGGGGGACCAGTGGTGCCGCGTGCTGAGACAGTCCCTGCCCCGAGGAGAAGATTCTCT  
 5 AGC  
 CAGACCTGCATCGCCAGAAGACACCTCGGCCCCGGTCCCACCCAGCACACACCCTCC  
 AGA  
 AGGGATAGGTGGATTAGGGGCCAGATTTTGCAAGCCGAGGTCCTCCAAGAAAGGCTG  
 GAA  
 10 TGGAGAATTAGGGGCGTGCAACAAGCCGCTAAAGAGCTGGGAGAGGTGAATCGCGG  
 CATC  
 TGGAGGGAGCTCTACTTCCGCGAGGACCAGAGGGGCGATTTCTCCGCATGGGGAGGC  
 TAC  
 CAGAGGGCACAAGAAAGGCTGTGGGGCGAGCAGAGCAGCCCCCGCGTCTTGAGGCC  
 15 CGGA  
 GACTCCAAAAGACGCCGCAAACACCTGTGAAGTCGAC

Table 3

- 20 Titres obtained from a representative experiment in which the vector-REV constructs were tested by transient 293T production assay. The vector constructs were cotransfected with pE synGP, the synthetic ELAV gag/pol expression plasmid, and pRV67, VSV-G expression plasmid. Titres were measured in D17 cells.

Plasmid	Titre (g.f.u./ml)
pONY8G SfiI FOR	$1.6 \times 10^4$
#pONY8G SfiI FOR PLUS pE syn REV	$5.2 \times 10^5$
pONY8.3G FB29 +	$8.8 \times 10^5$
pONY8.3G FB29 -	$7.8 \times 10^5$
pONY8.3G PGK +	$1.2 \times 10^6$
pONY8.3G PGK -	$1.2 \times 10^6$
pONY8G	$9.4 \times 10^5$

-66-

Titre was assessed on D17 cells and is expressed as green fluorescent protein cell units/ml (g.f.u./ml). Transfections were carried out with pE syn GP KOZAK and pRV67 as described previously.

- 5 \* pONY8G SfiI FOR is identical to the pONY8.3 derivatives except that there is no promoter-REV expression cassette is inserted in the SfiI site

# pE syn REV plasmid was also included in this transfection

- 10 pONY8G is a standard EIAV vector genome used for comparative purposes

pONY8.3G FB29 – is shown as SEQ ID No 45

pONY8.3G FB29 + is shown as SEQ ID No 46

- 15 pONY8.3GPGK – is shown as SEQ ID No 47

pONY8.3G PGK + is shown as SEQ ID No 48.

## SUMMARY

20

Thus, in summation, the present invention provides high titer regulated retroviral vectors. These regulated retroviral vectors include lentivectors, HRE-regulated vectors and functional SIN vectors which can be produced at high titres from derived producer cell lines.

25

The present invention also provides a method other than retroviral transduction for the transfer of a regulated retroviral vector into a derived producer cell line. This method comprises a recombinase assisted method which allows for the production of high titer regulated retroviral vectors.

30

In one broad aspect, the present invention relates to the selection of cells which express high levels of a retroviral vector genome and exchange of this retroviral genome for the

-67-

vector genome of choice, preferably a regulated retroviral vector genome or a lentiviral vector genome using a cre/loxP recombination system. Thus, the present invention enables regulated retroviral vectors to be produced at high titres from transduced producer cell lines.

5

In another broad aspect, the present invention relates to the selection of cells which express high levels of a retroviral vector genome and exchange of this retroviral genome for the vector genome of choice, preferably a regulated retroviral vector genome or a lentiviral vector genome using a cre/loxP recombination system and a retroviral vector  
10 production system which incorporates a REV protein production system. Thus, the present invention enables regulated retroviral vectors to be produced at high titres from transduced producer cell lines.

All publications mentioned in the above specification are herein incorporated by  
15 reference. Various modifications and variations of the described methods and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various  
20 modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the following claims.



CLAIMS

1. A method of modifying a producer cell which producer cell comprises integrated into its genome a provirus which provirus comprises one or more recombinase  
5 recognition sequences within or upstream of its 3' LTR, the method comprising:  
introducing into the cell a construct comprising a 5' recombinase recognition sequence, an LTR and a 3' recombinase recognition sequence in that order, in the presence of a recombinase which is capable of acting on the recombinase recognition site(s) such that the nucleotide sequence between the 5' and 3' recombinase recognition sequences in the  
10 construct is introduced into the provirus.
2. A method according to claim 1 wherein the construct further comprises at least one nucleotide sequence of interest (NOI) between the 5' recombinase recognition sequence and the LTR, which NOI is operably linked to a transcriptional regulatory  
15 sequence.
3. A method according to claim 1 or claim 2 wherein the construct further comprises a 5'LTR and/or a packaging signal.
- 20 4. A method according to any one of claims 1 to 3 wherein the LTR is a heterologous regulatable LTR.
5. A method according to claim 4 wherein the regulatable LTR comprises an ischaemic like response element (ILRE).  
25
6. A method according to any one of claims 1 to 3 wherein the LTR is inactive.
7. A method according to any one of the preceding claims wherein the provirus comprises an NOI encoding a selectable marker, which NOI is flanked by recombinase  
30 recognition sites
8. A method according to any one of the precedings claims wherein the provirus comprises an internal 5' LTR upstream of the recombinase site or the 5' recombinase site

where there is more than one site.

9. A method according to any one of the preceding claims wherein the U3 region of the 5' LTR is inactive.

5

10. A method according to any one of the preceding claims wherein the U3 region of the 5' LTR and/or the U3 region of the second internal 5'LTR comprises a heterologous promoter.

10 11. A method according to any one of the preceding claims wherein the provirus comprises two recombinase recognition sites and as a preliminary step, the recombinase is expressed in a host cell such that the nucleotide sequence present between the two sites is excised.

15 12. A method according to any one of the preceding claims wherein the producer cell is a high titre producer cell.

13. A method according to any one of the preceding claims wherein the provirus is a lentivirus.

20

14. A method according to claim 13 wherein the lentivirus is HIV or EIAV.

15. A method according to any one of claims 2-14 wherein the provirus further comprises a second NOI.

25

16. A producer cell obtainable by the method of any one of claims 1 to 15.

17. An infectious retroviral particle obtainable from the producer cell of claim 16.

30 18. A derived producer cell comprising integrated into its genome a retroviral vector comprising in the 5' to 3' direction a first 5' LTR; a second NOI operably linked to a second regulatable 3' LTR; and a third 3'LTR;

-70-

wherein the third 3'LTR is positioned downstream of the second regulatable 3'LTR in the producer cell.

19. A producer cell according to claim 18 wherein the first 5' LTR comprising 5'R  
5 and 5' U5 sequences is derivable from a first vector; the second NOI operably linked to a  
second regulatable 3' LTR is derivable from a second vector; and the third 3'LTR is  
derivable from the first vector.

20. A producer cell according to claim 18 or claim 19 wherein the first vector  
10 comprises a retroviral vector wherein the retroviral vector comprises a first NOI flanked  
by recombinase recognition sequences.

21. A producer cell according to claim 19 or claim 20 wherein the retroviral vector  
further comprises an internal LTR located upstream of the first NOI and downstream of a  
15 packaging signal wherein the internal LTR comprises a heterologous U3 sequence linked  
to heterologous R and U5 sequences.

22. A producer cell according to any one of claims 18 to 21 wherein the third 3'LTR  
is transcriptionally quiescent.

20 23. A producer cell according to claim 22 wherein the third 3' LTR comprises a  
deletion in the U3 sequence.

24. A producer cell according to any one of claims 18 to 23 wherein the first NOI is a  
25 selectable marker.

25. A producer cell according to claim 19 wherein the second vector comprises a  
second NOI operably linked to a second regulatable 3'LTR comprising at least one  
recombinase recognition sequence.

30 26. A producer cell according to 25 wherein the second regulatable 3'LTR comprises  
a deletion in the U3 sequences in the 3'LTR.

-71-

27. A producer cell according to claim 25 or claim 26 wherein the second NOI comprises a coding sequence operably linked to a promoter.

28. A producer cell according to claim 27 wherein the second NOI comprises a  
5 discistronic construct.

29. A producer cell according to claim 28 wherein the discistronic construct comprises a therapeutic gene, an internal ribosomal entry site (IRES) and a reporter gene.

10 30. A method for producing a high titre regulatable retroviral vector, the method comprising the steps of:

(i) providing a derived producer cell comprising integrated into its genome a first vector;

15 (ii) introducing a second vector into the derived producer cell using a recombinase assisted method;

wherein the derived producer cell comprises a retroviral vector comprising in the 5' to 3' direction a first 5' LTR; a second NOI operably linked to a second regulatable 3' LTR;  
20 and a third 3'LTR; wherein the third 3'LTR is positioned downstream of the second regulatable 3'LTR in the derived producer cell.

31. A method according to claim 30 wherein the third 3' LTR is transcriptionally active but expression is directed away from the second regulatable 3'LTR.

25

32. A method for introducing a second regulatable 3'LTR into a derived producer cell wherein the method comprises a recombinase assisted method.

33. A method according to claim 32 wherein the recombinase assisted method is a  
30 Cre/lox recombinase method.

-72-

34. A process for preparing a regulated retroviral vector as defined in claim 17 comprising performing the method according to any one of claims 30 to 33 and preparing a quantity of the regulated retroviral vector.
- 5 35. A regulated retroviral vector produced by the process according to claim 34.
36. A regulated retroviral vector according to claim 35 wherein the retroviral vector is capable of transducing a target site.
- 10 37. A regulated retroviral vector according to claim 36 wherein the retroviral vector is produced in sufficient amounts to effectively transduce a target site.
38. A regulated retroviral vector according to claim 36 or claim 37 wherein the target site is a cell.
- 15 39. A cell transduced with a regulated retroviral vector according to claim 38.
40. Use of a regulated retroviral vector according to any one of claims 35 to 38 in the manufacture of a pharmaceutical composition to deliver an NOI to a target site.
- 20 41. Use of a regulated retroviral vector according to any one of claims 35 to 38 in the manufacture of a medicament for diagnostic and/or therapeutic and/or medical applications.
- 25 42. Use of a recombinase assisted mechanism to introduce a regulated 3'LTR into a derived producer cell line to produce a high titre regulated retroviral vector.
43. A derived stable producer cell capable of expressing regulated retroviral vectors according to claims 35 to 38.
- 30 44. A derived stable producer cell according to claim 43 wherein the regulated retroviral vector is a high titre regulated retroviral vector.

-73-

49. A nucleic acid molecule according to any one of claims 46 to 48 wherein the LTR is a heterologous regulatable LTR.

50. A nucleic acid molecule according to any one of claims 46 to 48 wherein the LTR  
5 is transcriptionally quiescent.

51. A method and/or a producer cell substantially as described herein and with reference to the accompanying Figures.

10

15

20

25

30

35

40


45

50

1 / 16

**FIG. 1**


MLV-based transduction using Cre/loxP system as previously described



2 / 16

## FIG. 2

EIAV-based transduction Cre/loxP system






3 / 16

## FIG. 3


MLV SIN vector approach, with EIAV components in blue



4 / 16

## FIG. 4


MLV-based transduction with HRE 3' LTR using Cre/loxP system



5 / 16

## FIG. 5


MLV-based transduction for SIN vector production using Cre/loxP system



6 / 16


## FIG. 6

MLV SIN-vector based transduction system. This general approach can be used with EIAV, HIV or MLV genomes



7 / 16

FIG. 7



8 / 16

FIG. 8







FIG. 9



9 / 16

**FIG. 10a**

FACS analysis of EV1 packaging cells prior to transduction with Trap2 vector

**FIG. 10b**


FACS analysis of EV1 packaging cell line transduced with Trap2 at an MOI of 0.3. A 5% top-slice of the highest expressers was carried out

10 / 16

## FIG. 11

Validation of the  $\Delta\Delta C_t$  method for quantitation of GFP mRNA, relative to  $\beta$ -actin.


A titration of total RNA from EV1 clone A was used. The difference in  $C_t$  values between the two assays is shown on the y-axis. The magnitude of the gradient must be  $<0.1$  for the method to be valid. The gradient is 0.077, so the method is suitable.



## FIG. 12

Quantitation of GFP mRNA relative to control  $\beta$ -actin mRNA. EV2 TD cells are transduced with Trap2 at an MOI of 0.3 and are the calibrator sample with the ratio designated 1.0.


Comparison of GFP expression levels in recombinase cell lines



BEST AVAILABLE COPY



FIG. 13



A) Original GFP expression of the clone.

B) GFP expression 7 days after transfection with Cre recombinase (pBS185). Excision frequency is 64%

C) Recombined clone 4 was identified as being negative for GFP




EV1 A4 cre/pONY8Z



EV2 D4 cre/pONY8Z



EV1 A4 pONY8Z



EV2 D4 pONY8Z

FIG. 14

13 / 16




FIG. 15

14 / 16

## FIG. 16

Alignment of leader and gag regions present in vectors pONY4Z, 8Z and ATG mutated 8Z vector. The later is referred to as pONY8ZA. The sequence aligned are from the NarI site in the leader to the XbaI site between the EIAV gag sequence and the CMV promoter. Sequences in the leader are shown in italic and a space is present upstream of the position of the gag ATG.


4Z	1	<i>cgcccgaacaggga</i> ccctgagaggggcgagaccctacctgttgaacctgg
8Z	1	<i>cgcccgaacaggga</i> ccctgagaggggcgagaccctacctgttgaacctgg
mutated 8Z	1	<i>cgcccgaacaggga</i> ccctgagaggggcgagaccctacctgttgaacctgg
4Z	51	<i>ctg</i> atcgtaggatccccgggacagcagaggagaacttacagaagtcttct
8Z	51	<i>ctg</i> atcgtaggatccccgggacagcagaggagaacttacagaagtcttct
mutated 8Z	51	<i>ctg</i> atcgtaggatccccgggacagcagaggagaacttacagaagtcttct
4Z	101	ggagggtgttcctggccagaacacaggaggacaggtlaag.at-gggagaccc
8Z	101	ggagggtgttcctggccagaacacaggaggacaggtlaag.attgggagaccc
mutated 8Z	101	ggagggtgttcctggccagaacacaggaggacaggtlaag.attgggagaccc
4Z	150	ttgacat-ggagcaaggcgctcaagaagttagagaaggtgacggtacaa
8Z	151	ttgacattggagcaaggcgctcaagaagttagagaaggtgacggtacaa
mutated 8Z	151	ttgacattggagcaaggcgctcaagaagttagagaaggtgacggtacaa
4Z	199	gggtctcagaaattaactactggtaactgtaattgggcgctaagtctagt
8Z	201	gggtctcagaaattaactactggtaactgtaattgggcgctaagtctagt
mutated 8Z	201	gggtctcagaaattaactactggtaactgtaattgggcgctaagtctagt
4Z	249	agacttatttcacat-gataccaactttgtaaaagaaaaggactggcagctg
8Z	251	agacttatttcacat-gataccaactttgtaaaagaaaaggactggcagctg
mutated 8Z	251	agacttatttcattgataccaactttgtaaaagaaaaggactggcagctg

15 / 16

4Z	298	agggat-gtcattccattgctggaagat-gtaactcagacgctgtcagga
8Z	300	agggat-gtcattccattgctggaagat-gtaactcagacgctgtcagga
mutated 8Z	301	agggattgtcattccattgctggaagattgtaactcagacgctgtcagga
4Z	346	caagaaagagaggcctttgaaagaacat-ggtgggcaatttctgctgtaa
8Z	348	caagaaagagaggcctttgaaagaacat-ggtgggcaatttctgctgtaa
mutated 8Z	351	caagaaagagaggcctttgaaagaacattggtgggcaatttctgctgtaa
4Z	395	agat-gggcctccagattaataat-gtagtagat-ggaaaggcatcattc
8Z	397	agat-gggcctccagattaataat-gtagtagat-ggaaaggcatcattc
mutated 8Z	401	agattgggcctccagattaataattgtagtagattggaaaggcatcattc
4Z	442	cagctcctaagagcgaaatat-gaaaagaagactgctaataaaaagcagt
8Z	444	cagctcctaagagcgaaatat-gaaaagaagactgctaataaaaagcagt
mutated 8Z	451	cagctcctaagagcgaaatattgaaaagaagactgctaataaaaagcagt
4Z	491	ctgagccctctgaagaatatct
8Z	493	ctgagccctctgaagaatatct
mutated 8Z	501	ctgagccctctgaagaatatct

FIG. 16 CONT'D

**FIG. 17**  
Schematic representation of the structure of pONY 8.3G +/- vector genome plasmids



## SEQUENCE LISTING PART OF THE DESCRIPTION

## pONY8.1Z MLVHyb (SEQ ID NO 10)

5 AGATCTTGAATAATAAAATGTGTGTTTGCCGAAATACGCGTTTTGAGATTTCTGTGCGCGACTAAATTCATGTGCGCGC  
ATAGTGGTGTATATCGCCGATAGAGATGGCGATATTGGAAAAATTGATATTTGAAAAATATGGCATATTGAAAAATGTGCGC  
CGATGTGAGTTTCTGTGTAACGTATATCGCCATTTTCCAAAAAGTGATTTTTGGGCATACCGGATATCTGGCGATAGCGC  
TTATATCGTTTACGGGGGATGGCGATAGACGACTTTGGTGACTTTGGCGATTCTGTGTGTGCGCAAAATATCGCAGTTTCGA  
TATAGGTGACAGACGATATGAGGCTATATCGCCGATAGAGGGGACATCAAGCTGGCACATGGCCAATGCATATCGATC  
10 TATACATTGAATCAATATTGGCCATTAGCCATATTATTCATTGGTTATATAGCATAAATCAATATTGGCTATTGGCCATT  
GCATACGTTGTATCCATATCGTAATATGTACATTTATATTGGCTCATGTCCAACATTACCGCCATGTTGACATTGATTATT  
GACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCGCGTTACATAAATTACGG  
TAAATGGCCCGCTGGCTGACCGCCCAACGACCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCC  
AATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTACGGTAACTGCCCACTTGGCAGTACATCAAGTGTATCAT  
15 ATGCCAAGTCCGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCTGGCATTATGCCCAGTACATGACCTTACGGG  
ACTTCTCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACCAATGGG  
CGTGGATAGCGGTTTGACTACGGGGATTTCGAAGTCTCCACCCCATTGACGTCAATGGGAGTTTGTTTGGCACCAAA  
ATCAACGGGACTTTCCAAAATGTCGTAACAACGTGCGATCGCCCGCCCGTTGACGCAAAATGGGCGGTAGGCGGTGACGG  
TGGGAGGTCTATATAAGCAGAGCTCGTTAGTGAACCGGCACTCAGATTCTGCGGTCTGAGTCCCTTCTGCTGGGCT  
20 GAAAAAGGCCTTTGTAATAAATAAATCTCTACTCAGTCCCTGTCTCTAGTTGTCTGTTTCGAGATCCTACAGTTGGCGC  
CCGAACAGGGACCTGAGAGGGGGCGCAGACCCTACCTGTTGAACCTGGCTGATCGTAGGATCCCCGGGACAGCAGAGGA  
GAACTTACAGAAGTCTTCTGGAGGTGTTCTGGCCAGAACACAGGAGGACAGGTAAGATTGGGAGACCTTTGACATT  
GGAGCAAGGCGCTCAAGAAGTTAGAGAAGGTGACGGTACAAGGTCTCAGAAATTAATACTGGTAACTGTAATTGGG  
CGCTAAGTCTAGTAGACTTATTTATGATACCAACTTTGTAAGAAAGAAAGGACTGGCAGCTGAGGGATGTCATTCCATT  
25 GCTGGAAGATGTAACCTCAGACGCTGTCAGGACAAGAAAGAGAGGCTTTGAAAGAACATGGTGGGCAATTTCTGCTGT  
AAAGATGGGCCTCCAGATTAATAATGTAGTAGATGGAAGGCAATCCAGCTCCTAAGAGCGAAATATGAAAAGAA  
GACTGCTAATAAAAAGCAGTCTGAGCCCTCTGAAGAATATCTCTAGAATACTAGTGGATCCCCGGGCTGCAGGAGTGGG  
GAGGCACGATGGCCGCTTGGTTCGAGGCGGATCCGGCCATTAGCCATATTATTCATTGGTTATATAGCATAAATCAATA  
TTGGCTATTGGCCATTGCATACGTTGTATCCATATCATAATATGTACATTTATATTGGCTCATGTCCAACATTACCGCCAT  
30 GTTGACATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCGCG  
GTTACATAACTTACGGTAAATGGCCCGCTGGCTGACCGCCCAACGACCCCGCCCATTGACGTCAATAATGACGTATG  
TTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAACTGCCCACTTGGCAGT  
ACATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCTGGCATTATGCCAG  
TACATGACCTTATGGGACTTTCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTG  
35 GCAGTACATCAATGGGCGTGGATAGCGGTTTGACTACGGGGATTTCGAAGTCTCCACCCCATTGACGTCAATGGGAGT  
TTGTTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAACAACCTCCGCCCCATTGACGCAAAATGGGCGGTAGGC  
ATGTACGGTGGGAGGTCTATATAAGCAGAGCTCGTTTGTGAACCGTCAGATCGCCTGGAGACGCCATCCACGCTGTTT  
TGACCTCCATAGAAGACACCGGGACCGATCCAGCCTCCGCGGCCCAAGCTTCAGCTGCTCGAGGATCTGCGGATCCGG  
GGAATTCGCCAGTCTCAGGATCCACCATGGGGGATCCCGTCGTTTTACAACGTCGTGACTGGGAAAACCTGGCGTTAC  
40 CCAACTTAATCGCCTTGACGACATCCCCCTTTCCGACGCTGGCGTAATAGCGAAGAGGCGCCGACCGATCGCCCTTCC  
CAACAGTTGCGCAGCCTGAATGGCGAATGGCGCTTTGCCTGGTTTCCGGCACCAAGAGCGGTGCCGGAAGCTGGCTG  
GAGTGGCATCTTCTGAGGCCGATACTGTCGTCGTCCTCAAACCTGGCAGATGCACGGTTACGATGCGCCCATCTACA  
CCAACGTAACTATCCATTACGGTCAATCCGCGCTTTGTTCCACGGAGAATCCGACGGGTTGTTACTCGCTCACATTT  
AATGTTGATGAAAGCTGGCTACAGGAAGGCCAGACGCGAATATTTTTGATGGCGTTAACTCGGCGTTTCATCTGTGGT  
45 GCAACGGGCGCTGGGTGCGTTACGGCCAGGACAGTCGTTTGGCGTCTGAATTTGACCTGAGCGCATTTTTACGGCCGG  
AGAAAACCGCCTCGCGGTGATGGTGCTGCGTTGGAGTGACGGCAGTTATCTGGAAGATCAGGATATGTGGCGGATGAG  
CGGCATTTCCGTGACGTCTCGTTGCTGCATAAACCGACTACACAAATCAGCGATTTCCATGTTGCCACTCGCTTAATG  
ATGATTTACGGCGCTGTACTGGAGGCTGAAGTTACAGATGTGCGCGAGTTGCGTGACTACCTACGGGTAAACAGTTTC  
TTTATGGCAGGGTGAAACGCAGGTCGCCAGCGGCACCGCGCTTTCCGCGGTGAAATTATCGATGAGCGTGGTGGTTAT

GCCGATCGCGTCACACTACGTCTGAACGTCGAAAACCCGAAACTGTGGAGCGCCGAAATCCCGAATCTCTATCGTGCGG  
TGTTGAACTGCACACCGCCGACGGCACGCTGATTGAAGCAGAAGCCTGCGATGTCGGTTTCCCGGAGGTGCGGATTGA  
AAATGGTCTGCTGCTGCTGAACGGCAAGCCGTGCTGATTGAGGGCTTAACCGTCACGAGCATCATCTCTGCATGGT  
CAGGTCATGGATGAGCAGACGATGGTGCAGGATATCCTGCTGATGAAGCAGAACAACCTTTAACGCCGTGCGCTGTTCCG  
5 ATTATCCGAACCATCCGCTGTGGTACACGCTGTGCGACCGCTACGGCCTGTATGTGGTGGATGAAGCCAATATTGAAAC  
CCACGGCATGGTGCCAATGAATCGTCTGACCGATGATCCGCGCTGGCTACCGCGATGAGCGAACCGTAACCGGAAT  
GGTGCAGCGGATCGTAATCACCCGAGTGTGATCATCTGGTCTGGGAATGAATCAGGCCACGGCGCTAATCAGCA  
CGCGCTGTATCGCTGGATCAAATCTGTCGATCCTTCCCGCCCGGTGCAGTATGAAGCGCGCGAGCCGACACCACGGCC  
ACCGATATTATTTGCCGATGTACGCGCGCTGGATGAAGACCAGCCCTTCCCGCTGTGCCGAAATGGTCCATCAAAA  
10 AATGGCTTTTCGCTACCTGGAGAGACGCGCCCGCTGATCCTTTGCGAATACGCCACGCGATGGGTAAACAGTCTTGGCGG  
TTTCGCTAAATACTGGCAGGGCTTTCGTAGTATCCCGCTTACAGGGCGCTTCTGCTGGGACTGGGTGGATCAGTCGC  
TGATTAATATGATGAAAACGGCAACCCGTGGTGGCTTACGGCGGTGATTTTGCGGATACGCCAAGCATCGCCAGTT  
CTGTATGAACGGTCTGGTCTTTGCCGACCGCACGCGCATCCAGCGCTGACGGAAGCAAAACACCAAGCAGCAGTTTTC  
CAGTTCGGTTTATCCGGGCAAACCATCGAAGTGACCAGCGAATACCTGTTCCGTCATAGCGATAACGAGCTCCTGCACT  
15 GGATGGTGGCGCTGGATGGTAAGCCGCTGGCAAGCGGTGAAGTGCTCTGGATGTGCTCCACAAGGTAAACAGTTGA  
TTGAACTGCCTGAACTACCGCAGCCGGAGAGCGCCGGCAACTCTGGCTCACAGTACCGGTAGTGCAACCGAACCGCA  
CCGCATGGTCAGAAGCCGGGCACATAGCGCTGGCAGCAGTGGCGTCTGGCGGAAAACCTCAGTGTGACGCTCCCCG  
CCGCGTCCACGCCATCCCGCATCTGACCACCAGCGAAATGGATTTTGCATCGAGCTGGGTAATAAGCGTTGGCAATT  
TAACCGCCAGTCAGGCTTTCTTTCACAGATGTGGATTGGCGATAAAAAACAAGTCTGACGCCGCTGCGCGATCAGTTC  
20 ACCCGTGCACCGCTGGATAACGACATTGGCGTAAGTGAAGCGACCCGATTGACCCTAACCGCTGGGTGCAACGCTGG  
AAGGCGGCGGCCATTACCAGGCCGAAGCAGCGTTGTTGCAGTGCACGGCAGATACACTTGCTGATGCGGTGCTGATT  
ACGACCGCTCACGCGTGGCAGCATCAGGGGAAAACCTTATTTATCAGCCGAAAACCTACCGGATTGATGGTAGTGGTC  
AAATGGCGATTACCGTTGATGTTGAAGTGGCGAGCGATACCCGATCCGCGCGGATTGGCTGAAGTGGCAGCTGGC  
GCAAGTAGCAGAGCGGGTAACTGGCTCGGATTAGGGCCGAAGAAAACCTATCCCGACCGCTTACTGCCGCTGTTTT  
25 GACCGCTGGGATCTGCCATTGTGACAGATGTATACCCCGTACGCTTCCCGAGCGAAAACGGTCTGCGTGGGGACGC  
GCGAATTGAATTATGCCCCACACCAAGTGGCGCGGCACTTCCAGTTCAACATCAGCCGCTACAGTCAACAGCAACTGAT  
GGAAACCAGCATCGCCATCTGCTGCACGGGAAGAAGGCACATGGTGAATATCGACGGTTTCCATATGGGGATTGG  
TGGCGAGCACTCCTGGAGCCCGTCAGTATCGGCGGAATTCAGCTGAGCGCCCGTCCGCTACCATTACCAGTTGGTCTGG  
TGTCAAAAATAATAAACCAGGCGAGGGGGATCCGAGATCCGGCTGTGGAATGTGTGTCAGTTAGGGTGTGGAAG  
30 TCCCCAGGCTCCCCAGCAGGCAGAAGTATGCAAAGCATGCCTGCAGGAATTCGATATCAAGCTTATCGATACCGTCGAA  
TTGGAAGAGCTTTAAATCCTGGCAGATCTCATGTATCAATGCCTCAGTATGTTTAGAAAAACAAGGGGGAACTGTGGG  
GTTTTATGAGGGGTTTTATAATGAAAGACCCACCTGTAGGTTTGGCAAGCTAGCTTAAGTAACGCCATTTTGAAGG  
CATGGAAAAATACATAACTGAGAATAGAGAAGTTCAGATCAAGGTACAGGAACAGATGGAACAGCTGAATATGGGCCA  
AACAGGATATCTGTGGTAAGCAGTTCTGCCCCGGCTCAGGGCCAAGAACAGATGGAACAGCTGAATATGGGCCAAAC  
35 AGGATATCTGTGGTAAGCAGTTCTGCCCCGGCTCAGGGCCAAGAACAGATGGTCCCAGATGCGGTCCAGCCCTCAGC  
AGTTTCTAGAGAACCATCAGATGTTTCCAGGGTCCCCAAGGACCTGAAATGACCCTGTGCCTTATTTGAACTAACCA  
TCAGTTCCGTTCTCGCTTCTGTTCCGCGCTTCTGCTCCCCGAGCTCAATAAAGAGCCCAACCCCTCACTCGGGGGG  
CACTCAGATTCTGCGGTCTGAGTCCCTTCTGCTGGGCTGAAAAGGCCCTTGTAAATAAATAAATCTCTACTCAGTCC  
CTGTCTCTAGTTTGTCTGTTGAGATCTACAGAGCTCATGCCCTGGCGTAATCATGGTCATAGCTGTTTCTGTGTGAA  
40 ATTGTTATCCGCTCACAATTCCACACAACATACGAGCCGGAAGCATAAAGTGTAAAGCCTGGGGTGCCTAATGAGTGAG  
CTAACTCACATTAATTGCGTTGCGCTCACTGCCCCGCTTCCAGTCGGGAAACCTGTCGTGCCAGCTGCATTAATGAATCG  
GCCAACGCGCGGGGAGAGGCGGTTTGGTATTGGGCGCTTCTCCGCTTCTCGCTCACTGACTCGCTGCGCTCGGTCTGTT  
CGGCTGCGGCGAGCGGTATCAGTCACTCAAAGGCGGTAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAG  
AACATGTGAGCAAAAAGGCCAGCAAAAAGGCCAGGAACCGTAAAAAGGCCGCTTGTGGCGTTTTTCCATAGGCTCCGC  
45 CCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAAGCG  
TTTCCCCCTGGAAGCTCCCTCGTGGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCTTTCTCCCTTCG  
GGAAGCGTGGCGCTTTCTCATAGCTCAGCTGTAGGTATCTCAGTTCCGGTGTAGTCTGCTCCAAGCTGGGCTGTGT  
GCACGAACCCCCGTTACGCCCCAGCGCTGCGCTTATCCGGTAACATCGTCTTGAAGTCCAACCCGGTAAGACACGAC  
TTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGT



GGTGGCCTAACTACGGCTACACTAGAAAGGACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAG  
AGTTGGTAGCTCTTGATCCGGCAAAACAAACCACCGCTGGTAGCGGTGGTTTTTTGTTTGCAAGCAGCAGATTACGGGC  
AGAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAAACGAAAACTCACGTTAAG  
GGATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAATAATGAAGTTTAAATCAATCTAA  
5 AGTATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTCCG  
TTCATCCATAGTTGCGTACTCCCGTCGTGTAGATAACTACGATACGGGAGGGCTTACCATCTGCCCCAGTGCTGCA  
ATGATACCGCGAGACCCACGCTACCGGCTCCAGATTTATCAGCAATAAACAGCCAGCCGGAAGGGCCGAGCGCAGA  
AGTGGTCTGCAACTTTATCCGCTCCATCCAGTCTATTAAATGTTGCCGGAAGCTAGAGTAAGTAGTTCGCCAGTTAA  
TAGTTTGGCAACGTTGTTGCCATTGCTACAGGCATCGTGGTGTACGCTCGTCGTTGGTATGGCTTCAITCAGCTCCG  
10 GTTCCCAACGATCAAGGCGAGTTACATGATCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCTCCGATCGTT  
GTCAGAAGTAAAGTTGGCCGAGTGTATCACTCATGGTTATGGCAGCACTGCATAATTCTCTTACTGTCTATGCCATCCGT  
AAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTGTATGGCGGACCGAGTTGCTCTTGCC  
CGGGCTCAATACGGGATAATACCGCGCCACATAGCAGAACTTTAAAAAGTGCTCATATTGGAAAACGTTCTTCGGGGCG  
AAAACCTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTGATGTAACCCACTCGTGCAACCAACTGATCTTCAGCATCTT  
15 TTACTTTACCAGCGTTTCTGGGTGAGCAAAAAACGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACGGA  
AATGTTGAATACTCATACTCTTCTTTTCAATATTATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGGATACATAT  
TTGAATGTATTTAGAAAAATAACAATAAGGGGTTCCGCGCACATTTCCCCGAAAAGTGCCACCTAAATTGTAAAGCGTT  
AATATTTGTTAAAAATTCGCGTTAAATTTTGTAAATCAGCTCATTTTTTAACCAATAGGCCGAAATCGGCAAAATCCC  
TTATAAATCAAAAAGATAGACCGAGATAGGGTTGAGTGTGTTCCAGTTTGAACAAGAGTCCACTATTAAGAAGCGT  
20 GACTCCAACGTCAAAGGGCGAAAAACCGTCTATCAGGGCGATGGCCCACTACGTGAACCATCACCTAATCAAGTTTTT  
TGGGGTCGAGGTGCCGTAAAGCACTAAATCGGAACCTTAAAGGGAGCCCCGATTTAGAGCTTGACGGGGAAAGCCAA  
CCTGGCTTATCGAAATTAATACGACTCACTATAGGGAGACCGGC

### pONY8.3G FB29 – (SEQ ID No 45)

25

AGATCTTGAATAATAAAATGTGTGTTTGTCCGAAATACGCGTTTTGAGATTTCTGTGCGC  
GACTAAATTCATGTCGCGGATAGTGGTGTATCGCCGATAGAGATGGCGATATTGGAA  
AAATTGATATTTGAAAATATGGCATATTGAAAATGTCGCGGATGTGAGTTTCTGTGTAA  
TGATATCGCCATTTTCCAAAAGTGATTTTTGGGCATACGCGATATCTGGCGATAGCGCT  
TATATCGTTTACGGGGGATGGCGATAGACGACTTTGGTGACTTGGGCGATTCTGTGTGTC  
GCAAAATATCGCAGTTTCGATATAGGTGACAGACGATATGAGGCTATATCGCCGATAGAGG  
CGACATCAAGCTGGCACATGGCCAATGCATATCGATCTATACATTGAATCAATATTGGCC  
ATTAGCCATATTATTCATTGGTTATATAGCATAAATCAATATTGGCTATTGGCCATTGCA  
TACGTTGTATCCATATCGTAATATGTACATTTATATTGGCTCATGTCCAACATTACCGCC  
ATGTTGACATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCA  
TAGCCCATATATGGAGTTCGCGTTACATAACTTACGGTAAATGGCCCGCTGGCTGACC  
GCCCCAACGACCCCGCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAAT  
AGGGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGT  
ACATCAAGTGTATCATATGCCAAGTCCGCCCCCTATTGACGTCAATGACGGTAAATGGCC  
CGCTGGCATTATGCCCAGTACATGACCTTACGGGACTTTCCTACTTGGCAGTACATCTA  
CGTATTAGTCATCGCTATTACCATGGTGTGCGGTTTGGCAGTACACCAATGGGCGTGG  
ATAGCGGTTTGACTCACGGGGATTTCGAAGTCTCCACCCATTGACGTCAATGGGAGTTT  
GTTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAACAACGCGATCGCCCGCC  
CCGTTGACGCAAAATGGGCGGTAGGCGGTACGGTGGGAGGTCTATATAAGCAGAGCTCGT  
TTAGTGAACCGGGCACTCAGATTCTGCGGTCTGAGTCCCTTCTCTGCTGGGCTGAAAAGG  
CCTTTGTAATAAATAAATTCTACTCAGTCCCTGTCTCTAGTTTGTCTGTTTCGAGATC  
CTACAGTTGGCGCCCGAACAGGGACCTGAGAGGGGCGCAGACCCTACCTGTTGAACCTGG  
CTGATCGTAGGATCCCCGGGACAGCAGAGGAGAACCTACAGAAGTCTTCTGGAGGTGTTT

CTGGCCAGAACACAGGAGGACAGGTAAGATTGGGAGACCCTTTGACATTGGAGCAAGGCG  
CTCAAGAAGTTAGAGAAGGTGACGGTACAAGGGTCTCAGAAATTAACACTGGTAACGTG  
AATTGGGCGCTAAGTCTAGTAGACTTATTTTCATGATACCAACTTTGTAAAAAGAAAGGAC  
TGGCAGCTGAGGGATGTCATTCCATTGCTGGAAGATGTAACTCAGACGCTGTCAGGACAA  
GAAAGAGAGGCCCTTTGAAAGAACATGGTGGGCAATTTCTGCTGTAAAGATGGGCCTCCAG  
ATTAATAATGTAGTAGATGGAAAGGCATCATTCCAGCTCCTAAGAGCGAAATATGAAAAAG  
AAGACTGCTAATAAAAGCAGTCTGAGCCCTCTGAAGAATATCTCTAGAACTAGTGGATC  
CCCCGGGCTGCAGGAGTGGGGAGGCACGATGGCCGCTTTGGTCGAGGCGGATCCGGCCAT  
TAGCCATATTATTCATTGGTTATATAGCATAAATCAATATTGGCTATTGGCCATTGCATA  
CGTTGTATCCATATCATAATATGTACATTTATATTGGCTCATGTCCAACATTACCGCCAT  
GTTGACATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATA  
GCCCATATATGGAGTTCGCGTTACATAACTTACGGTAAATGGCCCGCTGGCTGACCGC  
CCAACGACCCCCGCCATTGACGTCAAT.AATGACGTATGTTCCCATAGTAACGCCAATAG  
GGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTAC  
ATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCG  
CCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACG  
TATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGAT  
AGCGGTTTTGACTACGGGGATTTCGAAGTCTCCACCCCATTTGACGTCAATGGGAGTTTGT  
TTTGGCACAAAATCAACGGGACTTTCCAAAATGTCGTAACAACCCGCCCCATTGACGC  
AAATGGGCGGTAGGCATGTACGGTGGGAGGTCTATATAAGCAGAGCTCGTTTAGTGAACC  
GTCAGATCGCTGGAGACGCCATCCACGCTGTTTTGACCTCCATAGAAGACACCGGGACC  
GATCCAGCTCCGCGGCCCAAGCTTGTGGGATCCACGGTCGCCACCATGGTGAGCAA  
GGGCGAGGAGCTGTTACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAA  
CGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGAC  
CCTGAAGTTTACTCTGCACACCGGCAAGCTGCCCGTGCCCTGGCCACCCCTCGTGACCAC  
CCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACTT  
CTTCAAGTCCGCCATGCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGA  
CGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCAT  
CGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTA  
CAACTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGT  
GAATTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACCA  
GCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCAC  
CCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCTGCTGGAGTT  
CGTGACCGCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAGTAAAGCGGCCGCGA  
CTCTAGAGTCGACCTGCAGGCATGCAAGCTTCAGCTGCTCGAGGGGGGGCCCGGTACCCA  
GCTTTTGTTCCTTTAGTGAGGGTTAATTGCGCGGAAGTATTTATCACTAATCAAGCAC  
AAGTAATACATGAGAACTTTTACTACAGCAAGCACAATCCTCCAAAAATTTTGTTTTT  
ACAAAATCCCTGGTGAACATGATTGGAAGGGACCTACTAGGGTGCTGTGGAAGGGTGATG  
GTGCAGTAGTAGTTAATGATGAAGGAAAGGGAATAATTGCTGTACCATTAAACAGGACTA  
AGTTACTAATAAAACCAAATTGAGTATTGTTGCAGGAAGCAAGACCCAACTACCATTGTC  
AGCTGTGTTTCTGACCTCAATATTTGTTATAAGGTTTGATATGAATCCAGGGGGAATC  
TCAACCCCTATTACCAACAGTCAGAAAAATCTAAGTGTGAGGAGAACAATGTTTCAA  
CCTTATTGTTATAATAATGACAGTAAGAACAGCATGGCAGAATCGAAGGAAGCAAGAGAC  
CAAGAATGAACCTGAAAGAAAGATCT.AAAGAAGAAAAAGAAATGACTGGTGAAAA  
TAGGTATGTTTCTGTTATGCTTAGCAGGAACACTACTGGAGGAATACTTTGGTGGTATGAAG  
GACTCCCACAGCAACATTATATAGGGTTGGTGGCGATAGGGGGAAGATTAAACGGATCTG  
GCCAATCAAATGCTATAGAATGCTGGGGTTCCTTCCCGGGGTAGACCATTTCAAAATT  
ACTTCAGTTATGAGACCAATAGAAGCATGCATATGGATAATAATACTGCTACATTATTAG  
AAGCTTTAACCAATATAACTGCTCTATAAATAACAAAACAGAATTAGAAACATGGAAGTT

AGTAAAGACTTCTGGCATAACTCCTTTACCTATTTCTCTGAAGCTAACACTGGACTAAT  
TAGACATAAGAGAGATTTTGGTATAAGTGCAATAGTGGCAGCTATTGTAGCCGCTACTGC  
TATTGCTGCTAGCGCTACTATGTCTTATGTTGCTCTAACTGAGGTTAACAAAATAATGGA  
AGTACAAAATCATACTTTTGGGTAGAAAATAGTACTCTAAATGGTATGGATTTAATAGA  
ACGACAAAATAAAGATATTATATGCTATGATTCTTCAAACACATGCAGATGTTCAACTGTT  
AAAGGAAAGACAACAGGTAGAGGAGACATTTAATTTAATTGGATGTATAGAAAGAACACA  
TGTATTTTGTCTACTGGTCATCCCTGGAATATGTCATGGGGACATTTAAATGAGTCAAC  
ACAATGGGATGACTGGGTAAAGCAAAATGGAAGATTTAAATCAAGAGATACTAACTACACT  
TCATGGAGCCAGGAACAATTTGGCACAATCCATGATAACATTCAATACACCAGATAGTAT  
AGCTCAATTTGGAAAAGACCTTTGGAGTCATATTGGAAATTGGATTCTGGATTGGGAGC  
TTCCATTATAAAATATATAGTGATGTTTTTGCTTATTTATTTGTTACTAACCTCTCGCC  
TAAGATCCTCAGGGCCCTCTGGAAGGTGACCAGTGGTGCAGGGTCTCCGGCAGTCGTTA  
CCTGAAGAAAAAATTCATCACAACATGCATCGCGAGAAGACACCTGGGACCAGGCCCA  
ACACAACATACCTAGCAGCGGTGACCGGTGGATCAGGGGACAAATACTACAAGCAGAA  
GTACTCCAGGAACGACTGGAATGGAGAATCAGAGGAGTACAACAGCGGCCAAAGAGCTG  
GGTGAAGTCAATCGAGGCATTTGGAGAGAGCTATATTTCCGAGAAGACCAAAGGGGAGAT  
TTCTCAGCCTGGGGCGGCTATCAACGAGCACAAGAACGGCTCTGGGGGGAACAATCCTCA  
CCAAGGGTCTTAGACCTGGAGATTCTGAAGCGAAGGAGGAAACATTTATGACTGTTGCAT  
TAAAGCCCAAGAAGGAACTCTCGCTATCCCTTGCTGTGGATTTCCCTTATGGCTATTTTG  
GGGACTAGTAATTATAGTAGGACGCATAGCAGGCTATGGATTACGTGGACTCGCTGTTAT  
AATAAGGATTTGTATTAGAGGCTTAAATTTGATATTTGAAATAATCAGAAAAATGCTTGA  
TTATATTGGAAGAGCTTAAATCCTGGCACATCTCATGTATCAATGCCTCAGTATGTTTA  
GAAAAACAAGGGGGGAAGTGTGGGGTTTTATGAGGGTTTTATAAATGATTATAAGAGT  
AAAAAGAAAGTTGCTGATGCTCTCATAACCTTGTATAACCCAAAGGACTAGCTCATGTTG  
CTAGGCAACTAAACCGCAATAACCGCATTTGTGACGCGAGTCCCCATTGGTGACGCGTT  
AACTTCCTGTTTTACAGTATATAAGTGCTTGTATTCTGACAATTGGGCACTCAGATTCT  
GCGGTCTGAGTCCCTTCTGCTGGGCTGAAAAGGCCTTTGTAATAAATATAATTCTCTA  
CTCAGTCCCTGTCTCTAGTTTGTCTGTTCTGAGATCCTACAGAGCTCATGCCTTGGCGTAA  
TCATGGTCATAGCTGTTTCTGTGTGAAATTGTTATCCGCTCACAATCCACACAACATA  
CGAGCCGGAAGCATAAAGTGTAAGCCTGGGGTGCTAATGAGTGAGCTAACTCACATTA  
ATTGCGTGTGCGCTCACTGCCCGCTTTCCAGTCGGGAAACCTGTGCTGCCAGTGATGCCCCG  
GGCGGCCGAGCGGCCCTACGTGAACCATCACCCAAATCAAGTTTTTTCGGTTCGAGGTGC  
CGTAAAGCTCTAAATCGGAACCTAAAGGGAGCCCCGATTTAGAGCTTGACGGGGAAAG  
CCGGCGAACGTGGCGAGAAAGGAAGGGAAGAAAGCGAAAGGAGCGGGCGCTAGGGCGCTG  
GCAAGTGTAGCGGTACGCTGCGCGTAACCAACACACCCGCGCGCTTAATGCGCGCTA  
CAGGGCGCGTCCATTCCGCAATTCAGGCTGCGCAACTGTTGGGAAGGGCGATCGGTGCGGG  
CCTCTTCGCTATTACGCCAGCCCGGATCGATCCTTATCGGATTTTACCACATTTGTAGAG  
GTTTTACTTGCTTTAAAAAACCTCCACATCTCCCCCTGAACCTGAAACATAAAATGAAT  
GCAATTGTTGTTGTTAACTTGTTTATTGCAGCTTATAATGGTTACAAATAAAGCAATAGC  
ATCACAAATTTACAAATAAAGCATTTTTTCACTGCATTCTAGTTGTGGTTGTCCAAA  
CTCATCAATGTATCTTATCATGTCTGCTCGAAGCATTAAACCTCACTAAAGGGAAGCGGC  
CGCCCGGGTCTGACTTCACAGGTGTTTGGCGCTCTTTGGAGTCTCCGGGCTCAAGACG  
CGGGGGCTGCTCTGCTCGCCCCACAGCCTTTCTTGCCCTCTGGTAGCCTCCCCATGCG  
GAGAAATCGCCCTCTGGTCTCGCGGAAGTAGAGCTCCCTCCAGATGCCGCGATTACC  
TCTCCAGCTCTTTAGCGGCTTGTTGCACGCCCTAATCTCCATTCCAGCCTTTCTTG  
AGGACCTCGGCTTGCAAAATCTGGCCCTAATCCACCTATCCCTCTGGAGGGTGTGTGC  
TGGGTGGGACCGGGGCGAGGTGTCTTGGCGATGCAGGTCTGGCTAGGAATCTTCTCC  
TCGGGCAGGACTGTCTCAGCACGCGGCACCACTGGTCCCCCTCCAGGGGGCTTGTGGG  
TCGATCTCCACCAGTCGTTGCGGCGCTTCTCCTTTGCTCTTCTTCTGAGGTTTCATC

TCTTGATCCCTGGCCTCCTTGCTCTCAGCCATGGTGGCGAATTCTCGAGGCTAGCCTCCC  
GGTGGTGGGTGGTGGTCCCTGGGCAGGGGTCTCCAGATCCCGGACGAGCCCCAAATGA  
AAGACCCCCGAGACGGGTAGTCAATCACTCTGAGGAGACCCTCCCAAGGAACAGCGAGAC  
CACGAGTCGGATGCAACAGCAAGAGGATTTATTGGATACACGGGTACCCGGGCGACTCAG  
TCTATCGGAGGACTGGCGGCCGAGTGAGGGGTTGTGAGCTCTTTATAGAGCTCGGGAA  
GCAGAAGCGCGCAACAGAAGCGAGAAGCAGGCTGATTGGTTAATTCAAATAAGGCACAG  
GGTCATTTCAGGTCCTTGGGGGAGCCTGGAAACATCTGATGGGTCTTAAGAACTGCTGA  
GGGTTGGGCCATATCTGGGGACCATCTGTCTTGGCCCCGGGCGGGGCCGAACCGCGGT  
GACCATCTGTTCTTGGCCCCGGGCGGGGCCGAAACTGCTCACCGCAGATATCCTGTTTG  
GCCCCACGTTAGCTGTTTTCTGTACCCGCCCTGATCTGAACCTCTCTATTCTTGGTTT  
GGTATTTTCCATGCCTTGCAAAATGGCGTTACTGCGGCTATCAGGCTAAGCAATTTGAG  
ATCTGGCCGAGGCGGCCTACTCTGCATTAATGAATCGGCCAACGCGGGGAGAGGCGGT  
TTGCGTATTGGGCGCTCTCCGCTTCTCGCTCACTGACTCGCTCGGCTCGGTCGTTCCG  
CTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGGTAATACGGTTATCCACAGAATCAGGG  
GATAACGCAGGAAAGAACATGTATAACTTCGTATAATGTATGCTATACGAAGTTATACAT  
GTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCTTGCTGGCGTTTTT  
CCATAGGCTCCGCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCG  
AAACCCGACAGGACTATAAAGATACCAAGGCGTTTCCCCCTGGAAGCTCCCTCGTGGCTC  
TCTGTTCGACCTGCGGCTTACCGGATACCTGTCCGCTTTCTCCCTTCGGGAAGCGT  
GGCGCTTCTCATAGCTACGCTGTAGGTATCTCACTTCGGTGTAGGTCGTTGCTCCAA  
GCTGGGCTGTGTGCACGAACCCCCGTTACGCCCCAGCGCTGCGCTTATCCGGTAACTA  
TCGTCTTGAGTCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAA  
CAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCTAA  
CTACGGCTACACTAGAAGGACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTT  
CGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAAACAAACCACCGCTGGTAGCGGTGGTTT  
TTTTGTTTGAAGCAGCAGATTACGCGCAGAAAAAAGGATCTCAAGAAGATCCTTTGAT  
CTTTCTACGGGTCTGACGCTCAGTGGAAACGAAACTCACGTTAAGGGATTTTGGTCAT  
GAGATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAGTTTAAATC  
AATCTAAAGTATATATGAGTAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGC  
ACCTATCTCAGCGATCTGTCTATTTCTGTTACCATAGTTGCCTGACTCCCCGTCGTGTA  
GATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGTGCAATGATACCGCGAGA  
CCCACGCTCACGGCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCG  
CAGAAGTGGTCTCTGCAACTTTATCCGCTCCATCCAGTCTATTAATTGTTGCCGGGAAGC  
TAGAGTAAGTAGTTCCGAGTTAATAGTTTGCACAACGTTGTTGCCATTGCTACAGGCAT  
CGTGGTGTACGCTCGTCGTTTGGTATGGCTTCATCAGCTCCGTTCCCAACGATCAAG  
GCGAGTTACATGATCCCCATGTTGTGCAAAAAGCGGTTAGCTCCTTCGGTCCTCCGAT  
CGTTGTGCAAGTAAGTTGGCCGAGTGTATCACTCATGGTTATGGCAGCACTGCATAA  
TTCTCTTACTGTATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAA  
GTCAATTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAATACGGGA  
TAATACCGCGCCACATAGCAGAACTTTAAAAGTGCTCATCATTTGAAAAACGTTCTTCGGG  
GCGAAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGC  
ACCCAAGTATCTTCAGCATCTTTACTTTTACCAGCGTTTCTGGGTGAGCAAAAAACAGG  
AAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACAGGAAATGTTGAATACTCATACT  
CTTCCTTTTCAATATTATTGAAGCATTATCAGGGTTATTGTCTCATGAGCGGATACAT  
ATTTGAATGTATTAGAAAAATAAACAAATAGGGGTTCGCGCACATTTCGCCAAAAAGT  
GCCACCTAAATTGTAAGCGTTAATATTTGTTAAAAATTCGCGTTAAATTTTGTAAAAATC  
AGCTCATTTTTTAACCAATAGGCCGAAATCGGCAAAATCCCTTATAAATCAAAAGAATAG  
ACCGAGATAGGGTTGAGTGTGTTCCAGTTTGAACAAGAGTCCACTATTAAGAACGTG  
GACTCCAACGTCAAAGGGCGAAAAACCGTCTATCAGGGCGATGGCCCACTACGTGATAAC

TTCGTATAATGTATGCTATACGAAGTTATCACTACGTGAACCATCACCTAATCAAGTTT  
TTTGGGGTCGAGGTGCCGTAAGCACTAAATCGGAACCTAAAGGGAGCCCCGATTAG  
AGCTTGACGGGGAAAGCCAACCTGGCTTATCGAAATTAATACGACTCACTATAGGGAGAC  
CGGC

**pONY8.3G FB29 + (SEQ ID No 46)**

AGATCTTGAATAATAAAATGTGTGTTGTCCGAAATACCGCTTTGAGATTTCTGTGCGC  
GACTAAATTCATGTGCGCGGATAGTGGTGTATCGCCGATAGAGATGGCGATATTGGA  
AAATTGATATTTGAAAATATGGCATATTGAAAATGTGCGCGATGTGAGTTTCTGTGTAAC  
TGATATCGCCATTTTCCAAAAGTGATTTTGGGCATACCGGATATCTGGCGATAGCGCT  
TATATCGTTTACGGGGGATGGCGATAGACGACTTGGTGACTTGGGCGATTCTGTGTGTC  
GCAAATATCGCAGTTTCGATATAGGTGACAGACGATATGAGGCTATATCGCCGATAGAGG  
CGACATCAAGCTGGCACATGGCCAATGCATATCGATCTATACATTGAATCAATATTGGCC  
ATTAGCCATATTATTCATTGGTTATATAGCATAAATCAATATTGGCTATTGGCCATTGCA  
TACGTTGTATCCATATCGTAATATGTACATTTATATTGGCTCATGTCCAACATTACCGCC  
ATGTTGACATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCA  
TAGCCCATATATGGAGTTCCGCGTTACATAACTACGGTAAATGGCCCGCTGGCTGACC  
GCCCAACGACCCCGCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAAT  
AGGGACTTTCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGT  
ACATCAAGTGTATCATATGCCAAGTCCGCCCCCTATTGACGTCAATGACGGTAAATGGCC  
CGCCTGGCATTATGCCAGTACATGACCTTACGGGACTTCTCTACTTGGCAGTACATCTA  
CGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACACCAATGGGCGTGG  
ATAGCGGTTTGACTCACGGGGATTTCGAAGTCTCCACCCATTGACGTCAATGGGAGTTT  
GTTTTGGCACCAAAATCAACGGGACTTTCGAAGTGTGTAACAACCTGCGATCGCCCGCC  
CCGTTGACGCAAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTCGT  
TTAGTGAACCGGGCACTCAGATTCTGCGGTCTGAGTCCCTTCTCTGCTGGGCTGAAAAGG  
CCTTTGTAATAAATAAATCTCTACTCAGTCCCTGTCTCTAGTTTGTCTGTTGAGATC  
CTACAGTTGGGCGCCGAACAGGGACCTGAGAGGGGCGCAGACCCTACCTGTTGAACCTGG  
CTGATCGTAGGATCCCCGGGACAGCAGAGGAGAACTTACAGAAGTCTTCTGGAGGTGTTT  
CTGGCCAGAACACAGGAGGACAGGTAAAGATTGGGAGACCCTTTGACATTGGAGCAAGGCG  
CTCAAGAAGTTAGAGAAGGTGACGGTACAAGGGTCTCAGAAATTAATACTGGTAACTGT  
AATTGGGCGCTAAGTCTAGTAGACTTATTTATGATACCAACTTTGTAAAAGAAAAGGAC  
TGGCAGCTGAGGGATGTATTCCATTGCTGGAAGATGTAACCTCAGACGCTGTCAGGACAA  
GAAAAGAGAGGCCTTTGAAAAGACATGGTGGGCAATTTCTGCTGTAAAGATGGGCCTCCAG  
ATTAATAATGTAGTAGATGGAAGGCATCATTCCAGCTCCTAAGAGCGAAATATGAAAAG  
AAGACTGCTAATAAAAAGCAGTCTGAGCCCTCTGAAGAATATCTCTAGAACTAGTGGATC  
CCCCGGGCTGCAGGAGTGGGAGGCACGATGGCCGCTTTGGTCGAGGCGGATCCGGCCAT  
TAGCCATATTATTCATTGGTTATATAGCATAAATCAATATTGGCTATTGGCCATTGCATA  
CGTTGTATCCATATCATAATATGTACATTTATATTGGCTCATGTCCAACATTACCGCCAT  
GTTGACATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATA  
GCCCATATATGGAGTTCGCGTTACATAACTTACGGTAAATGGCCCGCTGGCTGACCGC  
CCAACGACCCCGCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAG  
GGACTTTCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTAC  
ATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCG  
CCTGGCATTATGCCAGTACATGACCTTATGGGACTTCTCTACTTGGCAGTACATCTACG  
TATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGAT  
AGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCATTGACGTCAATGGGAGTTTGT  
TTTGGCACCAAAATCAACGGGACTTTCGAAGTGTGTAACAACCTCCGCCCCATTGACGC

AAATGGGCGGTAGGCATGTACGGTGGGAGGTCTATATAAGCAGAGCTCGTTTAGTGAACC  
GTCAGATCGCCTGGAGACGCCATCCACGCTGTTTTGACCTCCATAGAAGACACCGGGACC  
GATCCAGCCTCCGCGGCCCAAGCTTGTTGGGATCCACCGGTCCGCCACCATGGTGAGCAA  
GGGCGAGGAGCTGTTACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAA  
CGGCCACAAGTTCAGCGTGTCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGAC  
CCTGAAGTTCTCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCACCCCTCGTGACCAC  
CCTGACCTACGGCGTGCACTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCAGCACTT  
CTTCAAGTCCGCCATGCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGA  
CGGCAACTACAAGACCCGCGCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCAT  
CGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTA  
CAACTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAAGACGGCATCAAGGT  
GAATTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGACGCTCGCCGACCACTACCA  
GCAGAACACCCCATCGGCGACGGCCCCGTGCTGCTGCCGACAACCACTACCTGAGCAC  
CCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCTGCTGGAGTT  
CGTGACCGCCGCGGGATCACTCTCGGCATGGACGAGCTGTACAAGTAAAGCGGCCGCGA  
CTCTAGAGTCGACCTGCAGGCATGCAAGCTTCAGCTGCTCGAGGGGGGGCCCGTACCCA  
GCTTTTGTTCCTTTAGTGAGGGTTAATTGCGCGGAAGTATTTATCACTAATCAAGCAC  
AAGTAATACATGAGAACTTTTACTACAGCAAGCACAATCCTCCAAAAAATTTGTTTTT  
ACAAAATCCCTGGTGAACATGATTGGAAGGGACCTACTAGGGTGTGTGGAAGGGTGATG  
GTGCAGTAGTAGTTAATGATGAAGGAAAGGGAATAATTGCTGTACCATTAAACAGGACTA  
AGTTACTAATAAAACCAAAATGAGTATTGTTGCAGGAAGCAAGACCCAACTACCATTTGTC  
AGCTGTGTTTCTGACCTCAATATTTGTTATAAGGTTTGATATGAATCCCAGGGGGAATC  
TCAACCCCTATTACCAACAGTCAGAAAAATCTAAGTGTGAGGAGAACACAATGTTTCAA  
CCTTATTGTTATAATAATGACAGTAAGAACAGCATGGCAGAATCGAAGGAAGCAAGAGAC  
CAAGAATGAACCTGAAAGAAGAACTCTAAAGAAGAAAAAGAAATGACTGGTGAAAA  
TAGGTATGTTTCTGTTATGCTTAGCAGGAACCTACTGGAGGAATACTTTGGTGGTATGAAG  
GACTCCCACAGCAACATTATATAGGGTTGGTGGCGATAGGGGGAAGATTAAACGGATCTG  
GCCAATCAAATGCTATAGAATGCTGGGGTTCCTTCCCGGGGTGTAGACCATTTCAAAT  
ACTTCAGTTATGAGACCAATAGAAGCATGCATATGGATAATAACTGCTACATTATTAG  
AAGCTTTAACCAATATAACTGCTCTATAAATAACAAAACAGAATTAGAAACATGGAAGTT  
AGTAAAGACTTCTGGCATAACTCCTTTACCTATTTCTTCTGAAGCTAACACTGGACTAAT  
TAGACATAAGAGAGATTTTGGTATAAGTGCAATAGTGGCAGCTATTGTAGCCGCTACTGC  
TATTGCTGCTAGCGCTACTATGTCTTATGTTGCTCTAACTGAGGTTAACAAAATAATGGA  
AGTACAAAATCATACTTTTGAGGTAGAAAATAGTACTCTAAATGGTATGGATTAAATAGA  
ACGACAAAATAAAGATATTATGCTATGATTCTTCAAACACATGCAGATGTTCAACTGTT  
AAAGGAAAGACAACAGGTAGAGGAGACATTTAATTTAATTGGATGTATAGAAAGAACACA  
TGTATTTTGTCACTAGGTATCCCTGGAATATGTCATGGGGACATTTAAATGAGTCAAC  
ACAATGGGATGACTGGGTAAGCAAAATGGAAGATTAAATCAAGAGATACTAACTACACT  
TCATGGAGCCAGGAACAATTTGGCACAATCCATGATAACATTCAATACACCAGATAGTAT  
AGCTCAATTTGGAAGACCTTTGGAGTCATATTGGAATTTGGATTCTGGATTGGGAGC  
TTCCATTATAAAATATATAGTGATGTTTTTGTCTATTTATTTGTTACTAACCTCTTCGCC  
TAAGATCCTCAGGGCCCTCTGGAAGGTGACCAGTGGTGCAGGGTCTCCGGCAGTCGTTA  
CCTGAAGAAAAAATTCATACAAACATGCATCGCGAGAAGACACCTGGGACCAGGCCCA  
ACACAACATACACCTAGCAGGCGTGACCGGTGGATCAGGGGACAAATACTACAAGCAGAA  
GTACTCCAGGAACGACTGGAATGGAGAATCAGAGGAGTACAACAGGCGGCCAAAGAGCTG  
GGTGAAGTCAATCGAGGCATTTGGAGAGAGCTATATTTCCGAGAAGACCAAGGGGAGAT  
TTCTCAGCCTGGGGCGGCTATCAACGAGCACAAGAACGGCTCTGGGGGGAACAATCCTCA  
CCAAGGGTCTTAGACCTGGAGATTCGAAGCGAAGGAGGAAACATTTATGACTGTTGCAT  
TAAAGCCCAAGAAGGAACTCTCGCTATCCCTTGCTGTGGATTCCCTTATGGCTATTTTG

GGGACTAGTAATTATAGTAGGACGCATAGCAGGCTATGGATTACGTGGACTCGCTGTTAT  
AATAAGGATTTGTATTAGAGGCTTAAATTTGATATTTGAAATAATCAGAAAAATGCTTGA  
TTATATTGGAAGAGCTTTAAATCCTGGCACATCTCATGTATCAATGCCTCAGTATGTTTA  
GAAAAACAAGGGGGGAAGTGTGGGGTTTTATGAGGGGTTTTATAAATGATTATAAGAGT  
AAAAAGAAAGTTGCTGATGCTCTCATAACCTTGATAACCCAAAGGACTAGCTCATGTTG  
CTAGGCACTAAACCGCAATAACCGCATTGTGACGCGAGTCCCCATTGGTGACGCGTT  
AACTTCTGTTTTTACAGTATATAAGTGCTTGATTCTGACAATTGGGCACTCAGATTCT  
GCGGTCTGAGTCCCTTCTGCTGGGCTGAAAAGGCCTTTGTAATAAATAAATTCTCTA  
CTCAGTCCCTGTCTCTAGTTTGCTGTTGAGATCCTACAGAGCTCATGCCTTGGCGTAA  
TCATGGTCATAGCTGTTTCTGTGTGAAATTGTTATCCGCTCACAATCCACACAACATA  
CGAGCCGGAAGCATAAAGTGTAAGCCTGGGGTGCTAATGAGTGAGCTAACTCACATT  
ATTGCGTTGCGCTCACTGCCCGCTTCCAGTCGGGAAACCTGTCGTGCCAGAGTAGGCCG  
CCTCGGCCAGATCTCAAATTGCTTAGCCTGATAGCCGAGTAACGCCATTTTGCAAGGCA  
TGGA AAAATACCAAACCAAGAATAGAGAAGTTCAGATCAAGGGCGGGTACACGAAAACAG  
CTAACGTTGGGCCAAACAGGATATCTGCGGTGAGCAGTTTCGGCCCCGGCCCGGGCCAA  
GAACAGATGGTACCGCGGTTCCGGCCCCGGCCCGGGCCAAAGAACAGATGGTCCCCAGAT  
ATGGCCCAACCCCTACGAGTTTCTTAAGACCCATCAGATGTTTCCAGGCTCCCCCAAGGA  
CCTGAAATGACCCTGTGCCTTATTTGAATTAACCAATCAGCCTGCTTCTCGCTTCTGTTT  
GCGCGCTTCTGCTTCCCGAGCTCTATAAAAGAGCTCACAACCCCTCACTCGGCGCGCCAG  
TCCTCCGATAGACTGAGTCGCCCGGGTACCCGTGTATCCAATAAATCCTTGTGCTGTTGC  
ATCCGACTCGTGGTCTCGCTGTTCCTTGGGAGGGTCTCCTCAGAGTGATTGACTACCCGT  
CTCGGGGGTCTTTCAATTGGGGGCTCGTCCGGGATCTGGAGACCCCTGCCAGGGACCAC  
CGACCCACCACCGGGAGGCTAGCCTCGAGAAATTCGCCACCATGGCTGAGAGCAAGGAGGC  
CAGGGATCAAGAGATGAACCTCAAGGAAGAGAGCAAAGAGGAGAAGCGCCGCAACGACTG  
GTGGAAGATCGACCCACAAGGCCCCCTGGAGGGGGACCAGTGGTGCCGCGTGCTGAGACA  
GTCCCTGCCCGAGGAGAAGATTCTAGCCAGACCTGCATCGCCAGAAGACACCTCGGCC  
CGGTCCCAACCAGCACACCCCTCCAGAAGGGATAGGTGGATTAGGGGCCAGATTTTGCA  
AGCCGAGGTCTCCAAGAAAGGCTGGAATGGAGAATTAGGGCGTGCAACAAGCCGCTAA  
AGAGCTGGGAGAGGTGAATCGCGCATCTGGAGGGAGCTCTACTTCCGCGAGGACCAGAG  
GGGCGATTTCTCCGATGGGAGGCTACCAGAGGGCACAAGAAAGGCTGTGGGGCGAGCA  
GAGCAGCCCCCGCTTGTAGGCCCGGAGACTCCAAAAGACGCCGCAACACCTGTGAAG  
TCGACCCGGGCGCGCGCTTCCCTTAGTGAGGGTTAATGCTTCGAGCAGACATGATAAGA  
TACATTGATGAGTTTGGACAAACCACAACCTAGAATGCAGTAAAAAAATGCTTTATTTGT  
GAAATTTGTGATGCTATTGCTTTATTTGTAACCATTAAGCTGCAATAAACAAGTTAAC  
AACAACAATTGCATTATTTATGTTTCAGGTTTCAGGGGAGATGTGGGAGGTTTTTAA  
AGCAAGTAAACCTCTACAAATGTGGTAAAAATCCGATAAGGATCGATCCGGGCTGGCGTA  
ATAGCGAAGAGGCCCGCACCGATCGCCCTTCCCAACAGTTGCGCAGCCTGAATGGCGAAT  
GGACGCGCCCTGTAGCGGCGCATTAAGCGCGGCGGGTGTGGTGGTTACGCGCAGCGTGAC  
CGCTACACTTGCCAGCGCCCTAGCGCCCGCTCTTTTCGCTTCTTCCCTTCTTTCTCGC  
CACGTTCCGCGGCTTTCCCGTCAAGCTCTAAATCGGGGGCTCCCTTTAGGGTTCCGATT  
TAGAGCTTACGGCACCTCGACCGCAAAAACTTGATTGGGTGATGTTTACGTAGGCC  
GCCTCGGCCCGCCGGCATCACTGCATTAATGAATCGGCCAACGCGCGGGGAGAGGCGGT  
TTGCGTATTGGGCGCTCTTCCGCTTCTCGCTCACTGACTCGCTCGCTCGGTGCTTCCG  
CTGCGGCGAGCGGTATCAGCTCACTCAAAGCGGTAAATACGGTTATCCACAGAATCAGGG  
GATAACGCAGGAAAGAACATGTATAACTTCGTATAATGTATGCTATACGAAGTTATACAT  
GTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCTTGTGGCGTTTTT  
CCATAGGCTCCGCCCCCTGACGAGCATCACA AAAATCGACGCTCAAGTCAGAGGTGGCG  
AAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCTGGAAGCTCCCTCGTGGCGTC  
TCCTGTTCCGACCTGCCGCTTACCGGATACCTGTCCGCTTCTCCCTTCGGGAAGCGT

GGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCCGCTCCAA  
GCTGGGCTGTGTGCACGAACCCCCGTTACGCCCCGACCGCTGCGCCTTATCCGGTAACTA  
TCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAA  
CAGGATTAGCAGAGCGAGGTATGTAGCGGTGTACAGAGTTCTTGAAGTGGTGGCCTAA  
CTACGGCTACACTAGAAGGACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTT  
CGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAAACAAACCACCGCTGGTAGCGGTGGTTT  
TTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAGGATCTCAAGAAGATCCTTTGAT  
CTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCAT  
GAGATTATCAAAAAGGATCTTACCTAGATCCTTTTAAATTAATAATGAAGTTTAAATC  
AATCTAAAGTATATAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGC  
ACCTATCTCAGCGATCTGTCTATTTGTTTCATCCATAGTTGCCTGACTCCCCGTCGTGTA  
GATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGA  
CCCACGCTCACCGGCTCCAGATTTATCAGCAATAAACAGCCAGCCGGAAGGGCCGAGCG  
CAGAAAGTGGTCTGCAACTTTATCCGCTCCATCCAGTCTATTAATTGTTGCCGGGAAGC  
TAGAGTAAGTAGTTCGCCAGTTAATAGTTTGCACAACGTTGTTGCCATTGCTACAGGCAT  
CGTGGTGTACGCTCGTCTTTGGTATGGCTTCATTCAGCTCCGGTCCCAACGATCAAG  
GCGAGTTACATGATCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCTCCGAT  
CGTTGTCAGAAGTAAGTTGGCCGAGTGTATCACTCATGGTTATGGCAGCACTGCATAA  
TTCTCTTACTGTATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAA  
GTCATTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTTGGCCGGCGTCAATACGGGA  
TAATACCGCGCCACATAGCAGAACTTTAAAAGTGCTCATCATTGGAAAACGTTCTTCGGG  
GCGAAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGC  
ACCCAAGTATCTTCAGCATCTTTTACTTTTACCAGCGTTTCTGGGTGAGCAAAAACAGG  
AAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACGGAAATGTTGAATACTCATACT  
CTTCTTTTCAATATTATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGGATACAT  
ATTTGAATGTATTTAGAAAAATAACAAATAGGGGTTCCGCGCACATTTCCCGAAAAAGT  
GCCACCTAAATTGTAAGCGTTAATATTTTGTAAAAATTCGCGTTAAATTTTGTAAATC  
AGCTCATTTTAAACCAATAGGCCGAAATCGGCAAAATCCCTTATAAATCAAAAGAATAG  
ACCGAGATAGGGTTGAGTGTGTTCCAGTTTGGAACAAGAGTCCACTATTAAGAACGTG  
GACTCCAACGTCAAAGGGCGAAAAACCGTCTATCAGGGCGATGGCCCACTACGTGATAAC  
TTCGTATAATGTATGCTATACGAAGTTATCACTACGTGAACCATCACCTAATCAAGTTT  
TTTGGGTCGAGGTGCCGTAAGCACTAAATCGGAACCTAAAGGGAGCCCCGATTAG  
AGCTTGACGGGGAAAGCCAACCTGGCTTATCGAAATTAATACGACTCACTATAGGGAGAC  
CGGC

**pONY8.3GPGK – (SEQ ID No 47)**

AGATCTTGAATAATAAAATGTGTGTTTGTCCGAAATACGCGTTTGTGAGATTTCTGTGCGC  
GACTAAATTCATGTGCGCGATAGTGGTGTATCGCCGATAGAGATGGCGATATTGGAA  
AAATTGATATTTGAAAATATGGCATATTGAAAATGTCGCCGATGTGAGTTTCTGTGTAAC  
TGATATCGCCATTTTCCAAAAGTGATTTTGGGCATACGCGATATCTGGCGATAGCGCT  
TATATCGTTTACGGGGGATGGCGATAGACGACTTTGGTGACTTGGGCGATTCTGTGTGTC  
GCAATATCGCAGTTTCGATATAGGTGACAGACGATATGAGGCTATATCGCCGATAGAGG  
CGACATCAAGCTGGCACATGGCCAATGCATATCGATCTATACATTGAATCAATATTGGCC  
ATTAGCCATATTATTCATTGGTTATATAGCATAAATCAATATTGGCTATTGGCCATTGCA  
TACGTTGTATCCATATCGTAATATGTACATTTATATTGGCTCATGTCCAACATTACCGCC  
ATGTTGACATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCA  
TAGCCCATATATGGAGTTCGCGTTACATAACTTACGGTAAATGGCCCGCTGGCTGACC  
GCCCAACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAAT



AGGGACTTTCATTGACGTCAATGGGTGGAGTATTTACGGTAACTGCCCCTTGGCAGT  
ACATCAAGTGTATCATATGCCAAGTCCGCCCCCTATTGACGTCAATGACGGTAAATGGCC  
CGCCTGGCATTATGCCCAGTACATGACCTTACGGGACTTTCCTACTTGGCAGTACATCTA  
CGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACACCAATGGGCGTGG  
ATAGCGGTTTGACTACGGGGATTTC AAGTCTCCACCCATTGACGTCAATGGGAGTTT  
GTTTTGGACCAAAATCAACGGGACTTTC AAAATGTCGTAACAACCTCGCATCGCCGCC  
CCGTTGACGCAAAATGGGCGGTAGCGGTGTACGGTGGGAGGTCTATATAAGCAGAGCTCGT  
TTAGTGAACCGGGCCTCAGATTCTGCGGTCTGAGTCCCTTCTCTGCTGGGCTGAAAAGG  
CCTTTGTAAATAATAAATTTCTCTACTCAGTCCCTGTCTCTAGTTTGTCTGTTTCGAGATC  
CTACAGTTGGCGCCCGAACAGGGACCTGAGAGGGGCGCAGACCCTACCTGTTGAACCTGG  
CTGATCGTAGGATCCCCGGGACAGCAGAGGAGAACTTACAGAAGTCTTCTGGAGGTGTTT  
CTGGCCAGAACACAGGAGGACAGGTAAGATTGGGAGACCCTTTGACATTGGAGCAAGGCG  
CTCAAGAAGTTAGAGAAGGTGACGGTACAAGGGTCTCAGAAATTACTACTGGTAACTGT  
AATTGGGCGCTAAGTCTAGTAGACTTATTTTCATGATACCAACTTTGTAAGAAAGAAAGGAC  
TGGCAGCTGAGGGATGTCATTCCATTGCTGGAAGATGTAACCTCAGACGCTGTCAGGACAA  
GAAAGAGAGGCCCTTTGAAAGAACATGGTGGGCAATTTCTGCTGTAAAGATGGGCTCCAG  
ATTAATAATGTAGTAGATGGAAGGCATCATTCCAGCTCCTAAGAGCGAAATATGAAAAG  
AAGACTGCTAATAAAAAGCAGTCTGAGCCCTCTGAAGAATATCTCTAGAACTAGTGGATC  
CCCCGGGCTGCAGGAGTGGGAGGCACGATGGCCGCTTTGGTCGAGGCGGATCCGGCCAT  
TAGCCATATTATTCATTGGTTATATAGCATAAATCAATATTGGCTATTGGCCATTGCATA  
CGTTGTATCCATATCATAATATGTACATTTATATTGGCTCATGTCCAACATTACCGCCAT  
GTTGACATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATA  
GCCCCATATATGGAGTTCGCGTTACATAACTTACGGTAAATGGCCCCCTGGCTGACCGC  
CCACGACCCCCCGCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAG  
GGACTTTCATTGACGTCAATGGGTGGAGTATTTACGGTAACTGCCCCTTGGCAGTAC  
ATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCG  
CCTGGCATTATGCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACG  
TATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGAT  
AGCGGTTTGACTACGGGGATTTC AAGTCTCCACCCATTGACGTCAATGGGAGTTTGT  
TTTTGGACCAAAATCAACGGGACTTTC AAAATGTCGTAACAACCTCGCCCCATTGACGC  
AAATGGGCGGTAGGCATGTACGGTGGGAGGTCTATATAAGCAGAGCTCGTTTAGTGAACC  
GTCAGATCGCCTGGAGACGCCATCCACGCTGTTTTGACCTCCATAGAAGACACCGGGACC  
GATCCAGCCTCCGCGGCCCAAGCTTGTGGGATCCACCGGTCGCCACCATGGTGAGCAA  
GGGCGAGGAGCTGTTACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAA  
CGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGAC  
CCTGAAGTTTCTGACACACCGGCAAGCTGCCCGTGCCCTGGCCACCCCTCGTGACCAC  
CCTGACCTACGGCGTGACGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACTT  
CTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGA  
CGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCAT  
CGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTA  
CAACTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAAGGCATCAAGGT  
GAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACCA  
GCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCAC  
CCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCTGCTGGAGTT  
CGTGACCGCCCGGGGATCACTCTCGGCATGGACGAGCTGTACAAGTAAAGCGGCCGCGA  
CTCTAGAGTCGACCTGCAGGCATGCAAGCTTCAGCTGCTCGAGGGGGGGCCCGGTACCCA  
GCTTTTGTTCCTTTAGTGAGGGTTAATTGCGCGGGAAGTATTTATCACTAATCAAGCAC  
AAGTAATACATGAGAACTTTTACTACAGCAAGCACAACTCTCAAAAAATTTTGTTTTT  
ACAAAATCCCTGGTGACATGATTGGAAGGGACCTACTAGGGTGTGTGGAAGGGTGATG

GTGCAGTAGTAGTTAATGATGAAGGAAAGGGAATAATTGCTGTACCATTAACCAGGACTA  
AGTTACTAATAAAACCAAAATTGAGTATTGTTGCAGGAAGCAAGACCCAACTACCATTGTC  
AGCTGTGTTTCCTGACCTCAATATTGTTATAAAGTTTGATATGAATCCCAGGGGGAATC  
TCAACCCCTATTACCCAACAGTCAGAAAAATCTAAGTGTGAGGAGAAACAAATGTTTCAA  
CCTTATTGTTATAATAATGACAGTAAGAACAGCATGGCAGAATCGAAGGAAGCAAGAGAC  
CAAGAATGAACCTGAAAGAAGAATCTAAAGAAGAAAAAGAAGAAATGACTGGTGGAAAA  
TAGGTATGTTTCTGTTATGCTTAGCAGGAACTACTGGAGGAATACTTTGGTGGTATGAAG  
GACTCCCAAGCAACATTATATAGGGTTGGTGGCGATAGGGGGAAGATTAACGGATCTG  
GCCAATCAAATGCTATAGAATGCTGGGGTTCCTTCCCGGGGTAGACCATTTCAAAATT  
ACTTCAGTTATGAGACCAATAGAAAGCATGCATATGGATAATAATACTGCTACATTATTAG  
AAGCTTTAACCAATAAAGTCTCTATAAATAACAAAACAGAAATTAGAAACATGGAAAGTT  
AGTAAAGACTTCTGGCATAACTCCTTTACCTATTTCTTGAAGCTAACACTGGACTAAT  
TAGACATAAGAGAGATTTTGGTATAAGTGCAATAGTGGCAGCTATTGTAGCCGCTACTGC  
TATTGCTGCTAGCGCTACTATGCTTATGTTGCTCTAACTGAGGTAAACAAAATAATGGA  
AGTACAAAATCATACTTTTGAGGTAGAAAATAGTACTCTAAATGGTATGGATTAAATAGA  
ACGACAAAATAAAGATATTATATGCTATGATTCTTCAAACACATGCAGATGTTCAACTGTT  
AAAGGAAAGACAACAGGTAGAGGAGACATTTAATTTAATTGGATGTATAGAAAGAACACA  
TGTATTTTGTCACTACTGGTCATCCCTGGAATATGTCATGGGGACATTTAAATGAGTCAAC  
ACAATGGGATGACTGGGTAAAGCAAAATGGAAAGATTTAAATCAAGAGATACTAACTACACT  
TCATGGAGCCAGGAACAATTTGGCACAATCCATGATAACATTCAATACACCAGATAGTAT  
AGCTCAATTTGGAAAAGACCTTTGGAGTCATATTGGAAATTGGATTCTGGATTGGGAGC  
TTCCATTATAAAATATATAGTGATGTTTTTGCTATTTATTTGTTACTAACCTCTTCGCC  
TAAGATCCTCAGGGCCCTCTGGAAGGTGACAGTGGTGCAGGGTCTCCGGCAGTCGTTA  
CCTGAAGAAAAAATTCATCACAAACATGCATCGCGAGAAGACACCTGGGACCAGGCCCA  
ACACAACATACACCTAGCAGGCGTGACCGGTGGATCAGGGGACAAATACTACAAGCAGAA  
GTACTCCAGGAACGACTGGAATGGAGAATCAGAGGAGTACAACAGGCGGCCAAAGAGCTG  
GGTGAAGTCAATCGAGGCATTTGGAGAGAGCTATATTTCCGAGAAGACCAAAGGGGAGAT  
TTCTCAGCCTGGGGCGGCTATCAACGAGCACAAGAACGGCTCTGGGGGGAACAATCCTCA  
CCAAGGGTCTTAGACCTGGAGATTCGAAGCGAAGGAGGAAACATTTATGACTGTTGCAT  
TAAAGCCCAAGAAGGAACTCTCGCTATCCCTTGCTGTGGATTTCCCTTATGGCTATTTTG  
GGGACTAGTAATTATAGTAGGACGCATAGCAGGCTATGGATTACGTGGACTCGCTGTTAT  
AATAAGGATTTGTATTAGAGGCTTAAATTTGATATTTGAAATAATCAGAAAAATGCTTGA  
TTATATTGGAAGAGCTTTAAATCCTGGCACATCTCATGTATCAATGCCTCAGTATGTTTA  
GAAAAACAAGGGGGAACTGTGGGGTTTTATGAGGGGTTTTATAAATGATTATAAGAGT  
AAAAAGAAAGTTGCTGATGCTCTCATAACCTTGTATAACCCAAAGGACTAGCTCATGTTG  
CTAGGCAACTAAACCGCAATAACCGCATTGTGACGCGAGTCCCCATTGGTGACGCGTT  
AACTTCTGTTTTTACAGTATATAAGTGCTTGTAATCTGACAATTGGGCACTCAGATTCT  
GCGGTCTGAGTCCCTTCTCTGCTGGGCTGAAAAGGCCCTTTGTAATAAATATAATTCTCTA  
CTCAGTCCCTGTCTCTAGTTTGTCTGTTTCGAGATCCTACAGAGCTCATGCCTTGGCGTAA  
TCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTATCCGCTCACAATTCCACACAACATA  
CGAGCCGGAAGCATAAAGTGTAAGCCTGGGGTGCTAATGAGTGAGCTAACTCACATTA  
ATTGCGTTGCGCTCACTGCCCCGTTTCCAGTCGGGAAACCTGTCGTGCCAGTGATGCCCCG  
GGCGGCCGAGGCGGCCTACGTGAACCATCACCCAAATCAAGTTTTTGGCGTCGAGGTGC  
CGTAAAGCTCTAAATCGGAACCTAAAGGGAGCCCCGATTTAGAGCTTGACGGGGAAAG  
CCGGCGAACGTGGCGAGAAAGGAAGGGAAGAAAGCGAAAGGAGCGGGCGCTAGGGCGCTG  
GCAAGTGATAGCGGTACGCTGCGGTAACCACCACACCCGCGCGCTTAATGCGCCGCTA  
CAGGGCGCGTCCATTCCGCAATTCAGGCTGCGCAACTGTTGGGAAGGGCGATCGGTGCGGG  
CCTCTTCGCTATTACGCCAGCCCGGATCGATCCTTATCGGATTTTACCACATTTGTAGAG  
GTTTTACTTGCTTTAAAAAACCTCCACATCTCCCCCTGAACCTGAAACATAAAATGAAT

GCAATTGTTGTTGTTAACTTGTATTGTCAGCTTATAATGGTTACAAATAAAGCAATAGC  
ATCACAAATTCACAAATAAAGCATTTTTTCACTGCATTCTAGTTGTGGTTTGTCCAAA  
CTCATCAATGTATCTTATCATGTCTGCTCGAAGCATTAACCCTCACTAAAGGGGAAGCGGC  
CGCCCGGGTCTGACTTCACAGGTGTTGCGGCGTCTTTGGAGTCTCCGGGCTCAAGACG  
CGGGGGCTGCTCTGCTCGCCCCACAGCCTTTCTTGTCCTCTGGTAGCCTCCCCATGCG  
GAGAAATCGCCCTCTGGTCTCGCGAAGTAGAGCTCCCTCCAGATGCCGCGATTACCC  
TCTCCAGCTCTTTAGCGGCTTGTGTCACGCCCTAATTCTCCATTCCAGCCTTTCTTG  
AGGACCTCGGCTTGCAAAATCTGGCCCTAATCCACCTATCCCTTCTGGAGGGTGTGTGC  
TGGGTGGGACCGGGGCGAGGTGTCTTCTGGCGATGCAGGTCTGGCTAGGAATCTTCTCC  
TCGGGCAGGGACTGTCTCAGCACGCGGCACTGGTCCCTCCAGGGGGCTTGTGGG  
TCGATCTTCCACAGTCGTTGCGGCGCTTCTCTCTTTGCTCTCTTCTTGAGGTTATC  
TCTTGATCCCTGGCCTCCTTGCTCTCAGCCATGGTGGCGAATTCTCGAGGCTAGCCTGGG  
GAGAGAGGTGGTGATTCGGTCAACGAGGGAGCCGACTGCCGACGTGCGCTCCGGAGGCT  
TGCAGAAATGCGGAACACCGCGCGGCGAGGAACAGGGCCCACTACCGCCCCACACCCG  
CCTCCCGCACCGCCCCCTCCCGGCGCTGCTCTCGGCGCGCCCGCTGAGCAGCCGCTAT  
TGGCCACAGCCATCGCGGTGCGGCGCTGCCATTGCTCCCTGGCGCTGTCCGTCTGCGA  
GGGTACTAGTGAGACGTGCGGCTTCCGTTTGTACGTCCGGCACGCCGGAACCGCAAGG  
AACCTTCCCGACTTAGGGGCGGAGCAGGAAGCGTCCCGGGGGGCCACAAGGGTAGCGG  
CGAAGATCCGGGTGACGTGCGAACGAGCGTGAAGAATGTGCGAGACCCAGGGTGGCGC  
CGCTGCGTTTCCCGGAACACGCCAGAGCAGCCGCTCCCTGCGCAAACCCAGGGTGC  
CTTGGAAGGCGCAACCCCAACCCAGATCTGGCCGAGCGGCGCTACTCTGCATTAATG  
AATCGGCCAACGCGCGGGGAGAGGCGGTTTGGTATTGGGCGCTTCCGCTTCTCGCT  
CACTGACTCGCTGCGCTCGGTCTCGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGC  
GGTAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTATAACTTCGT  
ATAATGTATGCTATACGAAGTTATACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACC  
GTAAAAAGGCCGCTTGTGCGGTTTTTCCATAGGCTCCGCCCCCTGACGAGCATCACA  
AAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGT  
TTCCCCCTGGAAGCTCCCTCGTGGCTCTCTGTTCCGACCCTGCCGCTTACCGGATACC  
TGTCGCGCTTCTCCCTTCGGAAGCGTGGCGCTTCTCATAGCTCAGCTGTAGGTATC  
TCAGTTCGGTGTAGGTGCTTCCGCTCAAGCTGGGCTGTGTGCACGAACCCCCGTTACG  
CCGACCGCTGCGCCTTATCCGGTAACCTATCGTCTTGAGTCCAACCCGGTAAGACACGACT  
TATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTG  
CTACAGAGTTCTTGAAGTGGTGGCTAACTACGGCTACACTAGAAGGACAGTATTTGGTA  
TCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAGAGTTGGTAGCTCTTGATCCGCA  
AACAAACCACCGCTGGTAGCGGTGTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAA  
AAAAAGGATCTCAAGAAGATCTTTGATCTTTCTACGGGGTCTGACGCTCAGTGGAACG  
AAAACCTCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGATCC  
TTTTAAATTAATAATGAAGTTTTAAATCAATCTAAAGTATATAGATAAAGTTGGTCTG  
ACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTCTGTTAT  
CCATAGTTGCTGACTCCCCGTCGTGTAGATAACTACGATACGGGAGGGCTTACCATCTG  
GCCCCAGTGCTGCAATGATACCGCGAGACCCACGCTCACCGGCTCCAGATTTATCAGCAA  
TAAACCAGCCAGCCGAAGGGCCGAGCGCAGAAGTGGTCTGCAACTTTATCCGCTCCA  
TCCAGTCTATTAATTGTTGCCGGAAGCTAGAGTAAGTAGTTGCCAGTTAATAGTTTGC  
GCAACGTTGTTGCCATTGCTACAGGCATCGTGGTGTACGCTCGTCTTGGTATGGCTT  
CATTAGCTCCGGTTCCCAACGATCAAGGCGAGTTACATGATCCCCATGTTGTGCAAAA  
AAGCGGTTAGCTCCTTCGGTCTCCGATCGTTGTGAGAAGTAAGTTGGCCGAGTGTAT  
CACTCATGGTTATGGCAGCACTGCATAATTCTCTTACTGTGATGCCATCCGTAAGATGCT  
TTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTGTATGCGGCGACCGA  
GTTGCTCTGCCCCGCGTCAATACGGGATAATACCGCGCCACATAGCAGAACTTTAAAG

TGCTCATCATTGGAAAACGTTCTTCGGGGCGAAAACCTCTCAAGGATCTTACCGCTGTTGA  
GATCCAGTTCGATGTAACCCACTCGTGCACCCAACTGATCTTCAGCATCTTTTACTTTCA  
CCAGCGTTTCTGGGTGAGCAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGG  
CGACACGGAAATGTTGAATACTCATACTCTTCCTTTTCAATATTATTGAAGCATTATC  
AGGGTTATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGAAAAATAAACAAATAG  
GGGTTCCGCGCACATTTCCCCGAAAAGTGCCACCTAAATTGTAAGCGTTAATATTTTGT  
AAAAATCGCGTTAAATTTTGTAAATCAGCTCATTTTTTAACCAATAGGCCGAAATCGG  
CAAAATCCCTTATAAATCAAAAGAATAGACCGAGATAGGGTTGAGTGTTGTTCCAGTTTG  
GAACAAGAGTCCACTATTAAAGAACGTGGACTCCAACGTCAAAGGGCGAAAAACCGTCTA  
TCAGGGCGATGGCCCACTACGTGATAACTTCGTATAATGTATGCTATACGAAGTTATCAC  
TACGTGAACCATCACCTAATCAAGTTTTTTGGGGTCGAGGTGCCGTAAAGCACTAAATC  
GGAACCCTAAAGGGAGCCCCGATTTAGAGCTTGACGGGAAAGCCAACCTGGCTTATCG  
AAATTAATACGACTCACTATAGGGAGACCGGC

**pONY8.3G PGK + (SEQ ID No 48)**

AGATCTTGAATAATAAAATGTGTGTTTGTCCGAAATACGCGTTTTGAGATTCTGTGCGCC  
GACTAAATTCATGTCGCGCGATAGTGGTGTATCGCCGATAGAGATGGCGATATTGGAA  
AAATTGATATTGAAAAATAGGCATATTGAAATGTGCGCGATGTGAGTTTCTGTGTAAC  
TGATATCGCCATTTTCCAAAAGTGATTTTGGGCATACGCGATATCTGGCGATAGCGCT  
TATATCGTTTACGGGGGATGGCGATAGACGACTTTGGTGACTTGGGCGATTCTGTGTGTC  
GCAAAATATCGCAGTTTCGATATAGGTGACAGACGATATGAGGCTATATCGCCGATAGAGG  
CGACATCAAGCTGGCACATGGCCAATGCATATCGATCTATACATTGAATCAATATTGGCC  
ATTAGCCATATTATTCATTGGTTATATAGCATAAATCAATATTGGCTATTGGCCATTGCA  
TACGTTGTATCCATATCGTAATATGTACATTTATATTGGCTCATGTCCAACATTACCGCC  
ATGTTGACATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCA  
TAGCCCATATATGGAGTTCGCGTTACATAAATTACGGTAAATGGCCCGCTGGCTGACC  
GCCCAACGACCCCGCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAAT  
AGGGACTTTCCATTGACGTCAATGGGTGGAGTATTACGGTAACTGCCCACTTGGCAGT  
ACATCAAGTGTATCATATGCCAAGTCCGCCCCCTATTGACGTCAATGACGGTAAATGGCC  
CGCCTGGCATTATGCCCAGTACATGACCTTACGGGACTTTCCTACTTGGCAGTACATCTA  
CGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACACCAATGGGCGTGG  
ATAGCGGTTTGACTCACGGGGATTTCGAAGTCTCCACCCCAATTGACGTCAATGGGAGTTT  
GTTTTGGACCAAAATCAACGGGACTTTCAAAATGTGTAACAACCTGCGATCGCCCGCC  
CCGTTGACGCAAAATGGGCGGTAGGCGGTACGGTGGGAGGTCTATATAAGCAGAGCTCGT  
TTAGTGAACCGGGCACTCAGATTCTGCGGTCTGAGTCCCTTCTCTGCTGGGCTGAAAAGG  
CCTTTGTAATAAATATAATTCTCTACTCAGTCCCTGTCTCTAGTTTGTCTGTTTCGAGATC  
CTACAGTTGGCGCCCGAACAGGGACCTGAGAGGGGCGCAGACCCCTACCTGTTGAACCTGG  
CTGATCGTAGGATCCCCGGGACAGCAGAGGAGAACCTACAGAAGTCTTCTGGAGGTGTTT  
CTGGCCAGAACACAGGAGGACAGGTAAGATTGGGAGACCCCTTGACATTGGAGCAAGGCG  
CTCAAGAAGTTAGAGAAGGTGACGGTACAAGGGTCTCAGAAATTAATACTGGTAACTGT  
AATTGGGCGCTAAGTCTAGTAGACTTATTTTCATGATACCACTTTGTAAGAAAAGGAC  
TGGCAGCTGAGGGATGTCAATTCATTGCTGGAAGATGTAACCTCAGACGCTGTGAGGACAA  
GAAAGAGAGGCCTTTGAAAGAACATGGTGGGCAATTTCTGCTGTAAAGATGGGCTCCAG  
ATTAATAATGTAGTAGATGGAAGGCATCATTCAGCTCCTAAGAGCGAAATATGAAAAG  
AAGACTGCTAATAAAAAGCAGTCTGAGCCCTCTGAAGAATATCTCTAGAACTAGTGGATC  
CCCCGGGCTGCAGGAGTGGGGAGGCACGATGGCCGCTTGGTTCGAGGCGGATCCGGCCAT  
TAGCCATATTATTCATTGGTTATATAGCATAAATCAATATTGGCTATTGGCCATTGCATA  
CGTTGTATCCATATCATAATATGTACATTTATATTGGCTCATGTCCAACATTACCGCCAT  
GTTGACATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATA  
GCCCATATATGGAGTTCGCGTTACATAAATTACGGTAAATGGCCCGCTGGCTGACCGC  
CCAACGACCCCGCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAG  
GGACTTTCCATTGACGTCAATGGGTGGAGTATTACGGTAACTGCCCACTTGGCAGTAC  
ATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCG  
CCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACG  
TATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGAT  
AGCGGTTTGACTCACGGGGATTTCGAAGTCTCCACCCCAATTGACGTCAATGGGAGTTTGT  
TTTTGGACCAAAATCAACGGGACTTTCAAAATGTGTAACAACCTCCGCCCCATTGACGC  
AAATGGGCGGTAGGCATGTACGGTGGGAGGTCTATATAAGCAGAGCTCGTTTATGTAACC  
GTCAGATCGCTGGAGACGCCATCCACGCTGTTTTGACCTCCATAGAAGACACCGGGACC  
GATCCAGCTCCGCGGGCCCCAAGCTTGTTGGGATCCACGGTCGCCACCATGGTGAGCAA  
GGGCGAGGAGCTGTTACCGGGGTGGTGGCCATCCTGGTCGAGCTGGACGGCGACGTAAA  
CGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGAC

CTTGAAGTTCTCTGCACCAACCGGCAAGCTGCCCGTGCCCTGCCCCACCTCGTGACCAC  
CCTGACCTACGGCGTGCACTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCAGCACTT  
CTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGA  
CGGC/AACTACAAGACCCGCGCGGAGGTGAAGTTCGAGGGCGACACCTGGTGAACCGCAT  
CGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTA  
CAACTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGT  
GAAGTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACCA  
GCAGAACACCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCAC  
CCAGTCCGCGCTGAGCAAAAGACCCCAACGAGAAGCGCGATCACATGGTCTGCTGGAGTT  
CGTGACCGCCGCGGGGATCACTCTCGGCATGGACGAGCTGTACAAGTAAAGCGGCCGGA  
CTCTAGAGTCGACCTGCAGGCATGCAAGCTTCAGCTGCTCGAGGGGGGGCCCGGTACCCA  
GCTTTTGTTCCTTTAGTGAGGGTTAATTGCGCGGGAAGTATTTACTACTAATCAAGCAC  
AAGTAATACATGAGAACTTTTACTACAGCAAGCACAATCCTCCAAAAAATTTGTTTTT  
ACAAAATCCCTGGTGAACATGATTGGAAGGGACCTACTAGGGTGTGTGGAAGGGTGATG  
GTGCAGTAGTAGTTAATGATGAAGGAAAGGGAATAATTGCTGTACCATTAACCAAGGACTA  
AGTTACTAATAAAACCAAATTGAGTATTGTTGCAGGAAGCAAGACCCAACTACCATTGTC  
AGCTGTGTTTCTGACCTCAATATTTGTTATAAGGTTTGATATGAATCCCAGGGGGGAATC  
TCAACCCCTATTACCCAAACAGTCAGAAAAATCTAAGTGTGAGGAGAACACAATGTTTCAA  
CCTTATTGTTATAATAATGACAGTAAGAACAGCATGGCAGAATCGAAGGAAGCAAGAGAC  
CAAGAATGAACCTGAAAGAAGAACTAAAGAAGAAAAAAGAAGAAATGACTGGTGGAAAA  
TAGGTATGTTTCTGTTATGCTTAGCAGGAACCTACTGGAGGAATACTTTGGTGGTATGAAG  
GACTCCACAGCAACATTATATAGGGTTGGTGGCGATAGGGGGAAGATTAAACGGATCTG  
GCCAATCAAAATGCTATAGAATGCTGGGGTTCCTTCCCGGGGTGTAGACCATTTCAAAT  
ACTTCAGTTATGAGACCAATAGAAGCATGCATATGGATAATAATACTGCTACATTATTAG  
AAGCTTTAACCAATATAACTGCTCTATAAATAACAAAACAGAATTAGAAACATGGAAGTT  
AGTAAAGACTTCTGGCATAACTCCTTTACCTATTTCTTCTGAAGCTAACACTGGACTAAT  
TAGACATAAGAGAGATTTTGGTATAAGTGCAATAGTGGCAGCTATTGTAGCCGCTACTGC  
TATTGCTGCTAGCGCTACTATGTCTTATGTTGCTCTAACTGAGGTTAACAAAAATAATGGA  
AGTACAAAATCATACTTTTGAGGTAGAAAAATAGTACTCTAAATGGTATGGATTTAATAGA  
ACGACAAAATAAAGATATTATATGCTATGATTCTTCAAACACATGCAGATGTTCAACTGTT  
AAAGGAAAGACAACAGGTAGAGGAGACATTTAATTTAATTGGATGTATAGAAAGAACACA  
TGTATTTTGTACTACTGGTCATCCCTGGAATATGTCATGGGGACATTTAAATGAGTCAAC  
ACAATGGGATGACTGGGTAAGCAAAATGGAAGATTTAAATCAAGAGATACTAACTACACT  
TCATGGAGCCAGGAACAATTTGGCACAATCCATGATAACATTCAATACACCAGATAGTAT  
AGCTCAATTTGGAAGACCTTTGGAGTCATATTGGAATTTGGATTCTGGATTGGGAGC  
TTCCATTATAAAATATATAGTGATGTTTTTGCTTATTTATTTGTTACTAACCTCTTCGCC  
TAAGATCCTCAGGGCCCTCTGGAAGGTGACCAGTGGTGCAGGGTCTCCGGCAGTCGTTA  
CCTGAAGAAAAAATTCATCACAAACATGCATCGCGAGAAGACACCTGGGACCAGGCCCA  
ACACAACATACACCTAGCAGGCGTGACCGGTGGATCAGGGGACAAATACTACAAGCAGAA  
GTACTCCAGGAACGACTGGAATGGAGAATCAGAGGAGTACAACAGGCGGCCAAAGAGCTG  
GGTGAAGTCAATCGAGGCATTTGGAGAGAGCTATATTCCGAGAAGACCAAAGGGGAGAT  
TTCTCAGCCTGGGGCGCTATCAACGAGCACAAGAACGGCTCTGGGGGGAACAATCCTCA  
CCAAGGGTCTTAGACCTGGAGATTGGAAGCGAAGGAGGAAACATTTATGACTGTTGCAT  
TAAAGCCCAAGAAGGAACCTCTGCTATCCCTTGCTGTGGATTTCCCTTATGGCTATTTTG  
GGGACTAGTAATTATAGTAGGACGCATAGCAGGCTATGGATTACGTGGACTCGCTGTTAT  
AATAAGGATTTGTATTAGAGGCTTAAATTTGATATTTGAAATAATCAGAAAAATGCTTGA  
TTATATTGGAAGAGCTTTAAATCCTGGCACATCTCATGTATCAATGCCTCAGTATGTTTA  
GAAAAACAAGGGGGGAACTGTGGGGTTTTATGAGGGGTTTTATAAATGATTATAAGAGT  
AAAAAGAAAGTTGCTGATGCTCTCATAACCTTGATAACCCAAAGGACTAGCTCATGTTG

CTAGGCAACTAAACCGCAATAACCGCATTTGTGACGCGAGTCCCCATTGGTGACGCGTT  
AACTTCCTGTTTTACAGTATATAAGTGCTTGTAATCTGACAATTGGGCACTCAGATTCT  
GCGGTCTGAGTCCCTTCTCTGCTGGGCTGAAAAGGCCTTTGTAATAAATATAATTCTCTA  
CTCAGTCCCTGTCTCTAGTTTGTCTGTTGAGATCCTACAGAGCTCATGCCTTGGCGTAA  
TCATGGTCATAGCTGTTTCTGTGTGAAATTGTTATCCGCTCACAATCCACACAACATA  
CGAGCCGGAAGCATAAAGTGTAAGCCTGGGGTGCCTAATGAGTGAGCTAACTCACATTA  
ATTGCGTTGCGCTCACTGCCCCTTTCCAGTCGGGAAACCTGTCGTGCCAGAGTAGGCCG  
CCTCGGCCAGATCTGGGGTTGGGGTTGCGCCTTTTCCAAGGCAGCCCTGGGTTTGGCGAG  
GGACGCGGCTGCTCTGGGCGTGGTTCCGGGAAACGACGCGCGCCGACCCTGGGTCTCGC  
ACATTCTTACGTCCGTTCCGACGCTCACCCGGATCTTCGCGCTACCCTTGTGGGCCCC  
CCGGCGACGCTTCTGCTCCGCCCTAAGTCGGGAAGGTTCTTGGCGTTCGCGGCGTGC  
CGGACGTGACAAACGGAAGCCGACGTCTCACTAGTACCCTCGCAGACGGACAGCGCCAG  
GGAGCAATGGCAGCGCGCCGACCGGATGGGCTGTGGCCAATAGCGGCTGCTCAGCGGGG  
CGCGCCGAGAGCAGCGGCCGGGAAGGGGCGGTGCGGGAGCGGGGTGTGGGGCGGTAGTG  
TGGGCCCTGTTCTGCCCGCGGGTGTCCGCATTCTGCAAGCCTCCGGAGCGCACGTCTG  
GCAGTCGGCTCCCTGTTGACCGAATCACCGACCTCTCTCCCAGGCTAGCCTCGAGAAT  
TCGCCACCATGGCTGAGAGCAAGGAGGCCAGGGATCAAGAGATGAACCTCAAGGAAGAGA  
GCAAAGAGGAGAAGCGCCGCAACGACTGGTGGAAGATCGACCCACAAGGCCCTGGAGG  
GGGACCAAGTGGTGCGCGTGTGAGACAGTCCCTGCCGAGGAGAAGATTCTAGCCAGA  
CCTGCATCGCCAGAAGACACCTCGGCCCGGTCCACCCAGCACACACCCTCCAGAAGGG  
ATAGGTGGATTAGGGGCCAGATTTTGAAGCCGAGGTCTCCAAGAAAGGCTGGAATGGA  
GAATTAGGGGCGTGCAACAAGCCGCTAAAGAGCTGGGAGAGGTGAATCGCGGCATCTGGA  
GGGAGCTCTACTCCGCGAGGACCAGAGGGCGGATTTCTCCGCATGGGGAGGCTACCAGA  
GGGCACAAGAAAGGCTGTGGGGCGAGCAGAGCAGCCCCCGCTTGTAGGGCCCGAGACT  
CCAAAAGACGCGCAACACCTGTGAAGTCGACCCGGCGCGCGCTTCCCTTTAGTGAGG  
GTTAATGCTTCGAGCAGACATGATAAGATACATTGATGAGTTTGACAAACCACAACCTAG  
AATGCAGTGAAAAAATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAAC  
CATTATAAGCTGCAATAAACAAGTTAACAACAACAATTGCATTATTTATGTTTCAGGT  
TCAGGGGGAGATGTGGGAGGTTTTTTAAAGCAAGTAAACCTCTACAAATGTGGTAAAAT  
CCGATAAGGATCGATCCGGGCTGGCGTAATAGCGAAGAGGCCCGCACCGATCGCCCTTCC  
CAACAGTTGCGCAGCCTGAATGGCGAATGGACGCGCCCTGTAGCGGCGCATTAAGCGCGG  
CGGGTGTGGTGGTTACGCGCAGCGTGACCGCTACACTTGCCAGCGCCCTAGCGCCCGCTC  
CTTTCGCTTTCTCCCTTCTTCTCGCCACGTTGCGCGCTTTCCCGTCAAGCTCTAA  
ATCGGGGGCTCCCTTTAGGGTTCCGATTTAGAGCTTTACGGCACCTCGACCGCAAAAAAC  
TTGATTTGGGTGATGGTTACGTAGGCCGCTCGGCCGCGCGGCATCACTGCATTAATG  
AATCGGCCAACGCGCGGGGAGAGGCGGTTTGGCGTATTGGGCGCTTCTCCGCTTCTCGCT  
CACTGACTCGCTGCGCTCGGTGCTTGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGC  
GGTAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTATAACTTCGT  
ATAATGTATGCTATACGAAGTTATACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACC  
GTAAAAAGGCCGCGTGTGCTGGCGTTTTTCCATAGGCTCGCCCCCTGACGAGCATACA  
AAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGT  
TTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCTGCGCGTTACCGGATACC  
TGTCCGCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCAGCTGTAGGTATC  
TCAGTTCGGTGTAGGTCGTTCCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCGTTTCAGC  
CCGACCGCTGCGCCTTATCCGGTAACATCGTCTTGAGTCCAACCCGTAAGACACGACT  
TATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTG  
CTACAGAGTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGGACAGTATTTGGTA  
TCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCA  
AACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTGTTGCAAGCAGCAGATTACGCGCAGAA

AAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACG  
AAAACTCACGTAAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGATCC  
TTTTAAATTAAAAATGAAGTTTAAATCAATCTAAAGTATATATGAGTAAACTTGGTCTG  
ACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTCTGTTTCT  
CCATAGTTGCTGACTCCCCGTCGTGTAGATAACTACGATACGGGAGGGCTTACCATCTG  
GCCCCAGTGCTGCAATGATACCGCGAGACCCACGCTCACCGGCTCCAGATTTATCAGCAA  
TAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGTCCTGCAACTTTATCCGCCTCCA  
TCCAGTCTATTAATTGTTGCCGGAAGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTGC  
GCAACGTTGTTGCCATTGCTACAGGCATCGTGGTGTACGCTCGTCTGTTTGGTATGGCTT  
CATTCAGTCCCGTTCCCAACGATCAAGGCGAGTTACATGATCCCCATGTTGTGCAAAA  
AAGCGGTTAGCTCCTTCGGTCTCCGATCGTTGTGAGAAGTAAGTTGGCCGAGTGTAT  
CACTCATGGTTATGGCAGCACTGCATAATTCTCTTACTGTATGCCATCCGTAAGATGCT  
TTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAAATAGTGTATGCGGCGACCGA  
GTTGCTCTTGCCCGGCGTCAATACGGGATAATACCGCGCCACATAGCAGAACTTTAAAAG  
TGCTCATCATTGGAAAACGTTCTTCGGGGCGAAAACCTCTCAAGGATCTTACCGCTGTGA  
GATCCAGTTCGATGTAACCCACTCGTGCACCCAAGTATCTTCAGCATCTTTTACTTTCA  
CCAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAGGGAATAAGGG  
CGACACGGAAATGTTGAATACTCATACTCTTCCTTTTCAATATTATTGAAGCATTTATC  
AGGGTTATTGTCTCATGAGCGGATACATAATTGAATGTATTTAGAAAAATAAACAAATAG  
GGGTTCCGCGCACATTTCCCGAAAAAGTGCCACCTAAATTGTAAGCGTTAATATTTTGT  
AAAATTCGCGTTAAATTTTGTAAATCAGCTCATTTTAAACCAATAGGCCGAAATCGG  
CAAAATCCCTTATAAATCAAAAGAATAGACCGAGATAGGGTTGAGTGTGTTCCAGTTTG  
GAACAAGAGTCCACTATTAAGAAGCTGGACTCCAACGTCAAAGGGCGAAAAACCGTCTA  
TCAGGGCGATGGCCCACTACGTGATAACTTCGTATAATGTATGCTATACGAAGTTATCAC  
TACGTGAACCATCACCTAATCAAGTTTTTTGGGGTCGAGGTGCCGTAAAGCACTAAATC  
GGAACCTAAAGGGAGCCCCGATTAGAGCTTGACGGGGAAAGCCAACCTGGCTTATCG  
AAATTAATACGACTCACTATAGGGAGACCGGC



SEQ ID No 51

## pONY3.2IRESHyg

AGATCTCCCGATCCCTATGGTCGACTCTCAGTACAATCTGCTCTGATGCCGCATAGTTA  
AGCCAGTATCTGCTCCCTGCTTGTGTGTTGGAGGTCGCTGAGTAGTCGCGAGCAAAATT  
5 TAAGCTACACAAGGCAAGGCTTGACCGACAATTGCATGAAGAATCTGCTTAGGGTTAGG  
CGTTTTGCGCTGCTTCGCGATGTACGGGCCAGATATACGCGTTGACATTGATTATTGACT  
AGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCCGC  
GTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCGCCCATTTG  
ACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAA  
10 TGGGTGGACTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGATCATATGCCA  
AGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTAC  
ATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGTATTACC  
ATGGTGATGCGGTTTTGGCAGTACACCAATGGGCGTGGATAGCGGTTTGACTCACGGGGA  
TTTCCAAGTCTCCACCCCAATTGACGTCAATGGGAGTTTGTTTTGGCACCAAAATCAACGG  
15 GACTTTCCAAAATGTCGTAACAACCTGCGATCGCCCGCCCGTTGACGCAATGGGCGGTA  
GGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTCGTTAGTGAACCGTCAGATCACTA  
GAAGCTTTATTGCGGTAGTTTATCACAGTTAAATTGCTAACGCACTCAGTGCTTCTGACA  
CAACAGTCTCGAACTTAAGCTGCAGTGACTCTTAAAGGTAGCCTTGCAAGATTGGTCG  
TGAGGCACTGGGCAAGTAAGTATCAAGGTTACAAGACAGGTTAAGGAGACCAATAGAAA  
20 CTGGGCTTGTGAGACAGAGAAGACTCTTGGCTTCTGATAGGCACCTATTGGTCTTACT  
GACATCCACTTTGCCCTTCTCTCCACAGGTGTCCACTCCAGTTCAATTACAGCTCTTAA  
GGCTAGAGTACTTAATACGACTCACTATAGGCTAGCCTCGAGGTCGACGGTATCGCCCGA  
ACAGGGACCTGAGAGGGGCGCAGACCCTACCTGTTGAACCTGGCTGATCGTAGGATCCCC  
GGGACAGCAGAGGAGAACTTACAGAAGTCTTCTGGAGGTGTTCTGGCCAGAACACAGGA  
25 GGACAGGTAAGATGGGAGACCCCTTGACATGGAGCAAGCGCTCAAGAAGTTAGAGAAGG  
TGACGGTACAAGGGTCTCAGAAATTAACCTACTGTTAACTGTAATTGGGCGCTAAGTCTAG  
TAGACTTATTTTCATGATACCAACTTTGTAAGAGAAAAGGACTGGCAGCTGAGGGATGTCA  
TTCCATTGCTGGAAGATGTAACCTCAGACGCTGTCAGGACAAGAAAGAGAGGCCCTTTGAAA  
GAACATGGTGGCAATTTCTGCTGTAAGATGGGCTCCAGATTAATAATGTAGTAGATG  
30 GAAAGGCATCATCCAGCTCCTAAGAGCGAAATATGAAAAGAAAGACTGCTAATAAAAAGC  
AGTCTGAGCCCTCTGAAGAAATATCCAATCATGATAGATGGGCTGGAAACAGAAATTTTA  
GACCTTAACACCTAGAGGATATACTACTTGGGTGAATACCATACAGACAAATGGTCTAT  
TAAATGAAGCTAGTCAAACTTATTTGGGATATTATCAGTAGACTGTACTTCTGAAGAAA  
TGAATGCATTTTGGATGTGGTACCTGGCCAGGACAGGACAAAAGCAGATATTACTTGATG  
35 CAATTGATAAGATAGCAGATGATTGGGATAATAGACATCCATTACCGAATGTCTCCACTGG  
TGGCACCACCAAGGGCCTATTCCCATGACAGCAAGGTTTATTAGAGGTTTAGGAGTAC  
CTAGAGAAAAGACAGATGGAGCCTGCTTTTGATCAGTTAGGCAGACATATAGACAAATGGA  
TAATAGAAAGCCATGTCAGAAAGGCATCAAGTGATGATTGGAAAACCTAAAGCTCAAAATA  
TTAGGCAAGGAGCTAAGGAACCTTACCCAGAAATTTGTAGACAGACTATTATCCCAATAA  
40 AAAGTGAGGGACATCCACAAGAGATTTCAAAATCTTGACTGATACACTGACTATTGAGA  
ACGCAAAATGAGGAATGTAGAAATGCTATGAGACATTTAAGACCAGAGGATACATTAGAAG  
AGAAAAATGTATGCTTGCAAGACATTGGAACATAAAAACAAAAGATGATGTTATTGGCAA  
AAGCACTTCAGACTGGTCTTGGCGGCCCATTTAAAGGTGGAGCCTTGAAGGAGGGCCAC  
TAAAGGCAGCACAAACATGTTATAACTGTGGGAAGCCAGGACATTTATCTAGTCAATGTA  
45 GAGCACCTAAAGTCTGTTTTAAATGTAAACAGCCTGGACATTTCTCAAAGCAATGCAGAA  
GTGTTCCAAAAAACGGGAAGCAAGGGGCTCAAGGGAGGCCCCAGAAACAACTTTCCCGA  
TACAACAGAAAGAGTCAGCACAACTCTGTTGTACAAGAGACTCCTCAGACTCAAAATC  
TGTACCCAGATCTGAGCGAAATAAAAAGGAATACAATGTCAAGGAGAAAGGATCAAGTAG  
AGGATCTCAACCTGGACAGTTTGTGGGAGTAACATATAATCTAGAGAAAAGGCCTACTAC  
50 AATAGTATTAATTAATGATACTCCCTTAAATGTACTGTTAGACACAGGAGCAGATACTTC  
AGTGTGACTACTGCACATTATAATAGGTTAAATATAGAGGGAGAAAAATCAAGGGAC  
GGGAATAATAGGAGTGGGAGGAAATGTGGAAACATTTTCTACGCCTGTGACTATAAAGAA  
AAAGGGTAGACACATTAAGACAAGAATGCTAGTGGCAGATATCCAGTGACTATTTTGGG  
ACGAGATATTCTTCAGGACTTAAAGTCAAAATTTGGTTTGGCACAGCTCTCCAAGGAAAT  
55 AAAATTTAGAAAAATAGAGTTAAAAGAGGGCACAAATGGGGCCAAAAATTCCTCAATGGCC  
ACTCACTAAGGAGAACTAGAAGGGGCCAAAAGAGATAGTCCAAAGACTATTGTGAGAGGG  
AAAAATATCAGAAGCTAGTGACAATAATCCTTATAATTCAACCATATTTGTAATAAAAAA  
GAGGTCTGGCAAAATGGAGGTTATTACAAGATCTGAGAGAATTAACAAAACAGTACAAGT  
AGGAACGGAAATATCCAGAGGATTGCCTACCCGGGAGGATTAAATTAATGTAACACAT  
60 GACTGTATTAGATATTGGAGATGCATATTTCACTATACCCTTAGATCCAGAGTTAGACC  
ATATACAGTTTCACTATTCCCTCCATTAATCAATCAAGAACAGATAAAGATATGTGTG  
GAAATGTTTACCACAAGGATTCTGTTGAGCCCATATATATATCAGAAAACATTACAGGA  
AATTTTACAACCTTTTAGGGAAGATATCTGAAGTACAATTGTATCAATATATGGATGA

TTTGTTTCATGGGAAAGTAATGGTTCTAAAAAACACAAAAGAGTTAATCATAGAATTAAG  
GGCGATCTTACTGGAAAAAGGTTTTGAGACACCAGATGATAAATTACAAGAAAGTGCCACC  
TTATAGCTGGCTAGGTTATCAACTTTGTCTGAAAAATTGGAAAGTACAAAAAATGCAATT  
AGACATGGTAAAGAATCCAACCCCTTAATGATGTGCAAAAAATTAATGGGGAAATATAACATG  
5 GATGAGCTCAGGGATCCCAGGGTTGACAGTAAAAACACATTGCAGCTACTACTAAGGGATG  
TTAGAGTTGAATCAAAAAAGTAATTTGGACGGAAGAGGCACAAAAAGACTTAGAAGAAAA  
TAATGAGAAGATTAAAAATGCTCAAGGGTTACAATATTATAATCCAGAAGAAGAAATGTT  
ATGTGAGGTTGAAATTACAAAAAATTATGAGGCAACTTATGTTATAAAACAATCACAAGG  
AATCCTATGGGCAGGTAAAAAGATTATGAAGGCTAATAAGGGATGGTCAACAGTAAAAAA  
10 TTTAATGTTATTGTTGCAACATGTGGCAACAGAAAGTATTACTAGAGTAGGAAATGTCC  
AACGTTTAAAGGTACCATTTACCAAAGAGCAAGTAATGTGGGAAATGCAAAAAAGGATGGTA  
TTATTCTTGGCTCCCAGAAATAGTATATACACATCAAGTAGTTTCATGATGATTGGAGAAT  
GAAATTGGTAGAAGAACCTACATCAGGAATAACAAATATACACTGATGGGGGAAAAACAAAA  
TGGAGAAGGAATAGCAGCTTATGTGACCAGTAATGGGAGAACTAAACAGAAAAAGGTTAGG  
15 ACCTGTCACTCATCAAGTTGCTGAAAGAATGGCAATACAAATGGCATTAGAGGATACCAG  
AGATAAACAAAGTAAATATAGTAAGTATGTTATTGTTGGAAAAATATTACAGAAGG  
ATTAGGTTTAGAAGGACCACAAAGTCTTGGTGGCCTATAATACAAAATATACGAGAAAA  
AGAGATAGTTTATTTTGGCTTGGGTACCTGGTCACAAAGGGATATATGGTAATCAATTGGC  
AGATGAAGCCGCAAAAAATAAAGAAAGAAATCATGCTAGCATACCAAGGCACACAAATTA  
20 AGAGAAAAGAGATGAAGATGCAGGGTTTGACTTATGTGTTCTTATGACATCATGATACC  
TGATCTGACACAAAAATCATACCCACAGATGTAATAAATCAAGTCTCTCTAATAGCTT  
TGGATGGGTCACTGGGAAATCATCAATGGCAAAACAGGGGTTATTAATTAATGGAGGAAT  
AATTAGTGAAGGATATACAGGAGAAATACAAGTGATGTACTAATATTGGAAAAAGTAA  
TATTAATTAATAGAGGGACAAAAATTGCAACAAATTAATTATACTACAGCATCACTCAA  
25 TTCCAGACAGCCTTGGGATGAAAAATAAATATCTCAGAGAGGGGATAAAGGATTTGGAAG  
TACAGGAGTATTCTGGGTAGAAAAATATTCAGGAAGCACAAGATGAACATGAGAATTGGCA  
TACATACCCAAAGATATTGGCAAGAAATTATAAGATACCATTTGACTGTAGCAAAACAGAT  
AATCAAGAATGTCCTCATTGCACTAAGCAAGGATCAGGACCTGCAGGTTGTGTCATGAG  
ATCTCCTAATCATTGGCAGGCAGATTGCACACATTTGGACAATAAGATAATATTGACTTT  
30 TGTAGAGTCAAAATCAGGATACATACATGCTACATTATGTCAAAAAGAAAAATGCATTATG  
TACTTCATTGGCTATTTAGAATGGGCAAGATTGTTTTCACCAAAAGTCTTACACACAGA  
TAACGGCACTAATTTTGTGGCAGAACCAGTTGTAATTTGTTGAAGTCTCTAAAGATAGC  
ACATACCACAGGAATACCATATCATCCAGAAAGTCAAGGGTATTGTAGAAAAGGGCAAAATAG  
GACCTTGAAAGGAGAAGATTCAAAGTCAATAGAGACAACACTCAAACACTGGAGGCAGCTTT  
35 ACAACTTGCTCTCACTTACTTGTAAACAAAGGGAGGGGAAAGTATGGGAGGACAGACCCATG  
GGAAGTATTTATCACTAATCAAGCACAAGTAATACATGAGAACTTTTACTACAGCAAGC  
ACAATCCTCCAAAAAATTTGTTTTTACAAAAATCCCTGGTGAACATGATTGGAAGGGACC  
TACTAGGGTGTGGAAGGGTGATGGTGCAGTAGTAAATGATGAAGGAAAGGGAAT  
AATTGCTGTACCATTAACCAAGGACTAAGTTACTAATAAAACCAAAATGAGTATTGTTGCA  
40 GGAAGCAAGACCAACTACCATTTGTCAGCTGTGTTCTGACCTCAATATTGTTATAAG  
GTTTGATATGAATCCCAGGGGGAATCTCAACCCCTATTACCAACAGTCAGAAAAATCTA  
AGTGTGAGGAGAACAACAATGTTTCAACCTTATTGTTATAATAATGACAGTAAGAACAGCA  
TGGCAGAAATCGAAGGGAAGCAAGAGACCAAGAAATGAACCTGAAAGAAGAATCTAAAGAAAG  
45 AAAAAAGAAGAAATGACTGGTGGAAAAATAGGTATGTTTCTGTTATGCTTAGCAGGAACCTA  
CTGGAGGAATACTTTGGTGGTATGAAGGACTCCACAGCAACATTATATAGGGTTGGTGG  
CGATAGGGGGAAGATTAAACGGATCTGGCCAATCAAATGCTATAGAATGCTGGGGTTCTCT  
TCCCGGGGTGTAGACCATTTCAAATTTACTTCAGTTATGAGACCAATAGAAGCATGCATA  
TGGATAATAATACTGCTACATTATTAGAAGCTTTAAACCAATATAACTGCTCTATAAATAA  
50 CAAAACAGAATTAGAAACATGGAAGTTAGTAAAGACTTCTGGCATAACTCCTTTACCTAT  
TTCTTCTGAAGCTAACACTGGACTAATTAGACATAAGAGAGATTTTGGTATAAGTGCAAT  
AGTGGCAGCTATTGTAGCCGCTACTGCTATTGCTGCTAGCGCTACTATGTCTTATGTTGC  
TCTAAGTGGTTAAACAAAATAATGGAAGTACAAAATCATACTTTGAGGTAGAAAAATAG  
TACTCTAAATGGTATGGATTAAATAGAACGACAAAATAAAGATATTATGCTATGATTCT  
TCAAACACATGCAGATGTTCAACTGTTAAAGGAAAGACAACAGGTAGAGGAGACATTTAA  
55 TTTAATTGGATGTATAGAAAGAACACATGATTTTGTCACTAGTTCATCCCTGGAATAT  
GTCATGGGGACATTTAAATGAGTCAACACAATGGGATGACTGGGTAAGCAAAATGGAAGA  
TTTAAATCAAGAGATACTAACTACACTTCATGGAGCCAGGAACAATTTGGCACAATCCAT  
GATAACATTCAATACACCAGATAGTATAGCTCAATTTGGAAAAAGACCTTTGGAGTCAAT  
TGGAAATTTGGATTCTCGGATTTGGGAGCTTCCATTATAAAATATATAGTGATGTTTTGCT  
60 TATTTATTTGTTACTAACCTCTTCGCCTAAGATCCTCAGGGCCCTCTGGAAGGTGACCAG  
TGGTGCAGGGTCTCCCGGCAGTCGTTACCTGAAGAAAAAATCCATCACAAACATGCATC  
GGGAGAAGACACCTGGGACCAGGCCCAACACAACATACACCTAGCAGGCGTGACCGGTGG  
ATCAGGGGACAAATACTAAGCAGAAGTACTCCAGGAACGACTGGAATGGAGAATCAGA  
GGAGTACAACAGCGGCCAAAGAGCTGGGTGAAGTCAATCGAGGCAATTTGGAGAGAGCTA  
65 TATTTCCGAGAAGACCAAAAGGGGAGATTCTCAGCCTGGGGCGGCTATCAACGAGCACAA  
GAACGGCTCTGGGGGGAACAATCCTACCAAGGGTCTTAGACCTGGAGATTGGAAGCGA  
AGGAGGAAACATTTATGACTGTTGCAATTAAGGCCAAGAAGGAACCTCTCGCTATCCCTTG  
CTGTGGATTTCCTTATGGCTATTTTGGGGGTGACCCGGCGGCGGCACTAGAGGAATT  
CGCCCTCTCCCTCCCCCCCCCTAACGTTACTGGCCGAAGCCGCTTGAATTAAGCCGG  
70 TGTGTGTTGTCTATATGTGATTTCCACCATTGCGCTCTTTTGGCAATGTGAGGGCC  
CGGAAACCTGGCCCTGTCTTCTGACGAGCATTCCTAGGGGTCTTTCCCTCTCGCCAAA  
GGAATGCAAGGTCTGTTGAATGTCGTGAAGGAAGCAGTTCTCTGGAAGCTTCTTGAAGA  
CAAACAACGTCTGTAGCGACCTTTGCAAGGACGGGAACCCCCACCTGGCGACAGGTGC  
CTCTGCGGCCAAAAGCCAGGTGTATAAGATACACCTGCAAGGGCGGCACAACCCAGTGC

CACGTTGTGAGTTGGATAGTTGTGGAAAGAGTCAAATGGCTCTCCTCAAGCGTAGTCAAC  
AAGGGGCTGAAGGATGCCCAGAAGGTACCCCATTTGTATGGGAATCTGATCTGGGGCTCG  
GTGCACATGCTTTACATGTGTTTGTAGTCAGGTTAAAAAGCTCTAGGCCCCCGAACCAC  
5 GGGGACGTGGTTTTCTTTGAAAAACACGATGATAAGCTTGCCACAACCCCGTACCAAAG  
ATGGATAGATCCGGAAGCCGTGAACCTACCGCGACGTCTGTGAGAAGTTTCTGATCGAA  
AAGTTTCGACAGCGTCTCCGACCTGATGACGCTCTCGGAGGGCGAAGAATCTCGTGCTTC  
AGCTTCGATGTAGGAGGGCGTGGATATGTCCTGCGGGTAAATAGCTGCGCCGATGGTTTC  
TACAAAGATCGTTATGTTTATCGGCACCTTTCATCGCCGCGCTCCCGATTCGGGAAGTG  
10 CTTGACATTTGGGGAATTACGCGAGAGCCTGACCTATTGCATCTCCCGCCGTGCACAGGGT  
GTCACGTTGCAAGACCTGCCTGAAACCGAACTGCCGCTGTTCTGCAGCCGGTCGCGGAG  
GCCATGGATGCGATCGCTGCGGCCGATCTTAGCCAGACGAGCGGGTTCGGCCATTCCGA  
CCGCAAGGAATCGGTCAATACACTACATGGCGTGATTTCAATAGCGCGATTGCTGATCCC  
CATGTGTATCACTGGCAAACCTGTGATGGACGACACCGTCACTGCGTCCGTCGCGCAGGCT  
CTCGATGAGCTGATGCTTTGGGCCGAGGACTGCCCGAAGTCCGGCACCTCGTGACCGG  
15 GATTTCCGGCTCCAACAATGTCCTGACGGACAATGCCCGCATAACAGCGGTCAATTGACTGG  
AGCGAGGCGATGTTCCGGGATTTCCCAATACGAGGTCCGCAACATCTTCTTGGAGGCCG  
TGGTTGGCTTGTATGGAGCAGCAGACGCGCTACTTCGAGCGGAGGCATCCGGAGCTTGCA  
GGATCGCCGCGGCTCCGGGCGTATATGCTCCGCTTGGTCTTGACCAACTCTATCAGAGC  
TTGGTTGACGGCAATTCGATGATGACGCTTGGGCGCAGGGTTCGATGCGACGCAATCGTC  
20 CGATCCGGAGCCGGGACTGTCCGGCGTACACAAATCGCCCGCAGAAGCGCGCCGCTGCG  
ACCGATGGCTGTGTAGAAGTACTCGCCGATAGTGGAAACCGACGCCCCAGCACTCGTCCG  
AGGGCAAAGGAATAGAGTAGATGCCGACCGAACAAGAGCTGATTCGAGAACGCCCTCAGC  
CAGCAACTCGCGCGAGCCTAGCAAGGCAATGCGAGAGAACGGCCTTACGCTTGGTGGCA  
CAGTTCTCGTCCACAGTTCCGTAAGCTCGCTCGGTCGGTTCGCGGAGGGCCGGTTCGCA  
25 TGATTCAGGCCCTTCTGGATTGTGTTGGTCCCGAGGGCAGATTGTCATGCCACGCACT  
CGGGTGATCTGACTGATCCCGCAGATTGGAGATCGCCGCCGTGCTGCGGATTGGGTGC  
AGATCTAGAGCTCGCTGATCAGCCTCGACTGTGCTCTAGTTGCCAGCCATCTGTTGTT  
GCCCTCCCGCGTCCCTTCCCTGACCCTGGAAAGGTGCCACTCCCACTGTCTTTCTAAT  
AAAATGAGGAAATTGCATCGCATTGTCTGAGTAGGTGTCACTATTCTGGGGGTGGGG  
30 TGGGGCAGGACAGCAAGGGGGAGGATTGGGAAGACAATAGCAGGCATGCTGGGGATCGCG  
TGGGCTCTATGGCTTCTGAGGCGGAAAGAACAGCTGGGGCTCGAGTGCATTCTAGTTGT  
GGTTTGTCCAAACTCATCAATGTATCTTATCATGTCTGTATACCGTCGACCTCTAGCTAG  
AGCTTGGCGTAATCATGGTCATAGCTGTTCTGTGTGAAATTGTTATCCGCTCACAATT  
CCACACAACATACGAGCCGGAAGCATAAAGTGTAAAGCCTGGGGTGCCTAATGAGTGAGC  
35 TAACTCACATTAATTGCGTTGCGCTCACTGCCGCTTTCCAGTCGGGAAACCTGTCTGTC  
CAGCTGCATTAATGAATCGGCCAACGCGCGGGGAGAGGGGTTTGGCTATTGGCGCTCT  
TCCGCTTCTCGCTCACTGACTCGCTGCGCTCGGTTCGGCTCGCGCGAGCGGTATCA  
GCTCACTCAAAGGCGGTAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAAC  
ATGTGAGCAAAAAGGCCAGCAAAAAGGCCAGGAACCGTAAAAAGGCCGCTGCTGGCGTTT  
40 TTCCATAGGCTCCGCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGG  
CGAAACCCGACAGGACTATAAAGATACAGGGCTTTCCCGCTGGAAAGCTCCCTCGTGCGC  
TCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCTTTCTCCCTTCGGGAAGC  
GTGGCGCTTTCTCAATGCTCAGCTGTAGGTATCTCAGTTCGGTGTAGGTGCTTCGCTCC  
AAGCTGGGCTGTGTGCACGAACCCCGGTTACGCCGACCGCTGCGCCTTATCCGGTAAC  
45 TATCGTCTTGAGTCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGT  
AACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCT  
AACTACGGCTACACTAGAAGGACAGTATTTGGTATCTGCGCTGCTGAAGCCAGTTACC  
TTCGGAAGAAAGAGTTGGTAGCTCTTGATCCGCAAAACAAACCCGCTGGTAGCGGTGGT  
TTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAGGATCTCAAGAAGATCCTTTG  
50 ATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAACCTACGTTAAGGGATTTTGGTC  
ATGAGATTATCAAAAAGGATCTTACCTAGATCCTTTAAATTAATAAGTATTAATAA  
TCAATCTAAAGTATATATGAGTAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAG  
GCACCTATCTCAGCATCTGTCTATTTTCGTTTATCCATAGTTGCCTGACTCCCGCTCGT  
TAGATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGGA  
55 GACCCACGCTCACC GGCTCCAGATTATCAGCAATAAACAGCCAGCCGGAAGGGCCGAG  
CGCAGAAAGTGGTCTGCACTTTATCCGCTCCATCCAGTCTATTAATTGTTGCCGGGA  
GCTAGAGTAAGTAGTTCCGCAAGTTAATAGTTTGCAGAACGTTGTTGCCATTGCTACAGGC  
ATCGTGGTGTACGCTCGTCTGTTGGTATGGCTTCATTACGCTCCGGTTCCCAACGATCA  
AGGCGAGTTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCTCCG  
60 ATCGTTGTGCAAGTAAGTTGGCCGAGTGTTATCACTCATGGTTATGGCAGCACTGCAT  
AATTCTTCTACTGTCTATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACC  
AAGTCATTCTGAGAATAGTGTATGCGCGACCGAGTTGCTCTTGCCCGGCGTCAATACGG  
GATAATACCGCGCCACATAGCAGAACTTTAAAGTGCTCATATTGGAACGTTCTTCG  
GGGCGAAAACCTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTTCGATGTAACCCACTCGT  
65 GCACCAACTGATCTTACGATCTTTACTTTTACCAGCGTTTCTGGGTGAGCAAAAAACA  
GGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACGGAATGTTGAATACTCAT  
CTCTTCTTTTCAATATTATTGAAGCATTTATCAGGGTATTGTCTCATGAGCGGATAC  
ATATTTGAATGATTATGAAAAATAAACAAATAGGGGTTCGCGCACATTTCCCGAAAA  
GTGCCACCTGACGTGACGGATCGGG

70

**pONY8ZA CMVHyb (SEQ ID No 52)**

AGATCTTGAATAATAAAATGTGTGTTGTCCGAAATACGCGTTTGTGAGATTCTGTCCG

5 GACTAAATTCATGTGCGCGGATAGTGGTGTATTCGCCGATAGAGATGGCGATATTGGAA  
AAATTGATATTTGAAAAATATGGCATATTGAAAAATGTCGCCGATGTGAGTTTCTGTGTAAC  
TGATATCGCCATTTTCCAAAAAGTGATTTTGGGCATACGCGATATCTGGCGATAGCGCT  
TATATCGTTTACGGGGGATGGCGATAGACGACTTTGGTGACTTGGGCGATTCTGTGTGTC  
10 GCAAATATCGCAGTTTCGATATAGGTGACAGACGATATGAGGCTATATCGCCGATAGAGG  
CGACATCAAGCTGGCACATGGCCAATGCATATCGATCTATACATTGAATCAATATTGGCC  
ATTAGCCATATTATTCATTGGTTATATAGCATAAATCAATATTGGCTATTGGCCATTGCA  
TACGTTGTATCCATATCGTAATATGTACATTTATATTGGCTCATGTCCAACATTACCGCC  
ATGTTGACATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCA  
15 TAGCCCATATATGGAGTTCCGCGTTACATAAATTACGGTAAATGGCCCGCTGGCTGACC  
GCCCCAACGACCCCCGCCATTGACGTCAATATGACGTATGTTCCCATAGTAACGCCAAT  
AGGGACTTTCCATTGACGTCAATGGGTGGAGTATTACGGTAAACTGCCCACTTGGCAGT  
ACATCAAGTGTATCATATGCCAAGTCCGCCCTATTGACGTCAATGACGGTAAATGGCC  
CGCTGGCATTATGCCAGTACATGACCTTACGGGACTTTCTACTTGGCAGTACATCTA  
20 CGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACACCAATGGGCGTGG  
ATAGCGGTTTGACTCACGGGGATTTCGAAGTCTCCACCCATTGACGTCAATGGGAGTTT  
GTTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTGTAACAACTGCGATCGCCCGCC  
CCGTTGACGCAAAATGGGCGGTAGGCGGTGACGGTGGGAGGTCTATATAAGCAGAGCTCGT  
TTAGTGAACCGGGCACTCAGATTCTGCGGTCTGAGTCCCTTCTGCTGGGCTGAAAAGG  
25 CCTTGTAAATAATAAATCTCTACTCAGTCCCTGTCTAGTTTGTCTGTTGAGATC  
CTACAGTTGGCGCCCGAACAGGGACCTGAGAGGGGCGCAGACCCTACCTGTTGAACCTGG  
CTGATCGTAGGATCCCGGGACAGCAGAGGAGAAGTACAGAAGTCTTCTGGAGGTGTTT  
CTGGCCAGAACACAGGAGGACAGGTAAGATTGGGAGACCCTTTGACATTGGAGCAAGGCG  
CTCAAGAAGTTAGAGAAGGTGACGGTACAAGGGTCTCAGAAATTAACACTGTTAACTGT  
30 AATTGGGCGCTAAGTCTAGTAGACTTATTTTATTGATACCACTTTGTAAGAAAAAGGA  
CTGGCAGCTGAGGGATTGTCAATTCATTGCTGGAAGATTGTAACCTCAGACGCTGTCAAGG  
CAAGAAAGAGAGGCTTTGAAAGAACATTGGTGGCAATTTCTGCTGTAAGATTGGGCC  
TCCAGATTAAATTTAGTAGATTGGAAAGGCATCATTCAGCTCCTAAGAGCGAAATA  
TTGAAAGAAGACTGCTAATAAAAAAGCAGTCTGAGCCCTCTGAAGAATATCTCTAGAAGT  
35 AGTGGATCCCCCGGGCTGCAGGAGTGGGGAGGCACGATGGCCGCTTTGGTTCGAGGCGGAT  
CCGGCCATTAGCCATATTATTCATTGGTTATATAGCATAAAATCAATATTGGCTATTGGCC  
ATTGCATACGTTGTATCCATATCATAATATGTACATTTATATTGGCTCATGTCCAACATT  
ACCGCCATGTTGACATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATT  
AGTTTCATAGCCCATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCTGG  
40 CTGACCGCCCAACGACCCCGCCCATTTGACGTCAATAATGACGTATGTTCCCATAGTAAC  
GCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTACGGTAAACTGCCCACTT  
GGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAA  
ATGGCCCGCTGGCATTATGCCAGTACATGACCTTATGGGACTTTCTACTTGGCAGTA  
CATCTACGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGG  
45 GCGTGGATAGCGGTTTGACTCACGGGGATTTCGAAGTCTCCACCCCATTTGACGTCAATGG  
GAGTTTTGTTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTGTAACAACTCCGCCCC  
ATTGACGCAAAATGGGCGGTAGGCATGTACGGTGGGAGGTCTATATAAGCAGAGCTCGTTT  
AGTGAACCGTCAGATCGCTGGAGACGCCATCCACGCTGTTTTGACCTCCATAGAAGACA  
CCGGGACCGATCCAGCCTCCGCGGCCCAAGCTTCAGTGTCTGAGGATCTGCGGATCCG  
50 GGGAAATCCCCAGTCTCAGGATCCACCATGGGGATCCCGTCGTTTTACAACGTCGTGAC  
TGGGAAAACCCCTGGCGTTACCCAATTAACTCGCCTTGACGACATCCCCCTTTCCGACG  
TGGCGTAATAGCGAAGAGGCCCGACCGATCGCCCTTCCCAACAGTTGCGCAGCCTGAAT  
GGCGAATGGCGCTTTGCCTGGTTTCCGCGACCAAGAGCGGTGCCGAAAGCTGGCTGGAG  
TGCGATCTTCTGAGGCGGATACGTGCTGCTCCCTCAAACTGGCAGATGCACGGTTAC  
55 GATGCGGCCCATCTACACCAACGTAACCTATCCCATACGGTCAATCCGCCGTTTGTTCCT  
ACGGAGAATCCGACGGGTTGTTACTCGCTCACATTAATGTTGATGAAAGCTGGCTACAG  
GAAGGCCAGACGCGAATTATTTTGTATGGCGTTAACTCGGCGTTTCACTGTGGTGCAAC  
GGGCGCTGGGTGGTTACGGCCAGGACAGTCTGTTTGGCGTGAATTTGACCTGAGCGCA  
TTTTTACGGCGCGGAGAAAACCGCCTCGCGGTGATGGTGTGCGTTGGAGTGACGGCAGT  
60 TATCTGGAAGATCAGGATATGTGGCGGATGAGCGGCATTTCCGTGACGTCTCGTTGCTG  
CATAAACCGACTACACAAATCAGCGATTTCCATGTTGCCACTCGCTTTAATGATGATTTC  
AGCCGCGCTGTACTGGAGGCTGAAGTTCAAGTGTGCGGCGAGTTGCGTGACTACCTACGG  
GTAACAGTTTCTTATGGCAGGGTGAAACGACGGTCCGACGGGACCGCGCCTTTCCGGC  
GGTGAAATATCGATGAGCGTGGTGGTTATGCCGATCGCGTCACACTACGTCTGAACGTC  
65 GAAAACCCGAAACTGTGGAGCGCCGAAATCCCGAATCTCTATCGTGGCGGTGTTGAACTG  
CACACCGCGACGGCACGCTGATTGAAGCAGAAGCCTGCGATGTCGGTTTCCGCGAGGTG  
CGGATTGAAAATGGTCTGCTGCTGTAACGCGCAAGCGGTTGCTGATTTCGAGGCGTTAAC  
CGTCACGAGCATCATCTCTGCATGGTCAGGTATGGATGAGCAGACGATGGTGCAGGAT  
ATCCTGTGATGAAGCAGAACAACTTTAACCGCGTGGCTGTTGCGATTATCCGAACCAT  
70 CCGCTGTGGTACACGCTGTGCGACCGCTACGGCCTGTATGTTGGTGGATGAAGCCAATATT  
GAAACCCACGGCATGGTGCCAATGAATCGTCTGACCGATGATCCGCGCTGGCTACCGGG  
ATGAGCGAACCGGTAACGCGAATGGTGCAGCGGATCGTAATACCCGAGTGTGATCATC  
TGGTCCGTTGGGGAATGAATCAGGCCACGGCGCTAATCAGACGCGCTGTATCGCTGGATC  
AAATCTGTGATCCTTCCCGCCGGTGCAGTATGAAGCGCGCGGAGCCGACACCGGGC  
ACCGATATTATTTGCCCGATGTACGCGCGCGTGGATGAAGACCGCCCTTCCCGGCTGTG  
CCGAAATGGTCCATCAAAAAATGGCTTTCGCTACCTGGAGAGACGCGCCCGCTGATCCTT  
TGCGAATACGCCACCGGATGGGTAAAGTCTTGGCGGTTTCGCTAAATACTGGCAGGCG  
TTTCGTACGATATCCCGTTTACAGGGCGGCTTCGTCTGGGACTGGGTGGATCAGTCGCTG  
ATTAAATATGATGAAAACGGCAACCCGTTGGTTCGGCTTACGGCGGTGATTTTGGCGATACG

CCGAACGATCGCCAGTTCTGTATGAACGGTCTGGTCTTTGCCGACCGACGCCGCATCCA  
GCGCTGACGGGAAGCAAAACACGAGCAGTCTTTTCCAGTTCCGTTTATCCGGGCAAAACC  
ATCGAAGTGACGAGCGAATACCTGTTCCGTCATAGCGATAACGAGCTCCTGCACTGGATG  
GTGGCGCTGGATGGTAAGCCGCTGGCAAGCGGTGAAGTGCTCTGGATGTGCTCCACAA  
5 GGTAAACAGTTGATTGAACTGCCTGAACACCGCAGCCGAGAGCGCCGGGCAACTCTGG  
CTCACAGTAGCGGTAGTGCAACCGAACGCGACCGCATGGTCAGAAGCCGGGCACATCAGC  
GCCTGGCAGCAGTGGCGTCTGGCGGAAAACCTCAGTGTGACGCTCCCCGCCGCTCCAC  
GCCATCCCGCATCTGACCACAGCGAAATGGATTTTGCATCGAGCTGGGTAATAAGCGT  
TGGCAATTTAACCGCCAGTCAGGCTTTCTTTCACAGATGTGGATTGGCGATAAAAAACAA  
10 CTGCTGACGCCGCTGCGCGATCAGTTCACCCGTGCACCGCTGGATAACGACATTGGCGTA  
AGTGAAGCGACCCGATTGACCCTAACGCTGGGTGCAACGCTGGAAGCGCGGGGCCAT  
TACGAGGCCGAAGCAGCGTTGTTGCAGTGCACGGCAGATACACTTGTGATGCGGTGCTG  
ATTACGACCGCTCAGCGGTGGCAGCATCAGGGGAAAACCTTATTTATCAGCCGAAAAACC  
TACCGGATTGATGGTAGTGGTCAATGGCGATTACCGTTGATGTTGAAGTGCGAGCGAT  
15 ACACCGCATCCGGCGCGGATTGGCCTGAACCTGCCAGTGGCGCAGGTAGCAGAGCGGGTA  
AACTGGCTCGGATTAGGGCCGCAAGAAAACCTATCCGACCGCTTACTGCCGCTGTTTT  
GACCGCTGGGATCTGCCATTGTACAGCATGTATACCCGTCAGTCTTCCCGAGCGAAAAAC  
GGTCTGCGCTGCGGGACGCGCAATTGAATTATGGCCACACAGTGGCGCGCGGACTTC  
CAGTTCAACATCAGCCGCTACAGTCAACAGCAACTGATGGAAACCAGCATCGCCATCTG  
20 CTGCACGCGGAAGAACGACATGGCTGAATATCGACGGTTTCCATATGGGGATTGGTGGC  
GACGACTCTGGAGCCCGTCAGTATCGGCGGAATTCAGCTGAGCGCCGGTCTGCTACCAT  
TACGAGTTGGTCTGGTGTCAAAAAATAATAAACCGGGCAGGGGGGATCCGCAGATCCGG  
CTGTGGAATGTGTGTCAGTTAGGGTGTGGAAAGTCCCCAGGCTCCCCAGCAGGCAGAAAT  
ATGCAAGCATGCTGCAGGAATTCGATATCAAGCTTATCGATACCGTCGACCTCGAGGG  
25 GGGGCCCGGTACCCAGCTTTGTCCCTTTAGTGAGGGTTAATTGCGCGGAAGTATTTA  
TCACTAATCAAGCACAAGTAATACATGAGAACTTTACTACAGCAAGCACAATCCTCCA  
AAAAATTTGTTTTACAAAAATCCCTGGTGAACATGATTGGAAGGGACCTACTAGGGTGC  
TGTGGAAGGGTATGGTGCAGTAGTATTAATGATGAAGGAAAGGAATAATTGCTGTAC  
CATTAAACAGGACTAAGTTACTAATAAAACCAAAATGAGTATTGTTGCAGGAAGCAAGAC  
30 CCAACTACCATTTGTGCTGCTGTTTCTGACCTCAATATTTGTTATAAGGTTTGATATGA  
ATCCCAAGGGGAATCTCAACCCCTATTACCAACAGTCAGAAAAATCTAAGTGTGAGGAG  
AACACAATGTTTCAACCTTATTGTTATAATAATGACAGTAAGAACAGCATGGCAGAATCG  
AAGGAAGCAAGAGACCAAGAATGAACCTGAAAGAAAGAACTAAAGAAAGAAAAAGAA  
ATGACTGGTGGAAAAATAGGTATGTTTCTGTTATGCTTACGAGGAACCTACTGGAGGAATAC  
35 TTTGGTGGTATGAAGGACTCCACAGCAACATTATATAGGGTTGGTGGCGATAGGGGAA  
GATTAACCGGATCTGGCCAATCAAAATGCTATAGAATGCTGGGGTTCCCTCCCGGGGTGTA  
GACCATTTCAAAATTACTTCAGTTATGAGACCAATAGAAGCATGCATATGGATAATAATA  
CTGCTACATTATTAGAAGCTTTAACCAATATAACTGCTCTATAAATAACAAAAACAGAAAT  
AGAAACATGGAAGTTAGTAAAGACTTCTGGCATAACTCCTTACCTATTTCTCTGAAGC  
40 TAACACTGGACTAATTAGACATAAGAGAGATTTTGGTATAAGTGCAATAGTGGCAGCTAT  
TGTAGCCGCTACTGCTATTGCTGTAGCGCTACTATGTCTTATGTTGCTCTAACTGAGGT  
TAACAAAAATAATGGAAAGTACAAAAATCATACTTTTGAAGTAGAAAAATAGTACTCTAAATGG  
TATGGATTTAATAGAACGACAAATAAGATATTATATGCTATGATTCTTCAACACATGC  
AGATGTTCAACTGTTAAAGGAAAGACAACAGGTAGAGGAGACATTTAATTTAATTGGATG  
45 TATAGAAAGAACACATGTATTTGTCTACTGCTCATCCCTGGAATATGTCATGGGGACA  
TTTAAATGAGTCAACACAATGGGATGACTGGGTAAGCAAAATGGAAGATTTAAATCAAGA  
GATACTAACTACACTTCATGGAGCCAGGAACAATTTGGCACAATCCATGATAACATTCAA  
TACACCAGATAGTATAGCTCAATTTGGAAAAAGACCTTTGGAGTCATATTGGAATTTGGAT  
50 TCTGGATTGGGAGCTTCCATTATAAAATATATAGTATGTTTTGCTTATTTATTTGTT  
ACTAACCTCTTCGCTAAGATCCTCAGGGCCCTCTGGAAGGTGACCAGTGGTGCAGGGTC  
CTCCGGCAGTCGTTACCTGAAGAAAAAATCCATCACAACATGCATCGCGAGAAGACAC  
CTGGGACCAGGCCAACACAACATACACCTAGCAGGCGTGACCGGTGGATCAGGGGACAA  
ATACTACAGCAGAAAGTACTCCAGGAACGACTGGAATGGAGAAATCAGAGGAGTACAACAG  
55 GCGGCCAAAGAGCTGGGTGAAGTCAATCGAGGCAATTTGGAGAGAGCTATATTTCCGAGAA  
GACCAAAAGGGGAGATTTCTCAGCTGGGGCGGCTATCAACGAGCACAAGAACGGCTCTGG  
GGGGAACAATCTCACCAAGGGTCTTAGACCTGGAGATTGGAAGCGAAGGAGGAAACAT  
TTATGACTGTTGCATTAAGGCCAAGAAGGAACTCTCGTATCCCTTGTGTGGATTTC  
CTTATGGCTATTTTGGGGACTAGTAATTATAGTAGGACGATAGCAGGCTATGGATTACG  
TGGACTCGCTGTTATAATAAGGATTTGTATTAGAGGCTTAAATTTGATATTTGAAATAAT  
60 CAGAAAAATGCTTGATTATATTGGAAGAGCTTTAAATCCTGGCACATCTCATGTATCAAT  
GCCTCAGTATGTTTAAAAACAAGGGGGAACTGTGGGGTTTTATAGGGGGTTTTATA  
AACTGCAGGAGTGGGGAGGCACGATGGCCGCTTTGGTTCGAGGCGGATCCGGCCATTAGCC  
ATATTATTCATTGGTTATATAGCATAAATCAATATTGGCTATTGGCCATTGCATACGTTG  
TATCCATATCATAAATATGTACATTTATTTGGCTCATGTCCAACATTACGCCATGTTGA  
65 CATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCA  
TATATGGAGTTCGCGTTACATAACTTACGGTAAATGGCCCGCTGGCTGACCGCCCAAC  
GACCCCGCCCATTTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACT  
TTCCATTGACGTCAATGGGTGGAGTATTACGGTAAACTGCCCACTTGGCAGTACATCAA  
GTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCTGG  
70 CATTATGCCAGTACATGACCTTATGGGACTTCTACTTGGCAGTACATCTACGTATTA  
GTCATCGCTATTACCATGGTATGCGGTTTTGGCAGTACATCAATGGGCGTGGATAGCGG  
TTTGACTCAGGGGATTTCCAAGTCTCCACCCATTGACGTCAATGGGAGTTTGTTTTGG  
CACCAAAATCAACGGGACTTTCCAAAATGTCTGAACAACTCCGCCCCATTGACGCAATG  
GGCGGTAGGCATGTACGGTGGGAGGTCTATATAAGCAGAGCTCGTTTATGTAACCGGGCA

CTCAGATTCTGCGGTCTGAGTCCCTTCTCTGCTGGGCTGAAAAGGCCTTTGTAATAAATA  
TAATTCTCTACTCAGTCCCTGTCTCTAGTTTGTCTGTTTCGAGATCCTACAGAGCTCATGC  
CTTGGCGTAATCATGGTCATAGCTGTTTCTGTGTGAAATTGTTATCCGCTCACAATTCC  
ACACAACATACGAGCCGGAAGCATAAAGTGTAAGGCCTGGGGTGCCTAATGAGTGAGCTA  
5 ACTCACATTAAATTGCGTTGCGCTCACTGCCCGCTTTCCAGTCGGGAAACCTGTCGTGCCA  
GCTGCATTAAATGAATCGGCCAACGCGCGGGGAGAGGCGGTTTGGCTATTGGGCGCTCTTC  
CGTTCTCGCTCACTGACTCGCTGCGCTCGGTCGTTCCGCTGCGGCGAGCGGTATCAGC  
TCACTCAAAGGCGGTAAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACAT  
GTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCTTGGTGGCGTTTTT  
10 CCATAGGCTCCGCCCTTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCG  
AAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCTGGAAGCTCCCTCGTGCGCTC  
TCCTGTTCCGACCTGCCGCTTACCGGATACCTGTCCGCTTTCTCCCTTCGGGAAGCGT  
GGCGCTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTGCTTCGCTCCAA  
GCTGGGCTGTGTGCAGAACCCCGTTTCAGCCGACCGCTGCGCTTATCCGGTAACTA  
15 TCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGCGCAGCAGCCACTGGTAA  
CAGGATTAGCAGAGCGAGGTATGTAGCGGCTGTACAGAGTTCTTGAAGTGGTGGCTAA  
CTACGGCTACACTAGAAGGACAGTATTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTT  
CGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAAACAAACCACCGCTGGTAGCGGTGGTTT  
TTTTGTTGCAAGCAGCAGATTACGCGCAGAAAAAAGGATCTCAAGAAGATCCTTTGAT  
20 CTTTTCTACGGGCTGACGCTCAGTGGAAACGAAACTCAGTTAAGGGATTTTGGTCAT  
GAGATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTTAAATC  
AATCTAAAGTATATATGAGTAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGC  
ACCTATCTCAGCGATCTGTCTATTTCTGTTATCCATAGTTGCTGACTCCCCGTCGTGTA  
GATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGA  
25 CCCACGCTCACCGGCTCCAGATTATCAGCAATAAACCCAGCCAGCCGGAAGGGCCGAGCG  
CAGAAGTGGTCTGCAACTTTATCCGCTCCATCCAGTCTATTAATTGTTGCCGGGAAGC  
TAGAGTAAGTAGTTCCGCACTTAATAGTTTGGCAACGTTGTTGCCATTGCTACAGGCAT  
CGTGGTGTACGCTCGTCTGTTGGTATGGCTTCATTACGCTCCGGTTCCCAACGATCAAG  
GCGAGTTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCTCCGAT  
30 CGTTGTCAGAAAGTAAGTTGGCCGCACTGTTATCACTCATGGTTATGGCAGCACTGCATAA  
TTCTCTTACTGTATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAA  
GTCATTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAATACGGGA  
TAATACCGCGCCACATAGCAGAACTTTAAAGTGCTCATATTGGAACGTTCTTCGGG  
GCGAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTAACCACTCGTGC  
35 ACCCACTGATCTTCAGCATCTTTTACTTTCACCAGCGTTTCTGGGTGAGCAAAACAGG  
AAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACAGGAAATGTTGAATACTCATACT  
CTTCTTTTCAATATTATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGGATACAT  
ATTTGAATGTATTTAGAAAAATAAACAAATAGGGGTTCCGCGCACATTTCCCGAAAAAGT  
GCCACCTAAATTGTAAGCGTTAATATTTTGTAAAAATTCGCGTTAAATTTTGTAAATC  
40 AGCTCATTTTTTAACCAATAGGCCGAAATCGGCAAAATCCCTTATAAATCAAAAGAATAG  
ACCGAGATAGGGTTGAGTGTTGTTCCAGTTTGGAAACAAGAGTCCACTATTAAGAACGTG  
GACTCCAACGTCAAAGGGCGAAAAACCGTCTATCAGGGCGATGGCCCACTACGTGAACCA  
TCACCCTAATCAAGTTTTTTGGGGTCGAGGTGCCGTAAGCACTAAATCGGAACCTAAA  
GGGAGCCCCGATTTAGAGCTTGACGGGAAAGCCAACCTGGCTTATCGAAATTAATACG  
45 ACTCACTATAGG

5

**PEsynGP (SEQ ID No 53)**

TCAATATTGGCCATTAGCCATATTATTCATTGGTTATATAGCATAAATCAATATTGGCTA  
TTGGCCATTGCATACGTTGTATCTATATCATAATATGTACATTTATATTGGCTCATGTCC  
10 AATATGACCGCCATGTTGGCATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGG  
GTCATTAGTTCATAGCCCATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCC  
GCCTGGCTGACCGCCCCAACGACCCCCGCCATTGACGTCAATAATGACGTATGTTCCCAT  
AGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGC  
CCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTCCGCCCCCTATTGACGTCAATGA  
15 CGGTAAATGGCCCGCTGGCATTATGCCCAGTACATGACCTTACGGGACTTTCCTACTTG  
GCAGTACATCTACGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACAC  
CAATGGGCGTGGATAGCGGTTTGACTCACGGGGATTTCGAAGTCTCCACCCCATGACGT  
CAATGGGAGTTTGTGTTTGGCACCAAAATCAACGGGACTTTCGAAGTGTGTAACAACGTG  
CGATCGCCCGCCCCGTTGACGCAATGGGCGGTAGGCGGTGACGGTGGGAGGTCTATATA  
20 AGCAGAGCTCGTTTAGTGAACCGTCAGATCACTAGAACTTTATTGCGGTAGTTTATCAC  
AGTTAAATTGCTAACGCAGTCAGTGCTTCTGACACAACAGTCTCGAACTTAAGCTGCACT  
GACTCTCTTAAGGTAGCCTTGCAGAAAGTTGGTCTGAGGCACTGGGCAGGTAAGTATCAA  
GGTTACAAGACAGGTTTAAGGAGACCAATAGAAACTGGGCTTGTGAGACAGAGAAGACT  
CTTGCGTTTCTGATAGGCACCTATTGGTCTTACTGACATCCACTTTGCTTCTCTCCAC  
25 AGGTGTCCACTCCCAGTTCAATTACAGCTCTTAAGGCTAGAGTACTTAATACGACTCACT  
ATAGGCTAGAGAAATTCGCCACCATGGGCGATCCCCTCACCTGGTCCAAAGCCCTGAAGAA  
ACTGGAAAAAGTCACCGTTCAGGGTAGCCAAAAGCTTACCACAGGCAATTGCAACTGGGC  
ATTGTCCTTGGTGGATCTTTTCCACGACACTAATTTCTGTTAAGGAGAAAAGATTGGCACT  
CAGAGACGTGATCCCCCTCTTGGAGGACGTGACCCAAACATTGTCTGGGCAGGAGCGCA  
30 AGCTTTCGAGCGCACCTGGTGGGCCATCAGCGCAGTCAAAAATGGGGCTGCAAAATCAACA  
CGTGGTTGACGGTAAAGCTAGCTTTCAACTGCTCCGCGCTAAGTACGAGAAGAAAACCGC  
CAACAAGAAACAATCCGAACCTAGCGAGGAGTACCCAATTATGATCGACGGCGCCGGCAA  
TAGGAACCTCCGCCCACTGACTCCAGGGGCTATACCACCTGGGTCAACACCATCCAGAC  
AAACGGACTTTTGAACGAAGCCTCCAGAACCTGTTCCGGCATCCTGTCTGTGGACTGCAC  
35 CTCCGAAGAAATGAATGCTTTTCTCGACGTGGTGCCAGGACAGGCTGGACAGAAAACAGAT  
CCTGCTCGATGCCATTGACAAGATCGCCGACGACTGGGATAATCGCCACCCCTGCCAAA  
CGCCCTCTGGTGGCTCCCCACAGGGGCTATCCCTATGACCGCTAGGTTTATTAGGGG  
ACTGGGGGTGCCCCGCGAACGCCAGATGGAGCCAGCATTTGACCAATTTAGGCAGACCTA  
CAGACAGTGGATCATCGAAGCCATGAGCGAGGGGATTAAAGTCATGATCGGAAAGCCCAA  
40 GGCACAGAACATCAGGCAGGGGGCCAAAGGAACCATACCCTGAGTTTGTGACAGGCTTCT  
GTCCCAGATTAATCCGAAGGCCACCCTCAGGAGATCTCCAAGTTCTTGACAGACACACT  
GACTATCCAAAATGCAATGAAGAGTGCAGAAACGCCATGAGGCACCTCAGACCTGAAGA  
TACCCTGGAGGAGAAAATGTACGCATGTCGCGACATTGGCACTACCAAGCAAAAGATGAT  
GCTGCTCGCCAAGGCTCTGCAAAACCGGCCTGGCTGGTCCATTCAAAGGAGGAGCACTGAA  
45 GGGAGGTCCATTGAAAGCTGCACAAACATGTTATAATTGTGGGAAGCCAGGACATTTATC  
TAGTCAATGTAGAGCACCTAAAGTCTGTTTTAAATGTAAACAGCCTGGACATTTCTCAA  
GCAATGCAGAAAGTGTTCAAAAAACGGGAAGCAAGGGGCTCAAGGGAGGCCCCAGAAAACA  
AACTTTCCCGATACAACAGAAGAGTCAGCACAAACAATCTGTTGTACAAGAGACTCCTCA  
GACTCAAAATCTGTACCCAGATCTGAGCGAAATAAAAAAGGAATACAATGTCAAGGAGAA  
50 GGATCAAGTAGAGGATCTCAACCTGGACAGTTTGTGGGAGTAACATACAATCTCGAGAAG  
AGGCCCACTACCATCGTCTGTATCAATGACACCCCTCTTAATGTGCTGCTGGACACCGGA  
GCCGACACCAAGCGTTTCTACTACTGCTCACTATAACAGACTGAAATACAGAGGAAGGAAA  
TACCAGGGCAGGCATCATCGGCGTTGGAGGCAACGTCGAAACCTTTTCACTCCTGTC  
ACCATCAAAAAAGAGGGGAGACACATTAACCAGAAATGCTGGTTCGCGACATCCCCGTC  
55 ACCATCCTTGGCAGAGACATTCTCAGGACCTGGGCGCTAAACTCGTGTGGCACAACCTG  
TCTAAGGAAATCAAGTTCGCAAGATCGAGCTGAAAGAGGGCACAATGGGTCCAAAAATC  
CCCCAGTGGCCCTGACCAAGAGAAGCTTGAGGGCGCTAAGGAAATCGTGCAGCGCCTG  
CTTCTGAGGGCAAGATTAGCGAGGCCAGCGACAATAACCCTTACAACAGCCCCATCTTT



GTGATTAAGAAAAGGAGCGGCAATGGAGACTCCTGCAGGACCTGAGGGAAGTCAACAAG  
ACCGTCCAGGTCGGAAGTGAAGATCTCTCGGGACTGCCTCAGCCCGGCGGCTGATTA  
TGCAAGCATGACAGTCCTTGACATTGGAGACGCTATTTTACCATCCCCCTCGATCCT  
GAATTCGCCCCCTATACTGCTTTTACCATCCCCAGCATCAATCACCAGGAGCCCGATAAA  
5 CGCTATGTGTGGAAGTGCCTCCCCAGGGATTGTGCTTAGCCCTACATTTACCAGAAG  
ACACTTCAAGAGATCCTCCAACCTTTCCGCGAAAGATACCCAGAGGTTCAACTCTACCA  
TATATGGACGACCTGTTTATGGGGTCCAACGGGTCTAAGAAGCAGCACAAGGAAGTCA  
ATCGAACTGAGGGCAATCCTCCTGGAGAAAGGCTTCGAGACACCCGACGACAAGCTGCAA  
10 GAAGTTCTCCATATAGCTGGCTGGGCTACAGCTTTGCCCTGAAAAGTGGAAAGTCCAG  
AAGATGCAGTTGGATATGGTCAAGAACCCAACTGAACGACGTCCAGAAGCTCATGGGC  
AATATTACCTGGATGAGCTCCGGAATCCCTGGGCTTACCGTTAAGCACATTGCCGCAACT  
ACAAAAGGATGCCTGGAGTTGAACCAGAAGGTCATTTGGACAGAGGAAGCTCAGAAGGAA  
CTGGAGGAGAAATATGAAAAGATTAAGAATGCTCAAGGGCTCCAATACTACAATCCCGAA  
GAAGAAATGTTGTGCGAGGTGCAAACTAAGAAGTACGAAGCCACCTATGTCATCAAA  
15 CAGTCCCAAGGCATCTTGTGGGCCGGAAGAAAATCATGAAGGCCAACAAGGCTGGTCC  
ACCGTTAAAAATCTGATGCTCCTGCTCCAGCACGTGCCACCGAGTCTATCACCCGCGTC  
GGCAAGTGGCCACCTTCAAAGTTCCCTTCACTAAGGAGCAGGTGATGTGGGAGATGCAA  
AAAGGCTGGTACTACTCTTGGCTTCCCGAGATCGTCTACACCCACCAAGTGGTGACGAC  
GACTGGAGAAATGAAGCTTGTGAGGAGGCCACTAGCGGAATTACAATCTATACCGACGGC  
20 GGAAGCAAAAACGGAGAGGGAATCGCTGCATACGTCACATCTAACGGCCGACCAAGCAA  
AAGAGGCTCGGCCCTGTCACTACCAGGTGGCTGAGAGGATGGCTATCCAGATGGCCCTT  
GAGGACACTAGAGACAAGCAGGTGAACATTGTGACTGACAGCTACTACTGCTGGAAAAAC  
ATCACAGAGGGCCTTGGCCTGGAGGGACCCAGTCTCCCTGGTGGCTATCATCCAGAAT  
ATCCGCGAAAAGGAAATTTGCTATTTCCGCTGGGTGCCTGGACACAAAGGAATTTACGGC  
25 AACCAACTCGCCGATGAAGCGCCGCAAAATTAAGAGGAAATCATGCTTGCCTACCAGGGC  
ACACAGATTAAGGAGAAGAGAGACGAGGACGCTGGCTTTGACCTGTGTGTGCCATACGAC  
ATCATGATTTCCCGTTAGCGACACAAAGATCATTCCAACCGATGTCAAGATCCAGGTGCCA  
CCCAATTCATTTGGTTGGGTGACCGGAAAGTCCAGCATGGCTAAGCAGGGTCTTCTGATT  
AACGGGGGAATCATTGATGAAGGATACACCGCGAAATCCAGGTGATCTGCACAAATATC  
30 GGCAAAAGCAATATTAAGCTTATCGAAGGGCAGAAATTCGCTCAACTCATCTCTCCAG  
CACCACAGCAATTCAAGACAACCTTGGGACGAAAACAAGATTAGCCAGAGAGGTGACAAG  
GGCTTCGGCAGCACAGGTGTGTTCTGGGTGGAGAATCCAGGAAGCACAGGACGAGCAC  
GAGAATTGGCACACCTCCCCTAAGATTTTGGCCCGCAATTACAAGATCCCACTGACTGTG  
GCTAAGCAGATCACACAGGAATGCCCCACTGCACCAAAACAAGGTTCTGGCCCCGCGGG  
35 TCGCTGATGAGGTCCCCAATCACTGCGAGGCAGATTGCACCCACCTCGACAACAAATTT  
ATCCTGACCTTCGTGGAGAGCAATTCGCGCTACATCCACGCAACACTCCTCTCCAAGGAA  
AATGCATTGTGCACCTCCCTCGCAATTTGGAATGGGCCAGGCTGTTCTCTCCAAATCC  
CTGCACACCGACAACGGCACCAACTTTGTGGCTGAACCTGTGGTGAATCTGCTGAAGTTC  
CTGAAAATCGCCACACCACTGGCATTCCCTATCACCTGAAAGCCAGGGCATTGTGAG  
40 AGGGCCAACAGAACTCTGAAAGAAAAGATCCAATCTCACAGAGACAATACACAGACATTG  
GAGGCCGCACTTCAGCTCGCCCTTATCACCTGCAACAAAGGAAGAGAAAGCATGGGCGGC  
CAGACCCCTTGGGAGGTCTTCACTAACCAGGCCCAGGTATCCATGAAAAGCTGCTC  
TTGCAGCAGGCCAGTCTCTCAAAAAGTTCTGCTTTTATAAGATCCCCGGTGAGCACGAC  
TGGAAGGTCCTACAAGAGTTTGTGGAAGGAGACGGCGCAGTTGTGGTGAACGATGAG  
45 GGCAAGGGGATCATCGCTGTGCCCCGACACGCACCAAGCTTCTCATCAAGCCAACTGA  
ACCCGGGGCGGCGCTTCCCTTTAGTGAGGGTTAATGCTTCGAGCAGACATGATAAGATA  
CATTGATGAGTTTGGACAAACCACTAGAATGCAGTGAACAAAAATGCTTTATTTGTGA  
AATTTGTGATGCTATTGCTTTATTTGTAACCATTATAAGCTGCAATAAACAAGTTAACA  
CAACAATTGCATTCAATTTATGTTTCAGGTTACGGGGGAGATGTGGGAGGTTTTTAAAG  
50 CAAGTAAAACCTCTACAAATGTGGTAAATCCGATAAGGATCGATCCGGGCTGGCGTAAT  
AGCGAAGAGGCGCCGACCGATCGCCCTTCCCAACAGTTGCGCAGCCTGAATGGCGAATGG  
ACGCGCCCTGTAGCGCGCGATTAAAGCGCGGGGGTGTGGTGGTTACGCGCAGCGTGACCG  
CTACACTTGCCAGCGCCCTAGCGCCGCTCCTTTCGCTTTCTTCCCTTCTTCTCGCCA  
CGTTCCGCGGCTTTCCCGTCAAGCTCTAAATCGGGGGCTCCCTTTAGGGTTCCGATTTA  
55 GAGCTTTACGGACCTCGACCGCAAAAACTTGATTTGGGTGATGGTTCACGTAGTGGG  
CATCGCCCTGATAGACGGTTTTTCGCCCTTTGACGTTGGAGTCCACGTTCTTTAATAGT  
GACTCTTGTTCCAAACCTGGAACAACACTCAACCTATCTCGGTCTATTCTTTGATTTAT  
AAGGGATTTTGGCGATTTGGGCTATTGGTTAAAAAATGAGCTGATTTAACAATATTTA  
ACGCGAATTTTAAACAAATATTAACGTTTACAATTTGCCTGATGCGGTATTTCTCCTT  
60 ACGCATCTGTGCGGTATTTACACCGCATACCGGATCTGCGCAGCACCATGGCCTGAA  
TAACCTCTGAAGAGGAACCTTGGTATAGTACCTTCTGAGGCGGAAGAACAGCTGTGGA  
ATGTGTGTCAGTTAGGGTGTGGAAGTCCCGAGGCTCCCGCAGCAGGAGATGCAAA  
GATGCATCTCAATTAGTCAGCAACAGGTGTGGAAGTCCCGAGGCTCCCGCAGGCA  
GAAGTATGCAAGCATGCATCTCAATTAGTCAGCAACCATAGTCCCGCCCTAACTCCGC  
65 CCATCCCGCCCTAACTCCGCCAGTTCGCCCATTTCTCGCCCATGGCTGACTAATTT  
TTTTATTTATGCAGAGGCGGAGGCGCCTCGGCTCTGAGCTATTCCAGAAGTAGTGAG



GAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAAAGCTTGATTCTTCTGACACAACAGTCT  
CGAACTTAAGGCTAGAGCCACCATGATTGAACAAGATGGATTGCACGCAGGTTCTCCGGC  
CGCTTGGGTGGAGAGGCTATTTCGGCTATGACTGGGCACAAAGACAATCGGCTGCTCTGA  
TGGCGCCGTGTTCCGGCTGTCAGCGCAGGGGCGCCCGTTCTTTTGTCAAGACCGACCT  
5 GTCCGGTGCCCTGAATGAACTGCAGGACGAGGCAGCGCGGCTATCGTGGCTGGCCACGAC  
GGGCGTTCCTTGCGCAGCTGTGCTCGACGTTGCTACTGAAGCGGGAAGGGACTGGCTGCT  
ATTGGGCGAAGTGCCGGGGCAGGATCTCCTGTATCTACCTTGCTCCTGCCGAGAAAAGT  
ATCCATCATGGCTGATGCAATGCGGCGGCTGCATACGCTTGATCCGGCTACCTGCCCCATT  
CGACCACCAAGCGAAACATCGCATCGAGCGAGCAGTACTCGGATGGAAGCCGGTCTTGT  
10 CGATCAGGATGATCTGGACGAAGAGCATCAGGGGCTCGCGCCAGCCGAACCTGTTCCGCCAG  
GCTCAAGGCGCGCATGCCCGACGGCGAGGATCTCGTCGTGACCCATGGCGATGCCTGCT  
GCCGAATATCATGGTGGAAAAATGGCCGCTTTTCTGGATTATCGACTGTGGCCGGCTGGG  
TGTGGCGGACCGCTATCAGGACATAGCGTTGGCTACCGTGATATTGCTGAAGAGCTTGG  
CGGCGAATGGGCTGACCGCTTCTCGTCTTACGGTATCGCCGCTCCCGATTGCGACGG  
15 CATCGCCTTCTATCGCCTTCTTGACGAGTCTTCTGAGCGGACTCTGGGGTTCGAAATG  
ACCGACCAAGCGACGCCAACCTGCCATCAGGATGGCCGCAATAAAATATCTTTATTTTC  
ATTACATCTGTGTGTTGGTTTTTGTGTGAATCGATAGCGATAAGGATCCGCGTATGGTG  
CACTCTCAGTACAATCTGCTCTGATGCCGCATAGTTAAGCCAGCCCCGACACCCGCCAAC  
ACCCGCTGACGCGCCCTGACGGGCTTGCTGCTGCTCCCGCATCCGCTTACAGACAAGCTGT  
20 GACCGTCTCCGGGAGCTGCATGTGTGAGAGGTTTTACCGTCATCACCGAAACGCGCGAG  
ACGAAAGGGCCTCGTGATACGCCTATTTTATAGGTTAATGTCATGATAAATAGGTTTC  
TTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTT  
CTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATA  
ATATTGAAAAAGGAAGATATGAGTATTCAACATTCCGTGTCGCCCTTATTCCCTTTTT  
25 TGGCGCATTTTGGCTTCTGTTTTTGTCTACCCAGAAACGCTGGTGAAAGTAAAGATGC  
TGAAGATCAGTTGGGTGCACGAGTGGGTACATCGAAGTGGATCTCAACAGCGGTAAGAT  
CCTTGAGAGTTTTCGCCCCGAAGACGTTTTTCCAATGATGAGCACTTTTAAAGTTCTGCT  
ATGTGGCGCGGTATTATCCCGTATTGACGCCGGGAAGAGCAACTCGGTGCGCGCATACA  
CTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGG  
30 CATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAAAGTGGGCCAA  
CTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGACAACATGGG  
GGATCATGTAAGTGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGA  
CGAGCGTGACACCAGGATGCCTGTAGCAATGGCAACAACGTTGCGCAAACTATTAAGTGG  
CGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGT  
35 TGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTATTGCTGATAAATCTGG  
AGCCGGTGAGCGTGCGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTC  
CCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACA  
GATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACTC  
ATATATACTTTAGATTGATTTAAAACTTCATTTTTAATTTAAAGGATCTAGGTGAAGAT  
40 CCTTTTGTAAATCTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTC  
AGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCTTTTTTCTGCGCGTAATCTG  
CTGCTTGCAAAACAAAAAACACCAGCTACCAGCGGTGGTTGTTTGGCGGATCAAGAGCT  
ACCAACTCTTTTTCCGAAGGTAAGTGGCTTCAGCAGAGCGCAGATACCAATACTGTCTT  
TCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCAGCTACATACCT  
45 CGCTCTGCTAATCCTGTTACCACTGGCTGCTGCCAGTGGCGATAAGTCTGTCTTACCGG  
GTTGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTGGGCTGAACGGGGGGTTC  
GTGCACACAGCCAGCTTGGAGCGAACGACCTACACCGAAGTGAATACCTACAGCGTGA  
GCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGG  
CAGGGTGGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGAAACGCCTGGTATCTTTA  
50 TAGTCTGTGCGGTTTTCGCCACCTCTGACTTGAGCGTCGATTTTGTGATGCTCGTCAGG  
GGGGCGGAGCCTATGGAAAACGCCAGCAACGCGGCTTTTACGGTTCCTGGCCTTTTG  
CTGGCCTTTTGCTCACATGGCTCGACAGATCT

**PESDSYNGP (SEQ ID No 54)**

55 TCAATATTGGCCATTAGCCATATTATTCATTGGTTATATAGCATAAATCAATATTGGCTA  
TTGGCCATTGCATACGTTGTATCTATATCATAATATGTACATTATATTGGCTCATGTCC  
AATATGACCGCCATGTTGGCATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGG  
60 GTCATTAGTTATAGCCCATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCC  
GCCTGGCTGACCGCCCAACGACCCCGCCATTGACGTCAATAATGACGTATGTTCCCAT  
AGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTACGGTAAACTGC  
CCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTCCGCCCCCTATTGACGTCAATGA  
CGGTAAATGGCCCGCTGGCATTATGCCAGTACATGACCTTACGGGACTTTCTACTTG  
65 CCAGTACATCTACGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACAC  
CAATGGGCGTGATAGCGGTTTGAATCAGGGGATTTCCAAGTCTCCACCCATTGACGT

CAATGGGAGTTTGTGTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAACAACCTG  
CGATCGCCCGCCCGTTGACGCAAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATA  
AGCAGAGCTCGTTTAGTGAAACCGTCAGATCACTAGAAAGCTTTATTGCGGTAGTTTATCAC  
AGTTAAATTGCTAACGCAGTCAGTGCTTCTGACACAACAGTCTCGAACTTAAGCTGCAGT  
5 GACTCTCTTAAGGTAGCCTTGCAGAAAGTTGGTCTGTAGGCACTGGGCAGGTAAGTATCAA  
GGTTACAAGACAGGTTTAAAGGAGACCAATAGAAACTGGGCTTGTGAGACAGAGAAAGACT  
CTTGCGTTTCTGATAGGCACCTAATTGGTCTTACTGACATCCACTTTGCCTTTCTCTCCAC  
AGGTGTCCACTCCCAGTTCATTACAGCTCTTAAGGCTAGAGTACTTAATACGACTCACT  
ATAGGCTAGAGAATTCCAGGTAAGATGGGCGATCCCCTCACCTGGTCCAAAGCCCTGAAG  
10 AAAGTGGAAAAAGTCACCGTTCAGGGTAGCCAAAAGCTTACCACAGGCAATTGCAACTGG  
GCATTGTCCCTGGTGGATCTTTTCCACGACACTAATTCGTAAAGGAGAAAAGATTGGCAA  
CTCAGAGACGTGATCCCCCTCTTGGAGGACGTGACCCAAACATTGTCTGGGCAGGAGCGC  
GAAGCTTTCGAGCGCACCTGGTGGGCCATCAGCGCAGTCAAAATGGGGCTGCAAAATCAAC  
AACGTGGTTGACGGTAAAGCTAGCTTTCAACTGCTCCGCGCTAAGTACGAGAAGAAACC  
15 GCCAACAAAGAAACATCCGAACCTAGCGAGGAGTACCCAATTATGATCGACGGCGCCGGC  
AATAGGAACTTCCGCCCCTGACTCCCAGGGGCTATACCACCTGGGTCAACACCATCCAG  
ACAACCGACTTTTGAACGAAGCCTCCAGAACCTGTTCCGGCATCCTGTCTGTGGACTGC  
ACCTCCGAAGAAATGAATGCTTTTCTGACGTGGTGGCAGGACAGGCTGGACAGAAACAG  
ATCCTGCTCGATTGCCATTGACAAGATCGCGACGACTGGGATAAATCGCCACCCCTGCCA  
20 AACGCCCCCTGTGGTGGCTCCCCACAGGGGCTATCCCTATGACCGCTAGGTTTATTAGG  
GGACTGGGGGTGCCCCGCAACGCCAGATGGAGCCAGCATTGACCAATTTAGGCAGACC  
TACAGACAGTGGATCATCGAAGCCATGAGCGAGGGGATTAAAGTCATGATCGGAAAGCCC  
AAGGCACAGAACATCAGGCAGGGGGCCAAGGAACCATACCTGAGTTTGTGACAGGCTT  
CTGTCCAGATTAATCCGAAGGCCACCTCAGGAGATCTCCAAGTTCTTGACAGACACA  
25 CTGACTATCCAAAATGCAAAATGAAGATGACAGAAACGCCATGAGGCACCTCAGACCTGAA  
GATACCTGGAGGAGAAAATGTACGCATGTGCGGACATTGGCACTACCAAGCAAAAGATG  
ATGCTGCTCGCAAGGCTCTGCAAAACCGGCTGGCTGGTCCATTCAAAGGAGGAGCACTG  
AAGGGAGGTCCATTGAAAGCTGCACAAAATGTTATAATTGTGGGAAGCCAGGACATTTA  
TCTAGTCAATGTAGAGCACCTAAAGTCTGTTTAAATGTAACAGCCTGGACATTTCTCA  
30 AAGCAATGCAGAAGTGTTCAAAAAACGGGAAGCAAGGGGCTCAAGGGAGGCCCCAGAAA  
CAAACTTTCCCGATACAACAGAAAGAGTCAGCACAACAAATCTGTTGTACAAGAGACTCCT  
CAGACTCAAAATCTGTACCCAGATCTGAGCGAAATAAAAAAGGAATACAATGTCAAGGAG  
AAGGATCAAGTAGAGGATCTCAACCTGGACAGTTTGTGGGAGTAACATACAATCTCGAGA  
AGAGGGCCACTACCATCGTCCTGATCAATGACACCCCTCTTAATGTGCTGCTGGACACC  
35 GAGCCGACACCAGCGTTCTCACTACTGCTCACTATAACAGACTGAAATACAGAGGAAGGA  
AATACCAGGGCACAGGCATCATCGGCGTTGGAGGCAACGTCGAAACCTTTTCCACTCCTG  
TCACCATCAAAAAGAAGGGGAGACACATTAACCAGAAATGCTGGTCGCCGACATCCCCG  
TCACCATCCTTGGCAGAGACATTCTCCAGGACCTGGGCGCTAAACTCGTGCTGGCACAA  
TGTCTAAGGAAATCAAGTTCCGCAAGATCGAGCTGAAAGAGGGCACAATGGGTCCAAAA  
40 TCCCCAGTGGCCCCTGACCAAGAGAAAGCTTGAGGGCGCTAAGGAAATCGTGCAGCGCC  
TGCTTTCTGAGGGCAAGATTAGCGAGGCCAGCGACAATAACCTTACAACAGCCCCATCT  
TTGTGATTAAGAAAAGGAGCGGCAATGGAGACTCCTGCAGGACCTGAGGGAACCTCAACA  
AGACCGTCCAGGTGGAAGTGAAGATCTCTCGCGGACTGCCTACCCCGCGCGCCTGATTA  
AATGCAAGCACATGACAGTCTTGACATTGGAGACGCTTATTTTACCATCCCCCTCGATC  
45 CTGAATTTGCCCCCTATACTGCTTTTACCATCCCCAGCATCAATCACCAGGAGCCCGATA  
AACGCTATGTGTGGAAGTGCCTCCCCAGGGATTGTGCTTAGCCCCATATTACCAGA  
AGACACTTCAAGAGATCTCCAACCTTTCCGCGAAAGATACCCAGAGGTCAACTCTACC  
AATATATGGACGACCTGTTATGGGGTCCAACGGGTCTAAGAAGCAGCACAAGGAACCTCA  
TCATCGAACTGAGGGCAATCCTCTGGAGAAAGGCTTCGAGACACCCGACGACAAGCTGC  
50 AAGAAGTTCTCCATATAGCTGGCTGGGCTACCAGCTTTGCCCTGAAAAGTGGAAAGTCC  
AGAAGATGCAGTTGGATATGGTCAAGAACCACCACTGAACGACGTCCAGAAGCTCATGG  
GCAATATTACCTGGATGAGCTCCGGAATCCCTGGGCTTACCGTTAAGCACATTGCCGCAA  
CTACAAAAGGATGCCTGGAGTTGAACCAGAAGGTCAATTGGACAGAGGAAGCTCAGAAGG  
AAGTGGAGGAGAATAATGAAAAGATTAAGAATGCTCAAGGGCTCCAATACTACAATCCCC  
55 AAGAAGAAATGTTGTGCGAGGTGCAAACTACTAAGAAGTACGAAGCCACCTATGTCATCA  
AACAGTCCCAAGGCATCTTGTGGGCGGAAAGAAAATCATGAAGGCCAACAAAGGCTGGT  
CCACCGTTAAAAATCTGATGCTCCTGCTCCAGCAGTCCGCCACCGAGTCTATACCCGCG  
TCGGCAAGTGGCCACCTTCAAAGTTCCTTCACTAAGGAGCAGGTGATGTGGGAGATGC  
AAAAAGGCTGGTACTACTCTTGGCTTCCCGAGATCGTCTACACCCACCAAGTGGTGCACG  
60 ACGACTGGAGAATGAAGCTTGTGAGGAGCCCACTAGCGGAATTACAATCTATACCGACG  
GCGGAAAGCAAAACGGAGAGGGAATCGCTGCATACGTACATCTAACGGCCGACCAAGC  
AAAAGAGGCTCGGCCCTGTCACTACCAGGTGGGCTGAGAGGATGGCTATCCAGATGGCCC  
TTGAGGACACTAGAGACAAGCAGGTGAACATTGTGACTGACAGTACTACTGCTGGAAAA  
ACATCACAGAGGGCCTTGGCCTGGAGGGACCCCACTCCTGGTGGCCTATCATCCAGA  
65 ATATCCGCGAAAAGGAAATTGTCTATTCGCTGGGTGCCTGGACACAAAGGAATTTACG  
GCAACCAACTCGCCGATGAAGCCGCCAAAATTAAGAGGAAATCATGCTTGCCTACCAGG

GCACACAGATTAAGGAGAAGAGAGACGAGGACGCTGGCTTTGACCTGTGTGTGCCATACG  
ACATCATGATTCCTGTTAGCGACACAAAGATCATTCACACCGATGTCAAGATCCAGGTGC  
CACCCAATTCATTTGGTTGGGTGACCGGAAAGTCCAGCATGGCTAAGCAGGGTCTTCTGA  
TTAACGGGGGAATCAATGATGAAGGATACACCGGCGAAATCCAGGTGATCTGCACAAATA  
5 TCGGCAAAAGCAATATTAAGCTTATCGAAGGGCAGAAGTTCGCTCAACTCATCATCTCC  
AGCACCACAGCAATTCAAGACAACCTTGGGACGAAAACAAGATTAGCCAGAGAGGTGACA  
AGGGCTTCGGCAGCACAGGTGTGTTCTGGGTGGAGAACATCCAGGAAGCACAGGACGAGC  
ACGAGAATTGGCACACCTCCCTAAGATTTTGGCCCGCAATTACAAGATCCCCTGACTG  
10 TGGCTAAGCAGATCACACAGGAATGCCCCACTGCACCAAAACAAGTTCTGGCCCGCCG  
GCTGCGTGATGAGGTCCCCAATCACTGGCAGGCAGATTGCACCCACCTCGACAACAAAA  
TTATCTGACCTTCGTGGAGAGCAATTCGGCTACATCCACGCAACACTCCTCTCCAAAG  
AAAAATGCATTGTGCACCTCCCTCGCAATTCTGGAATGGGCCAGGCTGTTCTCTCCAAAT  
CCCTGCACACCGACAACGGCACCAACTTTGTGGCTGAACCTGTGGTGAATCTGCTGAAGT  
TCCTGAAAATCGCCACACCACTGGCATTCCCTATCACCTGAAAGCCAGGGCATTGTCTG  
15 AGAGGGCAACAGAACTCTGAAAGAAAAGATCCAATCTCACAGAGACAATACACAGACAT  
TGGAGGCGCACTTCAGCTCGCCCTTATCACTGCAACAAAGGAAGAGAAAGCATGGGCG  
GCCAGACCCCTGGGAGGTCTTCATCTAACCAGGCCAGGTCTCCATGAAAAGCTGC  
TCTTGACGAGGCCAGTCTCCAAAAAGTTCTGCTTTTATAAGATCCCCGGTGAGCACG  
ACTGGAAAGGTCTTACAAGAGTTTTGTGGAAAGGAGACGGCGCAGTTGTGGTGAACGATG  
20 AGGGCAAGGGGATCATCGCTGTGCCCTGACACGCAACCAAGCTTCTCATCAAGCCAACT  
GAACCCGGGGCGGCGCTTCCCTTTAGTGAGGGTTAATGCTTCGAGCAGACATGATAAGA  
TACATTGATGAGTTTGGACAAACCACAAGTGAATGCAGTGAAAAAATGCTTTATTTGT  
GAAATTTGTGATGCTATTGCTTTATTTGTAACCATTTATAAGCTGCAATAAACAAAGTTAAC  
AACAACAATTCATTTCATTTATGTTTCAGGTTTCAAGGGGAGATGTGGGAGGTTTTTAA  
25 AGCAAGTAAACCTCTACAAATGTGGTAAATCCGATAAGGATCGATCCGGGCTGGCGTA  
ATAGCGAAGAGGCCCGCACCGATCGCCCTTCCCAACAGTTGCGCAGCCTGAATGGCGAAT  
GGACGCGCCCTGTAGCGGCGCATTAAGCGCGGCGGGTGTGGTGGTTACGCGCAGCGTGAC  
CGCTACACTTGCCAGCGCCCTAGCGCCCGCTCCTTTCTGCTTCTTCCCTTCTTCTCGC  
CACGTTCCGGGCTTTCCCGCTCAAGCTCTAAATCGGGGGCTCCCTTTAGGGTTCCGATT  
30 TAGAGCTTACGGCACCTCGACCGCAAAAACTTGATTGGGTGATGGTTCACGTAGTG  
GCCATCGCCCTGTAGACGGTTTTTCGCCCTTTGACGTTGGAGTCCACGTTCTTTAATAG  
TGGACTCTTGTTCCAACTGGAACAACACTCAACCCTATCTCGGTCTATTCTTTGATT  
ATAAGGGATTTTCCGATTTCCGGCTATTGGTTAAAAAATGAGCTGATTAAACAAATATT  
TAACGCGAATTTTAAACAAATATTAACGTTTACAATTTCCGCTGATGCGGTATTTCTCC  
35 TTACGCATCTGTGCGGTATTTACACCCGCATACGCGGATCTGCGCAGCACCATGGCCTGA  
AATAACCTCTGAAAGAGGAACTTGGTTAGGTACCTTCTGAGGCGGAAAGAACAGCTGTG  
GAATGTGTGTCAGTTAGGGTGTGGAAAGTCCCAGGCTCCCCAGCAGGCAGAAATATGCA  
AAGCATGCATCTCAATTAGTCAGCAACCAGGTGTGGAAAGTCCCAGGCTCCCCAGCAGG  
CAGAAGTATGCAAAGCATGCATCTCAATTAGTCAGCAACCATAGTCCCGCCCTAACTCC  
40 GCCCATCCCGCCCTAACTCCGCCAGTTCCGCCCATTTCTCCGCCCATGGCTGACTAAT  
TTTTTTATTTATGCAGAGGCCGAGGCCGCTCGGCCTCTGAGCTATTCCAGAAGTAGT  
AGGAGGCTTTTTTGGAGGCTAGGCTTTTGGCAAAAAGCTTGATTCTTCTGACACAACAGT  
CTCGAACTTAAGGCTAGAGCCACCATGATTGAACAAGATGGATTGCACGAGGTCTCCG  
GCCGCTTGGGTGGAGAGGCTATTCCGCTATGACTGGGCACAACAGACAATCGGCTGCTCT  
45 GATGCCGCGGTGTTCCGGCTGTGACGCGAGGGGCGCCGGTCTTTTTGTCAAGACCGAC  
CTGTCCGGTGCCCTGAATGAAGTGCAGGACGAGGCGCGGCTATCGTGGCTGGCCACG  
ACGGGCGTTCCTTGGCAGCTGTGCTCGACGTTGTCACTGAAGCGGGAAGGGACTGGCTG  
CTATTGGGCGAAGTGCCGGGGCAGGATCTCCTGTCTCTCACTTGTCTCTGCCGAGAAA  
GTATCCATCATGGCTGATGCAATGCGGCGGCTGCATACGCTTGATCCGGCTACCTGCCCA  
50 TTCGACCACCAAGCGAAACATCGCATCGAGCGAGCACGTAAGGATGGAAGCCGGTCTT  
GTGATCAGGATGATCTGGACGAAGAGCATCAGGGGCTCGCGCCAGCCGAAGTCTCGCC  
AGGCTCAAGGCGCGCATGCCGACGGGAGGATCTCGTCTGACCCATGGCGATGCCTGC  
TTGCCGAATATCATGGTGGAAATGGCCGCTTTTCTGGATTCTGACTGTGGCCGGCTG  
GGTGTGGCGGACCGCTATCAGGACATAGCGTTGGCTACCCGTGATTTGCTGAAGAGCTT  
55 GGCGGCGAATGGGCTGACCGCTTCTCGTGCTTTACGGTATCGCCGCTCCCGATTCCGAG  
CGCATCGCTTCTATCGCTTCTTGACGAGTTCTTCTGAGCGGGACTCTGGGGTTCGAAA  
TGACCGACCAAGCGACGCCCCAACCCTGCCATCAGATGGCCGCAATAAAATATCTTTATT  
TCATTACATCTGTGTGTTGTTTTTGTGTGAATCGATAGCGATAAGGATCCGCGTATGG  
TGCATCTCAGTACAATCTGCTCTGATGCCGCATAGTTAAGCCAGCCCCGACCCGCCA  
60 ACACCCGCTGACGCGCCCTGACGGGCTGTCTGCTCCCGGCATCCGCTTACAGACAAGCT  
GTGACCGTCTCCGGGAGCTGCATGTGTCAGAGGTTTTACCGTCATCACCGAAACGCGG  
AGACGAAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCATGATAAATAGGTT  
TCTTAGACGTCAAGGTGGCACTTTTCGGGAAATGTGCGCGGAACCCCTATTTGTTATTT  
TTCTAAATACATTTCAAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAA  
65 TAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCCGCTTATTCCTTT  
TTTGGCGCATTTTGCCTTCTGTTTTTGTCTACCCAGAAACGCTGGTGAAAGTAAAGAT

GCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAG  
ATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTAAAGTTCTG  
CTATGTGGCGCGGTATTATCCCGTATTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATA  
5 CACTATTCTCAGAATGACTTGGTTGAGTACTACCAAGTCACAGAAAAGCATCTTACGGAT  
GGCATGACAGTAAGAGAATTATGCAGTGTGCCATAACCATGAGTGATAAAGTGGCGCC  
AACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCCTTTTTTGCACAACATG  
GGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAAC  
GACGAGCGTGACACCAGATGCCTGTAGCAATGGCAACAACGTTGCGCAAACCTATTAAC  
10 GGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAA  
GTTGCAGGACCACCTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCT  
GGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCC  
TCCCGTATCGTAGTTATCTACACGACGGGAGTCAGGCAACTATGGATGAACGAAATAGA  
CAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTAC  
TCATATATACTTTAGATTGATTTAAACCTCATTTTTAATTTAAAAGGATCTAGGTGAAG  
15 ATCCTTTTTGATAATCTCATGACCAAAATCCCTTAACGTGAGTTTTCTGTTCCACTGAGCG  
TCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTCTGCGCGTAATC  
TGCTGCTTGCAACAAAAAACACCGCTACCAAGCGGTGGTTTGTGTCGGGATCAAGAG  
CTACCAACTCTTTTTCCGAAGGTAACCTGGCTTACGACAGCGCAGATACCAAATACTGTC  
CTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATAC  
20 CTCGCTCTGCTAATCCTGTTACCAAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACC  
GGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGGGGT  
TCGTGCACACAGCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTACAGCGT  
GAGCTATGAGAAAGCGCCACGCTTCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAAGC  
GGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGAAACGCCTGGTATCTT  
25 TATAGTCTGTGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCA  
GGGGGCGGAGCCTATGAAAAACGCCAGCAACGCGGCCTTTTACGGTTCTTGGCCTTT  
TGCTGGCCTTTTGCTCACATGGCTCGACAGATCT

**MLV construct CZCG (SEQ ID No 55)**

30 GTTACCTTCTGCTCTGCAGAATGGCCAACCTTTAACGTGCGATGGCCGCGAGACGGCACC  
TTTAACCGAGACCTCATACCCAGGTTAAGATCAAGGTCTTTTACCTGGCCCGCATGGA  
CACCCAGACCAGGTCCCTTACATCGTGACCTGGGAAGCCTTGGCTTTTGACCCCCCTCCC  
TGGGTCAAGCCCTTTGTACACCCTAAGCCTCCGCCTCCTCTTCTCCATCCGCCCCGTCT  
CTCCCCCTTGAACCTCCTCGTTCGACCCCGCCTCGATCCTCCCTTTATCCAGCCCTCACT  
35 CCTTCTCTAGGCGCCGGAATTTCGTTAACTCGAGAGCCCTGCCACCATGGGGACTGCTCCA  
AAGAAGAAGCGTAAGGTAGTCGTTTTACAACGTCGTGACTGGGAAAACCTGGCGTTACC  
CAACTTAATCGCCTTGCGACACATCCCCCTTTCCGCCAGCTGGCGTAATAGCGAAGAGGCC  
CGCACCGATCGCCCTTCCCAACAGTTGCGCAGCCTGAATGGCGAATGGCGCTTGCCTGG  
TTTCCGGCACCAGAAGCGGTGCCGAAAGCTGGCTGGAGTGCGATCTTCTGAGGCCGAT  
40 ACTGTCGTCTGCTCCCTCAAACCTGGCAGATGCACGTTACGATGCGCCCATCTACACCAAC  
GTAACCTATCCATTACGGTCAATCCGCCGTTTGTCCACGAGAAATCCGACGGGTGT  
TACTCGCTCACATTTAATGTTGATGAAAGCTGGCTACAGGAAGGCCAGACGCGAATATT  
TTTGATGGCGTTAACTCGGCGTTTCATCTGTGGTGCAACGGGCGCTGGGTGGTTACGGC  
45 CGCCTCGCGGTGATGGTGCTGCGTTGGAGTGACGGCAGTTATCTGGAAGATCAGGATATG  
TGGCGGATGAGCGGCATTTTCCGTGACGTCTCGTTGCTGCATAAACCGACTACACAAATC  
AGCGATTTCCATGTTGCCACTCGCTTTAATGATGATTTACGCCGCGCTGTACTGGAGGCT  
GAAGTTCAGATGTGCGGCGAGTTGCGTGACTACCTACGGGTAAACAGTTTCTTTATGGCAG  
GGTGAAACGCAGGTGCCAGCGGCACCGCGCCTTTCGGCGGTGAAATTATCGATGAGCGT  
50 GGTGGTTATGCCGATCGCGTCACACTACGTCTGAACGTGAAAACCCGAAACTGTGGAGC  
GCCGAAATCCCGAATCTCTATCGTGCGGTGGTTGAAGTGCACACCGCCGACGGCACGCTG  
ATTGAAGCAGAAGCCTGCGATGTGCGTTTCCGCGAGGTGCCGATTGAAAATGGTCTGCTG  
CTGCTGAACGGCAAGCCGTTGCTGATTGAGGCGTTAACCGTCACGAGCATCATCCTCTG  
CATGGTCAGGTATGGATGAGCAGCAGTGGTGCAGGATATCCTGCTGATGAAGCAGAAC  
55 AACTTTAACGCCGTGCGCTGTTCCGATTATCCGAACCATCCGCTGTGGTACACGCTGTGC  
GACCGTACGGCCTGTATGTGGTGGATGAAGCCAATATTGAAACCCACGGCATGGTGCCA  
ATGAATCGTCTGACCGATGATCCGCGCTGGCTACCGGCGATGAGCGAACGCGTAACGCGA  
ATGGTGCAGCGCATCGTAATCACCCGAGTGTGATCATCTGGTGGTGGGGAATGAATCA  
GGCCACGGCGCTAATCACGACGCGCTGTATCGCTGGATCAAATCTGTGATCCTTCCCGC

CCGGTGCAGTATGAAGGCGGCGGAGCCGACACCACGGCCACCGATATTATTTGCCCGATG  
TACGCGCGCGTGGATGAAGACCAGCCCTTCCCGGCTGTGCCGAAATGGTCCATCAAAAAA  
TGGCTTTTCGTACCTGGAGAGACGCGCCCGCTGATCCTTTGCGAATACGCCCACGCGATG  
5 GGTAACAGTCTTGGCGGTTTCGCTAAATACTGGCAGGCGTTTCGTAGTATCCCCGTTTA  
CAGGGCGGCTTCGTCTGGGACTGGGTGGATCAGTCGCTGATTAAATATGATGAAAACGGC  
AACCCGTGGTTCGGCTTACGGCGGTGATTTTGGCGATACGCCGAACGATCGCCAGTTCTGT  
ATGAACGGTCTGGTCTTTGCCGACCGCACGCCGCATCCAGCGCTGACGGAAGCAAAACAC  
CAGCAGCAGTTTTTCCAGTTCCGTTTATCCGGGCAAACCATCGAAGTGACCAGCGAATAC  
10 CTGTTCCGTCATAGCGATAACGAGCTCCTGCACTGGATGGTGGCGCTGGATGGTAAGCCG  
CTGGCAAGCGGTGAAGTGCTCTGGATGTGCTCCACAAGGTAACAGTTGATTGAACTG  
CCTGAACTACCGCAGCCGGAGAGCGCCGGCAACTCTGGCTCACAGTACGCGTAGTGCAA  
CCGAACCGCAGCCGCATGGTCAGAAGCCGGGCACATCAGCGCTGGCAGCAGTGGCGTCTG  
GCGGAAAACCTCAGTGTGACGCTCCCCGCCGCTCCACGCCATCCCGCATCTGACCACC  
AGCGAAATGGATTTTGCATCGAGCTGGGTAATAAGCGTTGGCAATTTAACCGCCAGTCA  
15 GGCTTCTTTTACAGATGTGGATTGGCGATAAAAAACAACCTGCTGACGCCGCTGCGCGAT  
CAGTTCACCCGTGCACCGCTGGATAACGACATTGGCGTAAGTGAAGCGACCCGCATTGAC  
CCTAACGCTGGGTGCAACGCTGGAAGGCGCGGGCCATTACCAGGCCGAAGCAGCGTTG  
TTGCAGTGCACGGCAGATACACTTGCTGATGCGGTGCTGATTACGACCGCTCACGCGTGG  
CAGCATCAGGGGAAAACCTTATTTATCAGCCGAAAACCTACCGGATTGATGGTAGTGGT  
20 CAAATGGCGATTACCGTTGATGTGAAGTGGCGAGCGATACACCGCATCCGGCGCGGATT  
GGCCTGAACTGCCAGCTGGCGCAGGTAGCAGAGCGGTAAGTGGCTCGGATTAGGGCCG  
CAAGAAAATATCCCGACCGCTTACTGCCGCTGTTTTGACCGCTGGGATCTGCCATTG  
TCAGACATGTATACCCGTACGCTTCCCGAGCGAAAACGGTCTGCGCTGCGGGACCGCG  
GAATTGAATTATGGCCACACAGTGGCGCGCGGACTTCCAGTTCAACATCAGCCGCTAC  
25 AGTCAACAGCAACTGATGGAACACGCCATCGCCATCTGCTGCACGCGGAAGAAGGCACA  
TGGCTGAATATCGACGGTTTCCATATGGGGATTGGTGGCGACGACTCCTGGAGCCCGTCA  
GTATCGGCGGAATTCCAGCTGAGCGCCGGTCTGCTACCATTACCAGTTGGTCTGGTGTCAA  
AAATAATAATAACCGGGCAGGGGGGATCCGCAGATCCGGCTGTGGAATGTGTGTAGTTA  
GGGTGTGGAAGTCCCCAGGCTCCCCAGCAGGCAGAAGTATGCAAAGCATGCCTGCAGGA  
30 GTGGGGAGGACGATGGCCGCTTTGGTTCGAGGCGGATCCGGCCATTAGCCATATTATCA  
TTGGTTATATAGCATAAATCAATATTGGCTATTGGCCATTGCATACGTTGTATCCATATC  
ATAATATGTACATTTATATTGGCTCATGTCCAACATTACCGCCATGTTGACATTGATTAT  
TGACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTTATAGCCCATATATGGAGT  
TCCGCGTTACATAACTTACGGTAAATGGCCGCTGGCTGACCGCCCAACGACCCCCGCC  
35 CATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCATTGAC  
GTCAATGGGTGGAGTATTTACGGTAACTGCCCACTTGGCAGTACATCAAGTGTATCATA  
TGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCTGGCATTATGCCC  
AGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTA  
TTACCATGGTGATGCGGTTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTGACTCAC  
40 GGGGATTTCCAAGTCTCCACCCCATTGACGTCAATGGGAGTTTGTTTTGGCACCAAAATC  
AACGGGACTTTCAAAATGTCGTAACAACCCGCCCCATTGACGCAATGGGCGGTAGGC  
ATGTACGGTGGGAGGTCTATATAAGCAGAGCTCGTTTGTAGTAACCGTCAGATCGCCTGGA  
GACGCCATCCACGCTGTTTTGACCTCCATAGAAGACACCGGGACCGATCCAGCCTCCGCG  
GCCCCAAGCTTGTGGGATCCACCGGTGCGCCACCATGGTGAGCAAGGGCGAGGAGCTGTT  
45 CACCGGGGTGGTGCCATCCTGGTTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTTCAG  
CGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTTCATCTG  
CACCACCGGCAAGCTGCCGTGCCCTGGCCACCTCGTGACCACCTGACCTACGGCGT  
GCAGTGCTTCAGCCGCTACCCCGACCATATGAAGCAGCAGACTTCTTCAAGTCCGCCAT  
GCCCCAAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGAC  
50 CCGCGCCGAGGTGAAGTTCGAGGGCGACACCTGGTGAACCGCATCGAGCTGAAGGGCAT  
CGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAACACTACAACAGCCA  
CAACGTCTATATCATGGCCGACAAGCAGAAGACGGCATCAAGGTGAAGTCAAGATCCG  
CCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCCAT  
CGGCGACGGCCCCGTGCTGCTGCCGACAACCACTACCTGAGCACCAGTCCGCCCTGAG  
55 CAAAGACCCCAACGAGAAGCGCGATCACATGGTCTGCTGGAGTTCGTGACCGCCGCGG  
GATCACTCTCGGCATGGACGAGCTGTACAAGTAAAGCGCCGCGACTCTAGATCATAATC  
AGCCATACCACATTTGTAGAGTTTTACTTGCTTTAAAAACCTCCCACACCTCCCCCTG  
AACCTGAAACATAAAATGAATGCAATTGTTGTTGTTAACATCGATAAAATAAAGATTTT  
ATTTAGTCTCCAGAAAAGGGGGGAATGAAAGACCCACCTGTAGGTTTGGCAAGCTAGC  
60 TTAAGTAACGCCATTTTGAAGGCATGGAAAAATACATAACTGAGAATAGAGAAGTTTCAG

ATCAAGGTCAGGAACAGATGGAACAGCTGAATATGGGCCAAACAGGATATCTGTGGTAAG  
CAGTTCCTGCCCCGGCTCAGGGCCAAGAACAGATGGAACAGCTGAATATGGGCCAAACAG  
GATATCTGTGGTAAGCAGTTCTGCCCCGGCTCAGGGCCAAGAACAGATGGTCCCCAGAT  
GCGGTCCAGCCCTCAGCAGTTTCTAGAGAACCATCAGATGTTTCCAGGGTGCCCCAAGGA  
5 CCTGAAATGACCTGTGCCTTATTTGAACTAACCAATCAGTTCGCTTCTCGCTTCTGTTC  
GCGCGCTTCTGCTCCCCGAGCTCAATAAAAGAGCCCACAACCCCTCACTCGGGGCGCCAG  
TCCTCCGATTGACTGAGTCGCCCCGGGTACCCGTGTATCCAATAAACCCCTCTTGCAGTTGC  
ATCCGACTTGTGGTCTCGCTGTTCTTGGGAGGGTCTCCTCTGAGTGATTGACTACCCGT  
CAGCGGGGGTCTTTCATTTGGGGGCTCGTCCGGGATCGGGAGACCCCTGCCAGGGACCA  
10 CCGACCCACCACCGGAGGTAAGCTGGCCAGCAACTATCTGTGTCTGTCCGATTGTCTA  
GTGTCTATGACTGATTTTATGCGCCTGCGTCGGTACTAGTTAGCTAACTAGCTCTGTATC  
TGGCGGACCCGTGGTGGAAGTACGAGTTTCGGAACACCCGGCCGCAACCCCTGGGAGAGGA  
ATTCTCATGTTTGGACAGCTTATCATCGATAAGCTTTTTCGAAAAGCCTAGGCCTCCAAAA  
AAGCCTCCTCACTACTTCTGGAATAGCTCAGAGGCCGAGGCGCCTCGGCTCTGCATAA  
15 ATAAAAAAATTAGTCAGCCATGGGGCGGAGAATGGGCGGAACTGGGCGGAGTTAGGGGC  
GGGATGGGCGGAGTTAGGGGCGGACTATGGTTGCTGACTAATTGAGATGCATGCTTTTGC  
ATACTTCTGCCTGCTGGGGAGCCTGGGGACTTTCACACCTGGTTGCTGACTAATTGAGA  
TGCATGCTTTGCATACTTCTGCCTGCTGGGGAGCCTGGGGACTTTCACACCCTAAGTGA  
CACACATTCCACAGCCGGATCCTCTACGCCGACGCATCGTGGCCGGCATCACCAGCGCC  
20 ACAGGTGCGGTTGCTGGCGCCTATATCGCCGACATCACCAGTGGGGAAGATCGGGCTCGC  
CACTTCGGGCTCATGAGCGCTTGTTCGGCGTGGGTATGGTGGCAGGCCCGTGGCCGGG  
GGACTGTTGGGCGCCATCTCCTTGCATGCACCATTCCTTGCGGCGGCGGTGCTCAACGGC  
CTCAACCTACTACTGGGCTGCTTCTTAATGCAGGAGTCGCATAAGGGAGAGCGTCGACCG  
ATGCCCTTGAGAGCCTTCAACCCAGTCAGCTCCTTCCGGTGGGCGCGGGGCATGACTATC  
25 GTCGCCGCACTTATGACTGTCTTCTTATCATGCAACTCGTAGGACAGGTGCCGGCAGCG  
CTCTGGGTCATTTTCGGCGAGGACCGCTTTCGCTGGAGCGCGACGATGATCGGCCTGTCTG  
CTTGCGGTATTCGGAATCTTGCACGCCCTCGCTCAAGCCTTCGTCACTGGTCCCGCCACC  
AAACGTTTCGGCGAGAAGCAGGCCATTATCGCCGGCATGGCGGCCGACGCGCTGGGTAC  
GTCTTGCTGGCGTTCGCGACGCGAGGCTGGATGGCCTTCCCCATTATGATTCTTCTCGCT  
30 TCCGGCGGCATCGGGATGCCCGCGTTGCAGGCCATGCTGTCCAGGCAGGTAGATGACGAC  
CTCAGGGACAGCTTCAAGGATCGCTCGCGGCTCTTACCAGCCTAACTTCGATCACTGGA  
CCGCTGATCGTCACGGCGATTTATGCCGCTCGCGAGCACATGGAACGGGTGGCATGG  
ATTGTAGGCGCCGCCCTATACCTTGTCTGCCTCCCCGCGTTGCGTCGCGGTGCATGGAGC  
CGGGCCACCTCGACCTGAATGGAAGCCGGCGGCACCTCGCTAACGGATTACCACTCCAA  
35 GAATTGGAGCCAATCAATTCTTGCAGGAACTGTGAATGCGCAAACCAACCTTGGCAGA  
ACATATCCATCGCGTCCGCCATCTCCAGCAGCCGACGCGGCGCATCTCGGGCAGCGTTG  
GGTCTTGGCCACGGGTGCGCATGATCGTGCTCCTGTGTTGAGGACCCGGCTAGGCTGGC  
GGGTTGCGCTTACTGGTTAGCAGAATGAATCACCAGTACGCGAGCGAAGCTGAAGCGACT  
GCTGCTGCAAAACGCTTGCAGCTGAGCAACAACATGAATGGTCTTTCGGTTTCCGTGTTT  
40 CGTAAAGTCTGGAACGCGGAAGTCAGCGCCCTGCACCATATGTTCCGGATCTGCATCG  
CAGGATGCTGCTGGCTACCCTGTGGAACACCTACATCTGTATTAACGAAGCGCTGGCATT  
GACCCTGAGTGATTTTCTCTGGTCCCGCCGATCCATACCGCCAGTTGTTTACCCTCAC  
AACGTTCCAGTAACCGGGCATGTTTCATCATCAGTAACCCGTATCGTGAGCATCCTCTCTC  
GTTTCATCGGTATCATTACCCCCATGAACAGAAATTCCCCCTTACACGGAGGCATCAAGT  
45 GACCAAACAGGAAAAAACCGCCCTTAACATGCCCCGCTTTATCAGAAGCCAGACATTAAC  
GCTTCTGGAGAACTCAACGAGCTGGACGCGGATGAACAGGCAGACATCTGTGAATCGCT  
TCACGACCACGCTGATGAGCTTTACCGCAGCTGCCTCGCGCGTTTCGGTGATGACGGTGA  
AAACCTCTGACACATGCAGCTCCCGGAGACGGTCACAGCTTGTCTGTAAGCGGATGCCGG  
GAGCAGACAAGCCCGTCAGGGCGCGTCAGCGGGTGTGGCGGGTGTGGGGCGCAGCCAT  
50 GACCCAGTCACGTAGCGATAGCGGAGTGATACTGGCTTAACTATGCGGCATCAGAGCAG  
ATTGTACTGAGAGTGCACCATATGCGGTGTGAAATACCGCACAGATGCGTAAGGAGAAAA  
TACCGCATCAGGCGCTCTTCCGCTTCTCGCTCACTGACTCGCTGCGCTCGGTCTCGG  
CTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGGTAATACGGTTATCCACAGAATCAGGG  
GATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAG  
55 GCCGCGTTGCTGGCGTTTTCATAGGCTCCGCCCCCTGACGAGCATCACAAAAATCGA  
CGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCT  
GGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCT  
TTTCTCCCTTCGGGAAGCGTGGCGCTTCTCATAGCTCAGCTGTAGGTATCTCAGTTCTG  
GTGTAGGTGCTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTACGCCCCAGCGC  
60 TGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCA

CTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAG  
TTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAAGACAGTATTTGGTATCTGCGCT  
CTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACC  
ACCGCTGGTAGCGGTGGTTTTTTTGGTTTGAAGCAGCAGATTACGCGCAGAAAAAAGGA  
5 TCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGAACGAAAACTCA  
CGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAAT  
TAAAAATGAAGTTTTAAATCAATCTAAAGTATATATGAGTAACTTGGTCTGACAGTTAC  
CAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTTCGTTTCATCCATAGTT  
GCCTGACTCCCCGTCGTGTAGATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGT  
10 GCTGCAATGATACCGCGAGACCCACGCTCACC GGCTCCAGATTTATCAGCAATAAACCAG  
CCAGCCGGAAGGGCCGAGCGCAGAAGTGGTCTGCAACTTTATCCGGCTCCATCCAGTCT  
ATTAATTGTTGCCGGGAAGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTT  
GTTGCCATTGCTGCAGGCATCGTGGTGTACGCTCGTCTGTTGGTATGGCTTCATTACAGC  
TCCGGTTCCCAACGATCAAGGCGAGTTACATGATCCCCATGTTGTGCAAAAAAGCGGTT  
15 AGCTCCTTCGGTCTCCGATCGTCTGTCAGAAGTAAGTTGGCCGAGTGTATCACTC  
ATGGTTATGGCAGCACTGCATAATTCTTACTGTCTGATGCCATCCGTAAGATGCTTTTCT  
GTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTGTATGCGGCGACCGAGTTGC  
TCTTGCCCGGCGTCAATACGGGATAATACCGCGCCACATAGCAGAACTTTAAAGTGCTC  
ATCATTGGAAAACGTTCTTCGGGGCGAAAACCTCTCAAGGATCTTACCGCTGTTGAGATCC  
20 AGTTCGATGTAACCCACTCGTGCACCCAACTGATCTTCAGCATCTTTTACTTTCACCAGC  
GTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACA  
CGGAAATGTTGAATACTCATACTCTTCTTTTTCAATATTATTGAAGCATTATCAGGGT  
TATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGAAAAATAAACAAATAGGGGT  
CCGCGCACATTTCCCGAAAAGTGCCACCTGACGTCTAAGAAACCATTATTATCATGACA  
25 TTAACCTATAAAAAATAGGCGTATCAGAGGCCCTTTTCGTCTCGCGCGTTTCGGTGATGAC  
GGTGAAAACCTCTGACACATGCAGCTCCCGGAGACGGTCACAGCTTGTCTGTAAGCGGAT  
GCCGGGAGCAGACAAGCCCGTCAGGGCGCGTCAGCGGGTGTGGCGGGTGTGCGGGCTGG  
CTTAACATATGCGGCATCAGAGCAGATTGTACTGAGAGTGCACCATATCGACGCTCTCCCT  
TATGCGACTCCTGCATTAGGAAGCAGCCAGTAGTAGGTTGAGGCCGTTGAGCACCGCCG  
30 CCGCAAGGAATGGTGCATGCAAGGAGATGGCGCCCAACAGTCCCCCGGCCACGGGGCCTG  
CCACCATACCCACGCCGAACAAGCGCTCATGAGCCCGAAGTGGCGAGCCCGATCTTCCC  
CATCGGTGATGTGCGCGATATAGGCGCCAGCAACCGCACCTGTGGCGCGGTGATGCCGG  
CCACGATGCGTCCGGCGTAGAGGATCTGGCTAGCGATGACCCTGCTGATTGGTTTCGCTGA  
CCATTTCGGGGGTGCGGAACGGCGTTACCAGAACTCAGAAGGTTTCGTCCAACCAAACCG  
35 ACTCTGACGCGAGTTTACGAGAGAGATGATAGGGTCTGCTTCAGTAAGCCAGATGCTACA  
CAATTAGGCTTGTACATATTGTCTGTAGAACGCGGCTACAATTAATACATAACCTTATGT  
ATCATACACATACGATTTAGGTGACACTATAGAATACAAGCTGGAAGATCTTCCAGCTTG  
GGCTGCAGGTGACTCTAGAGTCCGTTACATAACTTACGGTAAATGGCCCGCTGGCTGA  
CCGCCCCAACGACCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCA  
40 ATAGGGACTTTCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGA  
GTACATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGG  
CCCGCTGGCATTATGCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATC  
TACGTATTAGTCATCGCTATTACCATGGTGTATGCGGTTTTGGCAGTACATCAATGGGCGT  
GGATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATTGACGTCAATGGGAGT  
45 TTGTTTTGGCACCAAAAATCAACGGGACTTTCAAAATGTCGTAACAACCTCCGCCCCATTG  
ACGCAAATGGGCGGTAGGCGGTACGGTGGGAGGTCTATATAAGCAGAGCTCGTTTAGTG  
AACCGCGCCAGTCTCCGATAGACTGCGTCGCCCCGGTACCCGTATTTCCAATAAAGCCT  
CTTGCTGTTTGCATCCGAATCGTGGTCTCGCTGTTTCTTGGGAGGGTCTCCTCTGAGTGA  
TTGACTACCCACGACGGGGTCTTTTCATTTGGGGGCTCGTCCGGGATTTGGAGACCCCTG  
50 CCCAGGGACCACCGACCCACCACGGGAGGTAAGCTGGCCAGCAACTTATCTGTGTCTGT  
CCGATTGTCTAGTGTCTATGTTTGATGTTATGCGCCTGCGTCTGTACTAGTTAGCTAACT  
AGCTCTGTATCTGGCGGACCCGTGGTGGAACCTGACGAGTTCTGAACACCCGGCCGCAACC  
CTGGGAGACGTCCAGGGACTTTGGGGGCGGTTTTTGTGGCCCGACCTGAGGAAGGGAGT  
CGATGTGGAATCCGACCCCGTCAGGATATGTGGTTCTGGTAGGAGACGAGAACCTAAAC  
55 AGTTCGCGCTCCGTCTGAATTTTTGCTTTTCGGTTTGGAAACGAAGCCGCGCTCTTGTC  
TGCTGCAGCGCTGCAGCATCGTTCTGTGTTGTCTGTCTGACTGTGTTCTGTATTTGT  
CTGAAAATTAGGGCCAGACTGTTACCACTCCCTTAAGTTTGACCTTAGGTCACTGGAAAG  
ATGTCGAGCGGATCGCTCACAACCAGTCGGTAGATGTCAAGAAGAGACGTTGG



GTTACCTTCTGCTCTGCAGAATGGCCAACCTTTAACGTCGGATGGCCGCGAGACGGCACC  
TTTAACCGAGACCTCATCACCAGGTAAAGATCAAGGTCTTTTACCTGGCCCGCATGGA  
CACCAGACCAGGTCCCTTACATCGTGACCTGGGAAGCCTTGGCTTTTGACCCCCCTCCC  
5 TGGGTCAAGCCCTTTGTACACCCTAAGCCTCCGCCTCCTCTTCTCCATCCGCCCCGTCT  
CTCCCCCTTGAACCTCCTCGTTCGACCCCGCCTCGATCCTCCCTTTATCCAGCCCTCACT  
CCTTCTCTAGGCGCCGGAATTCTGTTAACTCGAGAGGCCTGCCACCATGGGGACTGCTCCA  
AAGAAGAAGCGTAAGGTAGTCGTTTTACAACGTCGTGACTGGGAAAACCTGGCGTTACC  
CAACTTAATCGCCTTGACGACATCCCCCTTTCCGCGAGCTGGCGTAATAGCGAAGAGGCC  
10 CGCACCGATCGCCCTTCCCAACAGTTGCGCAGCCTGAATGGCGAATGGCGCTTTGCCTGG  
TTTCCGGCACCAGAAGCGGTGCCGGAAGCTGGCTGGAGTGCGATCTTCTGAGGCCGAT  
ACTGTCGTCTCCCTCAAACCTGGCAGATGCACGGTTACGATGCGCCCATCTACACCAAC  
GTAACCTATCCATTACGGTCAATCCGCCGTTTGTTCACGAGAGAATCCGACGGGTTGT  
TACTCGCTCACATTTAATGTTGATGAAAGCTGGCTACAGGAAGGCCAGACGCGAATTATT  
15 TTTGATGGCGTTAACTCGGCCTTCATCTGTGGTGCAACGGGCGCTGGGTCTGTTACGGC  
CAGGACAGTCGTTTGCCGTCTGAATTTGACCTGAGCGCATTTTACGCGCCGGAGAAAAC  
CGCCTCGCGGTGATGGTGCTGCGTTGGAGTGACGGCAGTTATCTGGAAGATCAGGATATG  
TGGCGGATGAGCGGCATTTTCCGTGACGTCTCGTTGCTGCATAAACCGACTACACAAATC  
AGCGATTTCCATGTTGCCACTCGCTTAAATGATGATTTACGCGCGCTGTACTGGAGGCT  
20 GAAGTTCAGATGTGCGGCGAGTTGCGTGACTACCTACGGGTAACAGTTTCTTTATGGCAG  
GGTGAAACGACAGGTCCGACGCGCACCGCGCCTTTCGGCGGTGAAATTATCGATGAGCGT  
GGTGGTTATGCCGATCGCGTCACACTACGTCTGAACGTCGAAAACCCGAAACTGTGGAGC  
GCCGAAATCCCGAATCTCTATCGTGCGGTGGTTGAACGTCACACCGCCGACGGCAGCGTG  
ATTGAAGCAGAAGCCTGCGATGTCGGTTTCCGCGAGGTGCGGATTGAAAATGGTCTGCTG  
25 CTGCTGAACGCGCAAGCCGTTGCTGATTGAGGCGTTAACCGTCACGAGCATCATCCTCTG  
CATGGTCAGGTCATGGATGAGCAGACGATGGTGAGGATATCCTGCTGATGAAGCAGAAC  
AACTTTAACGCCGTGCGCTGTTCCGATTATCCGAACCATCCGCTGTGGTACACGCTGTGC  
GACCGCTACGGCCTGTATGTGGTGGATGAAGCCAATATTGAAACCCACGGCATGGTGCCA  
ATGAATCGTCTGACCGATGATCCGCGCTGGCTACCGGCGATGAGCGAACCGGTAACGCGA  
30 ATGGTGCAGCGCATCGTAATCACCAGGTGTGATCATCTGGTCGCTGGGGAATGAATCA  
GGCCACGGCGCTAATCACGACGCGCTGTATCGCTGGATCAAATCTGTGATCCTTCCCGC  
CCGGTGCAGTATGAAGGCGGCGGAGCCGACACACGGCCACCGATATTATTGCCCCGATG  
TACGCGCGCTGGATGAAGACCAGCCCTTCCCGCTGTGCGGAAATGGTCCATCAAAAAA  
TGGCTTTTCGCTACCTGGAGAGACGCGCCCGCTGATCCTTTGCGAATACGCCCACGCGATG  
35 GGTAACAGTCTTGGCGGTTTCGCTAAATACTGGCAGGCGTTTCGTGAGTATCCCCGTTTA  
CAGGGCGGCTTCGTCTGGGACTGGGTGGATCAGTCGCTGATTAAATATGATGAAAACGGC  
AACCCGTGGTGGCTTACGGCGGTGATTTTGGCGATACGCCGAACGATCGCCAGTTCTGT  
ATGAACGGTCTGGTCTTTGCCGACCGCACGCGCATCCAGCGCTGACGGAAGCAAAACAC  
CAGCAGCAGTTTTTCCAGTTCGGTTTATCCGGGCAAACCATCGAAGTGACCAGCGAATAC  
40 CTGTTCCGTCTAGCGATAACGAGCTCCTGCACTGGATGGTGGCGCTGGATGGTAAGCCG  
CTGGCAAGCGGTGAAGTGCTCTGGATGTGCTCCACAAGGTAACAGTTGATTGAATG  
CCTGAACCTACCGCAGCCGAGAGCGCGGCACTCTGGCTCACAGTACGCGTAGTGCAA  
CCGAACGCGACCGCATGGTCAGAAGCCGGGCACATCAGCGCCTGGCAGCAGTGGCGTCTG  
GCGGAAAACCTCAGTGTGACGCTCCCCGCGCGTCCCACGCCATCCCGCATCTGACCACC  
45 AGCGAAATGGATTTTTGCATCGAGCTGGGTAATAAGCGTTGGCAATTTAACCGCCAGTCA  
GGCTTTCTTTACAGATGTGGATTGGCGATAAAAAACAAGTGTGACGCCGTGCGCGAT  
CAGTTCACCCGTGCACCGCTGGATAACGACATTGGCGTAAGTGAAGCGACCCGATTGAC  
CCTAACGCCTGGGTGCAACGCTGGAAGGCGGCGGCCATTACCAGGCCGAAGCAGCGTTG  
TTGCAAGTGCACGGCAGATACACTTGCTGATGCGGTGCTGATTACGACCGCTCACGCGTGG  
50 CAGCATCAGGGGAAAACCTTATTTATCAGCCGAAAACCTACCGGATTGATGGTATGGT  
CAAATGGCGATTACCGTTGATGTTGAAGTGGCGAGCGATACACCGCATCCGGCCGCGATT  
GGCCTGAACCTGCGAGCTGGCGCAGGTAGCAGAGCGGGTAAACTGGCTCGGATTAGGGCCG  
CAAGAAAACCTATCCCGACCGCCTTACTGCCGCTGTTTTGACCGCTGGGATCTGCCATTG  
TCAGACATGTATACCCCGTACGTCTTCCCGAGCGAAAACGGTCTGCGCTGCGGGACGCGC  
55 GAATTGAATTATGGCCACACCACTGGCGCGGCGACTTCCAGTTCAACATCAGCCGCTAC  
AGTCAACAGCAACTGATGGAACACAGCCATCGCCATCTGCTGCACGCGGAAGAAGGCACA  
TGGCTGAATATCGACGGTTTCCATATGGGGATTGGTGGCGACGACTCCTGGAGCCCGTCA  
GTATCGGCGGAATTCCAGCTGAGCGCCGGTCTGCTACCATACCAGTTGGTCTGGTGTCAA  
AAATAATAAACCAGGCGAGGGGGATCCGAGATCCGGCTGTGGAATGTGTGTGAGTTA  
60 GGGTGTGGAAGTCCCCAGGCTCCCCAGCAGGAGAGTATGCAAAGCATGCCTGCAGGA



GTGGGGAGGCACGATGGCCGCTTTGGTCGAGGCGGATCCGGCCATTAGCCATATTATTCA  
TTGGTTATATAGCATAAATCAATATTGGCTATTGGCCATTGCATACGTTGTATCCATATC  
ATAATATGTACATTTATATTGGCTCATGTCCAACATTACCGCCATGTGACATTGATTAT  
TGACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTTCATAGCCCATATATGGAGT  
5 TCCGCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCGCC  
CATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCATTGAC  
GTCAATGGGTGGAGTATTTACGGTAACTGCCCACTTGGCAGTACATCAAGTGTATCATA  
TGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCC  
AGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTA  
10 TTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTGACTCAC  
GGGGATTTCCAAGTCTCCACCCCATGACGTCAATGGGAGTTTGTGTTTGGCACAAAATC  
AACGGGACTTTCCAAAATGTCGTAACAACCTCCGCCCCATTGACGCAATGGGCGGTAGGC  
ATGTACGGTGGGAGGTCTATATAAGCAGAGCTCGTTTAGTGAACCGTCAGATCGCCTGGA  
GACGCCATCCACGCTGTTTGGACCTCCATAGAAGACACCGGGACCGATCCAGCCTCCGCG  
15 GCCCCAAGCTTGTGGGATCCACCGTTCGCCACCATGGTGAGCAAGGGCGAGGAGCTGTT  
CACCGGGGTGGTGCCCATCCTGGTTCGAGCTGGACGGCAGCTAAACGGCCACAAGTTTACG  
CGTGTCGGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTG  
CACCACCGGCAAGCTGCCCGTGCCCTGGCCACCTCGTGACCACCTGACCTACGGCGT  
GCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCAGCACTTCTTCAAGTCCGCCAT  
20 GCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGAC  
CCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCAT  
CGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAACCTACAACAGCCA  
CAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAAGTTCAGATCCG  
CCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCAT  
25 CGGCGACGGCCCCGTGCTGCTGCCGACAACCACTACCTGAGCACCAGTCCGCCCTGAG  
CAAAGACCCCAACGAGAAGCGCGATCACATGGTCTGCTGGAGTTCGTGACCGCCCGCG  
GATCACTCTCGGCATGGACGAGCTGTACAAGTAAAGCGGCCGCGACTCTAGATCATAATC  
AGCCATACCACATTTGTAGAGTTTTACTTGCTTTAAAAAACCCTCCACACCTCCCCCTG  
AACCTGAAACATAAAATGAATGCAATTGTTGTTGTTAACATCGATAAAATAAAGATTTT  
30 ATTTAGTCTCCAGAAAAAGGGGGGAATGAAAGACCCACCTGTAGGTTTGGCAAGCTAGC  
ATAACTTCGTATAATGTATGCTATACGAAGTTATTCTAGAGAACCATCAGATGTTTCCAG  
GGTGCCCCAAGGACCTGAAATGACCCTGTGCCTTATTTGAACTAACCAATCAGTTCGCTT  
CTCGCTTCTGTTCGCGCGCTTCTGCTCCCGAGCTCAATAAAAGAGCCCAACCCCTCA  
CTCGGGGCGCCAGTCTCCGATTGACTGAGTCGCGCGGTACCCGTGTATCCAATAAACC  
35 CTCTTGCAAGTTCATCCGACTTGTGGTCTCGCTGTTCTTGGGAGGGTCTCCTCTGAGTG  
ATTGACTACCCGTGACGGGGGTCTTTTCAATTTGGGGGCTCGTCCGGGATCGGGAGACCC  
TGCCAGGGACCACCGACCCACCACCGGAGGTAAGCTGGCTGCCTCGCGCGTTTCGGTG  
ATGACGGTGAAACCTCTGACACATGCAGCTCCCGGAGACGGTCACAGCTTGTCTGTAAG  
CGGATGCCGGGAGCAGACAAGCCCGTCAGGGCGCGTCAGCGGGTGTGGCGGGTGTGGG  
40 GCGCAGCCATGACCCAGTCACGTAGCGATAGCGGAGTGTATACTGGCTTAACATGCGGC  
ATCAGAGCAGATTGTACTGAGAGTGCACCATATGCGGTGTGAAATACCGCACAGATGCGT  
AAGGAGAAAATACCGCATCAGGCGCTCTTCCGCTTCTCGCTCACTGACTCGCTGCGCTC  
GGTCGTTTCGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGGTAAACGGTTATCCAC  
AGAATCAGGGGATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAA  
45 CCGTAAAAAGGCCGCTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCTGACGAGCATCA  
CAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGC  
GTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATA  
CCTGTCCGCTTTCTCCCTTCGGGAAGCGTGGCGCTTCTCATAGCTCAGCTGTAGGTA  
TCTCAGTTCGGTGTAGGTGCTTCCGCTCAAGCTGGGCTGTGTGCACGAACCCCGTTCA  
50 GCCCCACCGCTGCGCCTTATCCGGTAACATATCGTCTTGAGTCCAACCCGGTAAGACACGA  
CTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGG  
TGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGGACAGTATTTGG  
TATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGG  
CAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTTGTTTGAAGCAGCAGATTACGCGCAG  
55 AAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGA  
CGAAAACCTCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCACTAGAT  
CCTTTTAAATTAATAATGAAGTTTTAAATCAATCTAAAGTATATATGAGTAAACTTGGTC  
TGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTCGTT  
ATCCATAGTTGCCTGACTCCCGTGTGTAGATAACTACGATACGGGAGGGCTTACCATC  
60 TGGCCCCAGTGCTGCAATGATACCGCGAGACCCACGCTCACGGGCTCCAGATTTATCAGC

AATAAACCCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGTCCTGCAACTTTATCCGCCCTC  
CATCCAGTCTATTAATTGTTGCCGGAAGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTT  
GCGCAACGTTGTTGCCATTGCTGCAGGCATCGTGGTGTACGCTCGTTCGTTGGTATGGC  
TTCATTACAGTCCGGTTCCCAACGATCAAGGCGAGTTACATGATCCCCATGTTGTGCAA  
5 AAAAGCGGTTAGCTCCTTCGGTCCCGATCGTTGTGAGAAGTAAGTTGGCCGAGTGT  
ATCACTCATGGTTATGGCAGCACTGCATAATTCTCTTACTGTATGCCATCCGTAAGATG  
CTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTGATGCGGCGACC  
GAGTTGCTCTTGCCCGGCGTCAACACGGGATAATACCGCGCCACATAGCAGAACTTTAAA  
AGTGCTCATCATTGAAAAACGTTCTTCGGGGCGAAAACCTCTCAAGGATCTTACCGCTGTT  
10 GAGATCCAGTTCGATGTAACCCACTCGTGCACCAACTGATCTTCAGCATCTTTTACTTT  
CACCAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAAATGCCGCAAAAAGGGAATAAG  
GGCGACACGGAAATGTTGAATACTCATACTCTTCTTTTCAATATTATTGAAGCATTTA  
TCAGGGTTATTGTCTCATGAGCGGATACATATTGAATGTATTTAGAAAAATAACAAAT  
AGGGGTTCCGCGCACATTTCCCCGAAAAGTCCACCTGACGTCTAAGAAACCATTATTAT  
15 CATGACATTAACTATAAAAATAGGCGTATCACGAGGCCCTTTCTGCTTCAAGAATTCAT  
ACCAGATCACCGAAAACGTCTCTCCAAATGTGTCCCCCTCACACTCCCAAATTCGCGGGC  
TTCTGCCTCTTAGACCACTCTACCCTATTCCCCCACTCACCGGAGCCAAAGCCGCGGCC  
CTTCCGTTTCTTTGCTTTTGAAAGACCCACCCGTAGGTGGCAAGCTAGCGATGACCCTG  
CTGATTGGTTTCGTGACCATTTCGCGGGTGCAGAACGCGGTTACCAGAACTCAGAAGGT  
20 TCGTCCAACCAACCGACTCTGACGGCAGTTTACGAGAGAGATGATAGGGTCTGCTTCAG  
TAAGCCAGATGCTACACAATTAGGCTTGTACATATTGTCGTTAGAACGCGGCTACAATTA  
ATACATAACCTTATGTATCATACATACGATTTAGGTGACACTATAGAATAACAAGCTGG  
AAGATCTTCCAGCTTGGGCTGCAAGTTCGACTCTAGAGTCCGTTACATAACTTACGGTAAA  
TGGCCCGCCTGGCTGACCGCCCAACGACCCCGCCCATTTGACGTCAATAATGACGTATGT  
25 TCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTACGGTA  
AACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGT  
CAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCC  
TACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTGGCA  
GTACATCAATGGGCGTGGATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCAT  
30 TGACGTCAATGGGAGTTTGTGTTGGCACCAAAATCAACGGGACTTTCCAAATGTCGTAA  
CAACTCCGCCCCATTGACGCAAAATGGGCGGTAGGCGGTACGGTGGGAGGTCTATATAAG  
CAGAGCTCGTTTAGTGAACCGCGCCAGTCTTCCGATAGACTGCGTTCGCCCCGGGTACCCGT  
ATTCCCAATAAAGCCTCTTGCTGTTTGCATCCGAATCGTGGTCTCGCTGTTCTTGGGAG  
GGTCTCTCTGAGTGATTGACTACCCACGACGGGGTCTTTCATTGTTGGGGCTCGTCCGG  
35 GATTTGGAGACCCCTGCCAGGGACACCGACCCACCACGGGAGGTAAGCTGGCCAGCA  
ACTTATCTGTGTCTGTCCGATTGTCTAGTGTCTATGTTGATGTTATGCGCCTGCGTCTG  
TACTAGTTAGCTAACTAGCTCTGTATCTGGCGGACCCGTGGTGGAAGTACGAGTTCTGA  
ACACCCGCGCCGAACCCCTGGGAGACGTCCCAGGGACTTTGGGGCCGTTTGTGGCCCG  
ACCTGAGGAAGGGAGTGCATGTGGAATCCGACCCCGTCAGGATATGTGGTTCTGGTAGGA  
40 GACGAGAACCTAAAACAGTTCCCGCCTCCGTCTGAATTTTGTCTTCGGTTTGGAAACCGA  
AGCCGCGCGTCTTGTCTGCTGCAGCGCTGCAGCATCGTTCTGTGTTGTCTGTCTGACT  
GTGTTTCTGTATTTGTCTGAAAAATAGGGCCAGACTGTTACCACTCCCTTAAGTTTGACC  
TTAGGTCACCTGGAAAGATGTCGAGCGGATCGCTCACAACCAGTCGGTAGATGTCAAGAAG  
AGACGTTGG

45

**PCGCLNGFR (SEQ ID No 57)**

GTTACCTTCTGCTCTGCAGAATGGCCAACCTTTAACGTCCGATGGCCGCGAGACGGCACC  
TTTAACCGAGACCTCATCACCCAGGTTAAGATCAAGGTCTTTTCACTGGCCCGCATGGA  
50 CACCCAGACCAGGTCCCCTACATCGTGACCTGGGAAGCCTTGGCTTTTGACCCCTCCC  
TGGGTCAAGCCCTTTGTACACCCTAAGCCTCCGCCTCCTCTTCTCCATCCGCCCGTCT  
CTCCCCCTGAACCTCCTCGTTGACCCCGCCTCGATCCTCCCTTTATCCAGCCCTCACT  
CCTTCTCTAGGCGCCGGAATTGTTAACTCGAGGATCCACCGGTGCGCACCATGGTGAGC  
AAGGGCGAGGAGCTGTTACCGGGGTGGTGCCCATCCTGGTTCGAGCTGGACGGCGACGTA  
55 AACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTG  
ACCCTGAAGTTCATCTGCACCACCGGAAGCTGCCCCGTGCCCTGGCCACCCTCGTGACC  
ACCCTGACCTACGGCGTGCAGTGCTTACGCGCTACCCCGACCATGAAGCAGCACGAC  
TTCTTCAAGTCCGCCATGCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGAC  
GACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGC  
60 ATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAG

TACAACTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAG  
GTGAAC TTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTAC  
CAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCCGACAACCACTACCTGAGC  
ACCCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCTCTGCTGGAG  
5 TTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAGTAAAGCGGCCCT  
AGGGGTCTTTCCCTCTCGCCAAAGGAATGCAAGGTCTGTTGAATGTCGTGAAGGAAGCA  
GTTCCCTCTGGAAGCTTCTTGAAGACAAACAACGTCTGTAGCGACCTTTGCAGGCAGCGG  
AACCCCCACCTGGCGACAGGTGCCTCTGCGGCCAAAAGCCACCGAGTTGGTTCAGCTGC  
TGCCTGAGGCTGGACGACCTCGCGGAGTTCTACCGGCAGTGCAAATCCGTGCGCATCCAG  
10 GAAACCAGCAGCGGCTATCCGCGCATCCATGCCCCGAACTGCAGGAGTGGGGAGGCACG  
ATGGCCGCTTTGGTTCGAGGCGGATCCGGCCATTAGCCATATTATTCATTGGTTATATAGC  
ATAAATCAATATTGGCTATTGCCCATTGCATACGTTGTATCCATATCATAATATGTACAT  
TTATATTGGCTCATGTCCAACATTACCGCCATGTTGACATTGATTATTGACTAGTTATTA  
ATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCCGCGTTACATA  
15 ACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCGCCATTGACGTCAAT  
AATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGA  
GTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCC  
CCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCAGTACATGACCTT  
ATGGGACTTTCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGGTGAT  
20 GCGGTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTGA CTACGGGGATTTCCAG  
TCTCCACCCCATTGACGTCAATGGGAGTTTGT TTTGGCACAAAATCAACGGGACTTTCC  
AAAATGTCGTAACAACCTCCGCCCATTTGACGCAAATGGGCGGTAGGCATGTACGGTGGGA  
GGTCTATATAAGCAGAGCTCGTTTAGTGAACCGTCAGATCGCTGGAGACGCCATCCACG  
CTGTTTTGACCTCCATAGAAGACACCGGGACCGATCCAGCCTCCGCGGCCCAAGCTTAC  
25 CATGGGGGAGGTGCCACCGCGCGCCATGGACGGGCGCGCCTGCTGCTGTTGCTGCT  
TCTGGGGGTGTCCCTTGGAGGTGCCAAGGAGGCATGCCCCACAGGCCTGTACACACACAG  
CGGTGAGTGCTGCAAAGCCTGCAACCTGGGCGAGGGTGTGGCCAGCCTTGTGGAGCCAA  
CCAGACCGTGTGTGAGCCCTGCCTGGACAGCGTGACGTTCTCCGACGTGGTGAGCGCGAC  
CGAGCCGTGCAAGCCGTGCACCGAGTGGTGGGGCTCCAGAGCATGTGCGCGCCGTGCGT  
30 GGAGGCCGACGACGCCGTGTGCCGCTGCGCCTACGGCTACTACCAGGATGAGACGACTGG  
GCGCTGCGAGGCGTGCCGCGTGTGCGAGGCGGGCTCGGGCCTCGTGTTCTCTGCCAGGA  
CAAGCAGAACACCGTGTGCGAGGAGTGCCCCGACGGCACGTATTCCGACGAGGCCAACCA  
CGTGGACCCGTGCCCTGCACCGTGTGCGAGGACACCGAGCGCCAGCTCCGCGAGTG  
CACACGCTGGGCCGACGCCGAGTGCGAGGAGATCCCTGGCCGTTGGATTACACGGTCCAC  
35 ACCCCCAGAGGGCTCGGACAGCACAGCCCCAGCACCCAGGAGCCTGAGGCACCTCCAGA  
ACAAGACCTCATAGCCAGCACGGTGGCAGGTGTGGTGACCACAGTGATGGGCAGCTCCCA  
GCCCCTGGTGACCCGAGGCACACCGACAACCTCATCCCTGTCTATTGCTCCATCCTGGC  
TGCTGTGGTTGTGGGCCTTGTGGCCTACATAGCCTTCAAGAGGTGGAACAGCTGCTGAGT  
CGACTCTAGAGGATCCCAACATCGATAAAATAAAAGATTTTATTTAGTCTCCAGAAAAA  
40 GGGGGGAATGAAAGACCCACCTGTAGGTTTGGCAAGCTAGCTTAAGTAACGCCATTTTG  
CAAGGCATGAAAAATACATAACTGAGAATAGAGAAGTTCAGATCAAGGTACAGGAACAGA  
TGGAACAGCTGAATATGGGCCAAACAGGATATCTGTGGTAAGCAGTTCTGCCCCGGCTC  
AGGGCCAAGAACAGATGGAACAGCTGAATATGGGCCAAACAGGATATCTGTGGTAAGCAG  
TTCCTGCCCCGGCTCAGGGCCAAGAACAGATGGTCCCCAGATGCGGTCCAGCCCTCAGCA  
45 GTTTCTAGAGAACCATCAGATGTTTCCAGGGTGCCCCAAGGACCTGAAATGACCCTGTGC  
CTTATTTGAACTAACCAATCAGTTCGCTTCTCGCTTCTGTTTCGCGCGCTTCTGCTCCCCG  
AGCTCAATAAAAGAGCCCAACCCCTCACTCGGGGCGCCAGTCTCCGATTGACTGAGT  
CGCCCGGGTACCCGTGTATCCAATAAACCCCTCTTGCAGTTGCATCCGACTTGTGGTCTCG  
CTGTTCTCTGGGAGGGTCTCCTCTGAGTGATTGACTACCCGTGACGGGGGTCTTTCATT  
50 TGGGGGCTCGTCCGGGATCGGGAGACCCCTGCCAGGGACCAACCGACCAACCGGGAG  
GTAAGCTGGCTGCCTCGCGCGTTTCGGTGATGACGGTGAAAACCTCTGACACATGCAGCT  
CCCGGAGACGGTCACAGCTTGTCTGTAAGCGGATGCCGGGAGCAGACAAGCCCGTCAGGG  
CGCGTCAGCGGGTGTGGCGGGTGTGCGGGGCGAGCCATGACCCAGTCACGTAGCGATAG  
CGGAGTGTATACTGGCTTA ACTATGCGGCATCAGAGCAGATTGTA CTGAGAGTGACCAT  
55 ATGCGGTGTGAAATACCGCACAGATGCGTAAGGAGAAAATACCGCATCAGGCGCTTCC  
GCTTCTCGCTCACTGACTCGTTCGCTCGGTCTGCTCGGTGCGGCGAGCGGTATCAGCT  
CACTCAAAGGCGGTAAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACATG  
TGAGCAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAGGCCGCGTGTGCTGGCGTTTTTC  
CATAGGCTCCGCCCCCTGACGAGCATCACAAAATCGACGCTCAAGTCAGAGGTGGCGA  
60 AACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCT

CCTGTTCCGACCCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTG  
GCGCTTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTGCTTCGCTCCAAG  
CTGGGCTGTGTGCACGAACCCCCGTTACGCCCAGCGCTGCGCCTTATCCGGTAACAT  
CGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAAC  
5 AGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAAC  
TACGGCTACACTAGAAGGACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTC  
GGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAAACAAACCACCGCTGGTAGCGGTGGTTTT  
TTTGTGTGCAAGCAGCAGATTACGCGCAGAAAAAAGGATCTCAAGAAGATCCTTTGATC  
TTTTCTACGGGGTCTGACGCTCAGTGGAAACGAAAACCTCACGTTAAGGGATTTTGGTCATG  
10 AGATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTAAATCA  
ATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCA  
CCTATCTCAGCGATCTGTCTATTTTCGTTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAG  
ATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGAC  
CCACGCTCACCGCTCCAGATTTATCAGCAATAAACAGCCAGCCGGAAGGGCCGAGCGC  
15 AGAAGTGGTCTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGAAGCT  
AGAGTAAGTAGTTCCGCCAGTTAATAGTTTGGCGAACGTTGTTGCCATTGCTGCAGGCATC  
GTGGTGTACGCTCGTCGTTTGGTATGGCTTCATTACGCTCCGGTTCCCAACGATCAAGG  
CGAGTTACATGATCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCCTCCGATC  
GTTGTGAGAAGTAAGTTGGCCGAGTGTTATCACTCATGGTTATGGCAGCACTGCATAAT  
20 TCTCTTACTGTCTATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAG  
TCATTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTTGCCCGCGTCAATACGGGAT  
AATACCGCGCCACATAGCAGAACTTTAAAGTGCTCATCATTGGAAACGTTCTTCGGGG  
CGAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGCA  
CCCAACTGATCTTCAGCATCTTTTACTTTTACCAGCGTTTCTGGGTGAGCAAAAACAGGA  
25 AGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACGGAAATGTTGAATACTCATACTC  
TTCCTTTTTCAATATTATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGGATACATA  
TTTGAATGTATTTAGAAAAATAACAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGTG  
CCACCTGACGTCTAAGAAACCATATTATCATGACATTAACCTATAAAAATAGCGGTATC  
ACGAGGCCCTTTTCGTCTCGCGCGTTTCGGTGATGACGGTGAAAACCTCTGACACATGCAG  
30 CTCCCGGAGACGGTCACAGCTTGTCTGTAAGCGGATGCCGGGAGCAGACAAGCCCGTCAG  
GGCGCGTCAGCGGGTGTGGCGGGTGTGGGGCTGGCTTAATATGCGGCATCAGAGCAG  
ATTGTACTGAGAGTGACCATATGGACATATTGTCGTTAGAACGCGGCTACAATTAATAC  
ATAACCTTATGTATCATACATACGATTTAGGTGACACTATAGAACTCGACTCTAGAGT  
CCGTTACATAAAGTTACGGTAAATGGCCCGCTGGCTGACCGCCCAACGACCCCCGCCCAT  
35 TGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTC  
AATGGGTGGAGTATTTACGGTAAACTGCCACTTGGCAGTACATCAAGTGTATCATATGC  
CAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCTGGCATTATGCCAGT  
ACATGACCTTATGGGACTTTCTTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTA  
CCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGATAGCGGTTTGAATCACGGG  
40 GATTTCCAAGTCTCCACCCATTGACGTCAATGGGAGTTTGTGTTTGGCACCAAAATCAAC  
GGGACTTTCCAAAATGTCGTAACAACTCCGCCCATTTGACGCAATGGGCGGTAGGCGTG  
TACGGTGGGAGGTCTATATAAGCAGAGCTCGTTTGTGTAACCGCGCCAGTCTTCCGATAG  
ACTGCCGTCGCCCGGGTACCCGTATTTCCCAATAAAGCCTCTTGCTGTTTGCATCCGAATCG  
TGGTCTCGCTGTTCTTTGGGAGGGTCTCCTCTGAGTGATTGACTACCCACGACGGGGTCT  
45 TTTCAATTTGGGGGCTCGTCCGGGATTGGAGACCCCTGCCAGGGACCACCGACCCACCA  
CCGGGAGGTAAGCTGGCCAGCAACTTATCTGTGTCTGTCCGATTGTCTAGTGTCTATGTT  
TGATGTTATGCGCCTGCGTCTGTACTAGTTAGCTAACTAGCTCTGTATCTGGCGGACCCG  
TGGTGGAACTGACGAGTTCTGAACACCCGGCCGAACCTGGGAGACGTCCCAGGGACTT  
TGGGGGCCGTTTTTGTGGCCCGACCTGAGGAAGGGAGTCGATGTGGAATCCGACCCCGTC  
50 AGGATATGTGGTCTGGTAGGAGACGAGAACCTAAACAGTTCCCGCCTCCGTCTGAATT  
TTTGCTTTCCGTTTGGAAACGAAGCCGCGCTCTTGTCTGCTGCAGCGCTGCAGCATCGT  
TCTGTGTGTCTCTGCTGACTGTGTTTCTGTATTTGCTGAAAATAGGGCCAGACTGT  
TACCACCTCCCTTAAGTTTGACCTTAGGTCACTGGAAAGATGTCGAGCGGATCGCTCACAA  
CCAGTCGGTAGATGTCAAGAAGAGACGTTGG  
55

**PLTRloxP (SEQ ID No 58)**

60 GCTAGCATAACTTCGTATAATGTATGCTATACGAAGTTATTCTAGAGAACCATCAGATGT  
TTCCAGGGTGCCCAAGGACCTGAAATGACCTGTGCCTTATTTGAACTAACCAATCAGT

TCGCTTCTCGCTTCTGTTTCGCGCGCTTCTGCTCCCCGAGCTCAATAAAAGAGCCCAAC  
CCCTCACTCGGGGCGCCAGTCTCTCCGATTGACTGAGTCGCCCCGGGTACCCGTGTATCCAA  
TAAACCTCTTGCAGTTGCATCCGACTTGTGGTCTCGCTGTTTCTTGGGAGGGTCTCCTC  
TGAGTGATTGACTACCCGTACGCGGGGTCTTTCATTGGGGGCTCGTCCGGGATCGGGA  
5 GACCCCTGCCAGGGACCACCGACCCACCACCGGGAGGTAAGCTGGCTGCCTCGCGCGTT  
TCGGTGATGACGGTGAAAACCTCTGACACATGCAGTCCCGGAGACGGTCACAGCTTGTC  
TGTAAGCGGATGCCGGGAGCAGACAAGCCCGTCAGGGCGCTCAGCGGGTGTGGCGGGT  
GTCGGGGCGCAGCCATGACCCAGTCACGTAGCGATAGCGGAGTGATACTGGCTTAACTA  
TGCGGCATCAGAGCAGATTGTACTGAGAGTGCACCATATGCGGTGTGAAATACCGCACAG  
10 ATGCGTAAGGAGAAAATACCGCATCAGGCGCTCTTCCGCTTCCTCGCTCACTGACTCGCT  
GCGCTCGGTGCTTCCGCTGCGGCGAGCGGTATCAGTCACTCAAAGCGGTAATACGGTT  
ATCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGC  
CAGGAACCGTAAAAAGGCCGCTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCTGACGA  
GCATCAGAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATA  
15 CCAGGCGTTTTCCCTGGAAGCTCCCTCGTGCGCTCTCTGTTCGACCTGCCGCTTAC  
CGGATACCTGTCCGCTTTCTCCCTTCGGGAAGCGTGGCGCTTCTCATAGCTCAGCGTG  
TAGGTATCTCAGTTCGGTGTAGGTGCTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCC  
CGTTCAGCCCGACCGCTGCGCTTATCCGGTAACATATCGTCTTGAGTCCAACCCGGTAAG  
ACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGT  
20 AGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGGACAGT  
ATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTG  
ATCCGGCAAAACAAACCCGCTGGTAGCGGTGGTTTTTTTGGTTGCAAGCAGCAGATTAC  
GCGCAGAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCA  
GTGGAACGAAAACTCACGTTAAGGGATTTTGGTTCATGAGATTATCAAAAGGATCTTAC  
25 CTAGATCCTTTTAAATTAATAATGAAGTTTTAAATCAATCTAAAGTATATATGAGTAAAC  
TTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATT  
TCGTTTCATCCATAGTTGCCTGACTCCCCGTGCTGTAGATAACTACGATACGGGAGGGCTT  
ACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGACCCACGCTCACCGGCTCCAGATT  
ATCAGCAATAAACAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGTCTGCAACTTTATC  
30 CGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAGAGTAAGTAGTTCGCCAGTTAA  
TAGTTTGCGCAACGTTGTTGCCATTGCTGCAGGCATCGTGGTGTACGCTCGTCTGTTGG  
TATGGCTTCATTAGCTCCGTTCCCAACGATCAAGGCGAGTTACATGATCCCCATGTT  
GTGCAAAAAAGCGTTAGCTCCTTCGGTCTCCGATCGTTGTGAGAAGTAAGTTGGCCGC  
AGTGTTATCACTCATGGTTATGGCAGCACTGCATAATTCTTACTGTCATGCCATCCGT  
35 AAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTGATGCG  
GCGACCGAGTTGCTCTTGCCCGGCGTCAACACGGGATAATACCGCGCCACATAGCAGAAC  
TTTAAAGTGCTCATATTGGAAAACGTTCTTCGGGGCGAAAACCTCAAGGATCTTACC  
GCTGTTGAGATCCAGTTTCGATGTAACCCACTCGTGACCCAACTGATCTTCAGCATCTTT  
TACTTTACCCAGCGTTTCTGGGTGAGCAAAACAGGAAGGCAAAATGCCGCAAAAAGGG  
40 AATAAGGGCGACACGGAAATGTTGAATACTCATACTCTTCTTTTCAATATTATTGAAG  
CATTTATCAGGGTTATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGAAAAATAA  
ACAAATAGGGTTCCGCGCACATTTCCCGAAAAGTGCCACCTGACGTCTAAGAAACCAT  
TATTATCATGACATTAACTATAAAAATAGGCGTATCAGAGGCCCTTTCGTCTCAAGA  
ATTCATACCAGATCACCGAAAACGTCTTCCAAATGTGTCCCCCTCACACTCCCAAAATTC  
45 GCGGGCTTCTGCCTCTTAGACCACTCTACCCTATTCCCACTACCGGAGCCAAAGCC  
GCGGCCCTTCGTTTCTTTGCTTTTGAAAGACCCACCCGTAGGTGGCAA

### LTR plasmid (SEQ ID No 59)

GCTAGCTTAAGTAACGCCATTTTGCAAGGCATGGAAAAATACATAACTGAGAATAGAGAA  
50 GTTCAGATCAAGGTACAGGAACAGATGGAACAGCTGAATATGGGCCAAACAGGATATCTGT  
GGTAAGCAGTTCTGCCCGGCTCAGGGCCAAGAACAGATGGAACAGCTGAATATGGGCC  
AAACAGGATATCTGTGGTAAGCAGTTCCTGCCCGGCTCAGGGCCAAGAACAGATGGTCC  
CCAGATGCGGTCCAGCCCTCAGCAGTTTCTAGAGAACCATCAGATGTTTCCAGGGTGGCC  
CAAGGACCTGAAATGACCCTGTGCCTTATTTGAACTAACCAATCAGTTCGCTTCTCGCTT  
55 CTGTTGCGCGCTTCTGCTCCCCGAGCTCAATAAAAGAGCCCAACCCCTCACTCGGGG  
CGCCAGTCTCCGATTGACTGAGTCGCCCCGGGTACCCGTGTATCCAATAAACCCCTTTCG  
AGTTGCATCCGACTTGTGGTCTCGCTGTTCTTGGGAGGGTCTCCTCTGAGTGATTGACT  
ACCCGTACGCGGGGTCTTTCATTGGGGGCTCGTCCGGGATCGGGAGACCCCTGCCAG  
GGACCACCGACCCACCACCGGGAGGTAAGCTGGCTGCCTCGCGCGTTTCGGTGTGACGG

TGAAAACCTCTGACACATGCAGCTCCCGGAGACGGTCACAGCTTGTCTGTAAGCGGATGC  
CGGGAGCAGACAAGCCCGTCAGGGCGCGTCAGCGGGTGTGGCGGGTGTGGGGCGCAGC  
CATGACCCAGTCACGTAGCGATAGCGGAGTGTATACTGGCTTAACATATGCGGCATCAGAG  
CAGATTGTACTGAGAGTGCACCATATGCGGTGTGAAATACCGCACAGATGCGTAAGGAGA  
5 AAATACCGCATCAGGCGCTCTTCCGCTTCCTCGCTCACTGACTCGCTGCGCTCGGTCTGTT  
CGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGGTAATACGGTTATCCACAGAATCA  
GGGGATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAA  
AAGGCCGCGTTGTGGCGTTTTTCCATAGGCTCCGCCCCCTGACGAGCATCACAAAAAT  
CGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCGGCGTTTCCC  
10 CCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCC  
GCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGT  
TCGGTGTAGGTCGTTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCGTTAGCCCCGAC  
CGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCG  
CCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACA  
15 GAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGGACAGTATTTGGTATCTGC  
GCTCTGCTGAAGCCAGTTACCTTCGGAAGAGTGGTAGCTCTTGATCCGGCAAACAA  
ACCACCGCTGGTAGCGGTGGTTTTTTTGTGCAAGCAGCAGATTACGCGCAGAAAAAA  
GGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAAACGAAAC  
TCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTACCTAGATCCTTTTA  
20 AATTAAGAAATGAAGTTTTAAATCAATCTAAAGTATATATGAGTAACTTGGTCTGACAGT  
TACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTTCGTTTCATCCATA  
GTTGCCTGACTCCCCGTCGTGTAGATAACTACGATACGGGAGGGCTTACCATCTGGCCCC  
AGTGCTGCAATGATACCGCGAGACCCACGCTCACGGGCTCCAGATTTATCAGCAATAAAC  
CAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGTCCTGCAACTTTATCCGCCTCCATCCAG  
25 TCTATTAATTGTTGCCGGAAGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTGCAGAAC  
GTTGTTGCCATTGCTGCAGGCATCGTGGTGTACGCTCGTCTTGGTATGGCTTCATTC  
AGCTCCGGTTCCCAACGATCAAGGCAGTTACATGATCCCCATGTTGTGCAAAAAGCG  
GTTAGCTCCTTCGGTCTCCGATCGTTGTGCAAGTAAGTTGGCCGAGTGTTATCACTC  
ATGGTTATGGCAGCACTGCATAATTCTCTTACTGTCTATGCCATCCGTAAGATGCTTTTCT  
30 GTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTGTATGCGGCGACCGAGTTGC  
TCTTGGCCGCGCTCAACACGGGATAATACCGCGCCACATAGCAGAACTTTAAAAGTGCTC  
ATCATTGGAAAACGTTCTTTCGGGGCGAAAACCTCTCAAGGATCTTACCGCTGTTGAGATCC  
AGTTTCGATGTAACCCACTCGTGACCCAACTGATCTTCAGCATCTTTACTTTTACCAGC  
GTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAGGGAATAAGGGCGACA  
35 CGGAAATGTTGAATACTCATACTCTTCTTTTCAATATTATTGAAGCATTTATCAGGGT  
TATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGAAAAATAAACAAATAGGGGT  
CCGCGCACATTTCCCCGAAAAGTGCCACCTGACGTCTAAGAAACCATTTATTCATGACA  
TTAACCTATAAAAAATAGGCGTATCACGAGGCCCTTTCGTCTTCAAGAATTCATACCAGAT  
CACCAGAACTGTCTCCAAATGTGTCCCCCTCACACTCCCAAATTCGCGGGCTTCTGCC  
40 TCTTAGACCACTCTACCCTATTCCCCACACTACCGGAGCCAAAGCCGCGGCCCTTCCGT  
TTCTTTGCTTTTGAAAGACCCACCCGTAGGTGGCAA

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 00/03837

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/867 C12N15/90 C12N5/10 C12N7/01 A61K48/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, MEDLINE, BIOSIS

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>VANIN E. F. ET AL.: "Development of high-titer retroviral producer cell lines by using Cre-mediated recombination." JOURNAL OF VIROLOGY, vol. 71, no. 10, 1997, pages 7820-7826, XP002161355 ISSN: 0022-538X cited in the application the whole document</p> <p style="text-align: center;">--- -/-</p>	1-51



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*G\* document member of the same patent family

Date of the actual completion of the international search

26 February 2001

Date of mailing of the international search report

13/03/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Mandl, B

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/GB 00/03837

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	KARREMAN S. ET AL.: "ON THE USE OF DOUBLE FLP RECOGNITION TARGETS (FRTS) IN THE LTR OF RETROVIRUSES FOR THE CONSTRUCTION OF HIGH PRODUCER CELL LINES" NUCLEIC ACIDS RESEARCH, vol. 24, no. 9, 1 May 1996 (1996-05-01), pages 1616-1624, XP000616161 ISSN: 0305-1048 cited in the application the whole document ---	1-51
A	IWAKUMA T. ET AL.: "SELF-INACTIVATING LENITVIRAL VECTORS WITH U3 AND U5 MODIFICATIONS" VIROLOGY, vol. 261, no. 1, 15 August 1999 (1999-08-15), pages 120-132, XP000882897 ISSN: 0042-6822 the whole document ---	1-51
A	BOAST K. ET AL.: "CHARACTERIZATION OF PHYSIOLOGICALLY REGULATED VECTORS OF THE TREATMENT OF ISCHEMIC DISEASE" HUMAN GENE THERAPY, vol. 10, no. 13, 1 September 1999 (1999-09-01), pages 2197-2208, XP000876772 ISSN: 1043-0342 the whole document -----	1-51



**FURTHER INFORMATION CONTINUED FROM PCT/SA/ 210**

Continuation of Box I.2

Claims Nos.: 45-48

Said claims 45-48 could not searched because they were not present in the application.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☒ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**